

FORM PTO-1390 (REV 11-2000) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTORNEY'S DOCKET NUMBER UCI1150-1
TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371		
INTERNATIONAL APPLICATION NO. PCT/US00/18856	INTERNATIONAL FILING DATE 08 July 2000	U.S. APPLICATION NO. (If known, see 37 CFR 1.5) 10/030441 PRIORITY DATE CLAIMED 08 July 1999
TITLE OF INVENTION A Lung Cancer Associated Retrovirus, Gene Delivery Vector and Methods of Use Thereof		
APPLICANT(S) FOR DO/EO/US Hung Y. Fan; Massimo Palmarini; and James M. Sharp		
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:		
<p>1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371.</p> <p>2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371.</p> <p>3. <input checked="" type="checkbox"/> This is an express request to begin national examination procedures (35 U.S.C. 371(f)). The submission must include items (5), (6), (9) and (21) indicated below.</p> <p>4. <input type="checkbox"/> The US has been elected by the expiration of 19 months from the priority date (Article 31).</p> <p>5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2))</p> <ul style="list-style-type: none"> a. <input type="checkbox"/> is attached hereto (required only if not communicated by the International Bureau). b. <input type="checkbox"/> has been communicated by the International Bureau. c. <input checked="" type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US). <p>6. <input type="checkbox"/> An English language translation of the International Application as filed (35 U.S.C. 371(c)(2))</p> <ul style="list-style-type: none"> a. <input type="checkbox"/> is attached hereto. b. <input type="checkbox"/> has been previously submitted under 35 U.S.C. 154(d)(4). <p>7. <input checked="" type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3))</p> <ul style="list-style-type: none"> a. <input type="checkbox"/> are attached hereto (required only if not communicated by the International Bureau). b. <input type="checkbox"/> have been communicated by the International Bureau. c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired d. <input checked="" type="checkbox"/> have not been made and will not be made. <p>8. <input type="checkbox"/> An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)).</p> <p>9. <input checked="" type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). Unexecuted (3 pages)</p> <p>10. <input type="checkbox"/> An English language translation of the annexes of the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)).</p> <p>11. <input checked="" type="checkbox"/> A copy of the International Preliminary Examination Report (PCT/IPEA/409) (8 pages)</p> <p>12. <input checked="" type="checkbox"/> A copy of the International Search Report (PCT/ISA/210). (7 pages)</p>		
Items 11 to 23 below concern document(s) or information included:		
<p>13. <input type="checkbox"/> An Information Disclosure Statement under 37 CFR 1.97 and 1.98.</p> <p>14. <input type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included.</p> <p>15. <input type="checkbox"/> A FIRST preliminary amendment.</p> <p>16. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment.</p> <p>17. <input type="checkbox"/> A substitute specification.</p> <p>18. <input type="checkbox"/> A change of power of attorney and/or address letter.</p> <p>19. <input type="checkbox"/> A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 – 1.825.</p> <p>20. <input type="checkbox"/> A second copy of the published international application under 35 U.S.C. 154(d)(4).</p> <p>21. <input type="checkbox"/> A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).</p> <p>22. <input checked="" type="checkbox"/> Certificate of Mailing by Express Mail EV047293899US</p> <p>23. <input checked="" type="checkbox"/> Other items or information: Formal Drawings (13 Sheets); PCT Request (6 pages); Written Opinion (7 pages); Notification of Receipt of Demand by Competent Examining Authority (1 page).</p>		

U.S. APPLICATION NO. (If known, see 37 CFR 10/030441	INTERNATIONAL APPLICATION NO. PCT/US00/18856	ATTORNEY'S DOCKET NUMBER UCII150-1		
<p>24. <input checked="" type="checkbox"/> The following fees are submitted:</p> <p>BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) – (5)):</p> <p>Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO \$1040.00</p> <p>International preliminary examination fee (37 CFR 1.482) not paid to USPTO but International Search Report prepared by the EPO or JPO..... \$890.00</p> <p>International preliminary examination fee (37 CFR 1.482) not paid to USPTO but international search fee (37 CFR 1.445(a)(2)) paid to USPTO..... \$740.00</p> <p>International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4)..... \$710.00</p> <p>International preliminary examination fee (37 CFR 1.482) paid to USPTO and all claims satisfied provisions of PCT Article 33(1)-(4) \$100.00</p>		CALCULATIONS PTO USE ONLY		
<p>ENTER APPROPRIATE BASIC FEE AMOUNT =</p> <p>Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input checked="" type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(c)).</p>		\$710.00		
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE	
Total claims	59 - 20 =	39	x \$18.00	\$702.00
Independent claims	11 - 3 =	8	x \$84.00	\$672.00
MULTIPLE DEPENDENT CLAIM(S) (if applicable)		+ 280.00		\$
TOTAL OF ABOVE CALCULATIONS =				\$2214.00
<input checked="" type="checkbox"/> Applicant claims small entity status. See 37 CFR 1.27. The fees indicated above are reduced by 1/2.				\$1107.00
SUBTOTAL =				\$1107.00
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).				\$
TOTAL NATIONAL FEE =				\$1107.00
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property				\$
TOTAL FEES ENCLOSED =				\$1107.00
				Amount to be refunded: \$
				charged: \$
<p>a. <input checked="" type="checkbox"/> A check in the amount of \$1107.00 to cover the above fees is enclosed.</p> <p>b. <input type="checkbox"/> Please charge my Deposit Account No. _____ in the amount of \$_____ to cover the above fees. A duplicate copy of this sheet is enclosed.</p> <p>c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 50-1355. A duplicate copy of this sheet is enclosed.</p> <p>d. <input type="checkbox"/> Fees are to be charged to a credit card. WARNING: Information on this form may become public. Credit card information should not be included on this form. Provide credit card information and authorization on PTO-2038.</p>				
<p>NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.</p> <p>SEND ALL CORRESPONDENCE TO: Lisa A. Haile, Ph.D.</p> <p>Gray Cary Ware & Freidenrich LLP 4365 EXECUTIVE DRIVE, SUITE 1100, SAN DIEGO, CA 92121-2133 Phone: (858) 677-1456 Facsimile: (858) 677-1465</p> <p>38.347</p> <p>REGISTRATION NUMBER</p> <p>17702</p> <p>DATE</p>				

A LUNG CANCER ASSOCIATED RETROVIRUS, GENE DELIVERY
VECTOR AND METHODS OF USE THEREOF

STATEMENT REGARDING FEDERALLY SPONSORED RESEARCH

5 The U.S. Government may have certain rights in this invention pursuant to
Grant No.: RO1CA82564 by the National Institute of Health (NIH).

FIELD OF THE INVENTION

10 The present invention relates generally to the field of virology and more
specifically to a novel retrovirus useful for the transfer and expression of nucleic acid
sequences in a targeted cell and methods of diagnosing and treating disease associated
with retroviruses.

BACKGROUND

15 Sheep pulmonary adenomatosis (SPA) is a contagious and experimentally
transmissible lung cancer of sheep resembling human bronchiolo-alveolar carcinoma.
A type D retrovirus, known as jaagsiekte sheep retrovirus (JSRV), has been associated
with the etiology of SPA, but its exact role in the induction of the tumor has not been
clear due to the lack of (i) a tissue culture system for the propagation of JSRV and (ii)
20 an infectious JSRV molecular clone.

Animal models of retrovirus-induced tumors have provided many insights into
the mechanisms governing cell transformation (Vogt, P. K. 1997. p. 1-25. *In* J. M.
Coffin, S. H. Hughes, and H. E. Varmus (ed.), *Retroviruses*. Cold Spring Harbor
25 Laboratory Press, Cold Spring Harbor, N.Y.). Sheep pulmonary adenomatosis (SPA),
also known as ovine pulmonary carcinoma, is a bronchiolo-alveolar carcinoma that is
present in widely distributed agricultural populations (Hecht *et al.* 1996. *Br. Vet. J.*
152:395-409; Palmarini *et al.* 1997. *Trends Microbiol.* 5:478-483). SPA strongly
resembles human bronchiolo-alveolar carcinoma (BAC); both tumors have the same
30 clinical, macroscopic, histopathologic, and ultrastructural features (Ives *et al.* 1983.
Am. Rev. Respir. Dis. 128:195-209; Perk, K., and I. Hod. 1982. *JNCI* 69:747-749).
BAC has many pathological and epidemiological characteristics that

distinguish it from other types of human lung cancer, including adenocarcinoma (Barkley *et al.* 1996 *J. Clin. Oncol.* 14:2377-2386; Carney and L. De Leij. 1988. *Semin. Oncol.* 15:199-214; Clayton, F. 1988. *Pathol. Annu.* 23:361-394). The incidence of BAC is rising, and now represents up to a quarter of primary lung 5 cancers in the United States (Barsky *et al.* 1994. *Cancer* 73:1163-1170). Most notably, lung cancer is the main cause of death from cancer in both men and women (Landis *et al.* 1998. *CA Cancer J. Clin.* 48:6-29; Wingo *et al.* 1998. *Cancer* 82:1197-1207), but very few animal models are available. The common characteristics between human BAC and SPA suggest that SPA could be a unique experimental model and could 10 offer novel insights into pulmonary carcinogenesis.

SPA also is a significant veterinary problem in countries such as the United Kingdom, South Africa, and Spain. The cumulative lifetime risk for developing SPA approaches 25% in high-risk flocks in these countries (Sharp and K. Angus. 1990. p. 15 177-185. *In* G. Petursson, and R. Hoff-Jørgensen (ed.), *Maedi-Visna and related diseases*. Kluwer Academic Publishers, Boston, Mass.).

Previous experiments provided evidence for the presence of a retrovirus (jaagsiekte sheep retrovirus (JSRV)) in the tumors and lung secretions of SPA- 20 affected sheep (Hecht *et al.* 1994. *Virology* 202:480-484; Martin *et al.* 1976. *Nature* 264:183-185; Rosadio *et al.* 1988. *Vet. Pathol.* 25:475-483; Sharp, J. M., and A. J. Herring. 1983. *J. Gen. Virol.* 64:2323-2327). An important development was the deduction of a nucleotide sequence of a South African strain of JSRV (JSRV-SA) (York *et al.* 1992. *J. Virol.* 66:4930-4939; York *et al.* 1991. *J. Virol.* 65:5061-5067). 25 This was accomplished by piecing together cDNA clones and reverse transcriptase PCR (RT-PCR) products from a cDNA library constructed from DNA isolated by isopycnic centrifugation from the lung fluid of an SPA-affected animal. However, competent viral particles have been unable to be developed using cells transfected with this sequence.

30

Despite the recent data strongly suggesting that JSRV is the cause of SPA, a reconstructed JSRV-SA provirus failed to reproduce SPA in sheep. Therefore, it has been unclear if JSRV is alone sufficient to induce lung cancer in sheep, if it is a helper

virus for an unidentified acutely transforming retrovirus, or if it simply is a passenger that replicates preferentially in SPA tumor cells.

5

SUMMARY OF THE INVENTION

The invention provides an isolated replication competent infectious Jaagsiekte sheep retrovirus (JSRV). In one embodiment, the invention provides an isolated retrovirus having a JSRV GAG protein; a JSRV POL protein; a JSRV ENV protein; a JSRV genome comprising Long-Termal Repeat (LTR) sequences at the 5' and 3' 10 end of the retroviral genome, wherein the LTR is active in pulmonary epithelial cells, a polynucleotide sequence encoding JSRV GAG protein, JSRV POL protein, and JSRV ENV protein; and cis-acting nucleic acid sequences necessary for reverse transcription, packaging and integration in a target cell. In another embodiment, the JSRV has a genomic sequence as set forth in GenBank accession no. AF105220.

15

The invention also provides an isolated Jaagsiekte sheep retrovirus (JSRV) genome, having a polynucleotide sequence as set forth in GenBank accession no. AF105220.

20

In yet another embodiment, the invention provides a method for producing an infectious Jaagsiekte sheep retrovirus (JSRV). The method includes transfecting a host cell with the vector containing a polynucleotide genome of JSRV, culturing the host cell under sufficient conditions and for sufficient time to allow expression of the vector to produce JSRV viral particles; and obtaining the JSRV viral particles.

25

In another embodiment, the invention provides a method of treating a subject having a cell proliferative disorder or a biochemical or genetic defect. The method includes contacting the subject with a retroviral vector, comprising, a JSRV GAG protein; a JSRV POL protein; a JSRV ENV protein; a JSRV genome comprising Long-Termal Repeat (LTR) sequences at the 5' and 3' end of the retroviral genome, wherein the LTR is active in pulmonary epithelial cells, a heterologous nucleic acid sequence operably linked to a regulatory nucleic acid sequence; and cis-acting nucleic

acid sequences necessary for reverse transcription, packaging and integration in a target cell.

5 The invention also provides a pharmaceutical composition useful for inducing an immune response to Jaagsiekte sheep retrovirus (JSRV) in an subject. The composition includes an immunogenically effective amount of a JSRV or JSRV polypeptide in a pharmaceutically acceptable carrier.

10 In another embodiment, a method of inducing an immune response to a JSRV or JSRV polypeptide in a subject is provided. The method includes immunizing an animal with the composition a pharmaceutical composition useful for inducing an immune response to Jaagsiekte sheep retrovirus (JSRV) in an subject. The composition includes an immunogenically effective amount of a JSRV or JSRV polypeptide in a pharmaceutically acceptable carrier.

15 In another embodiment, the invention provides an antibody which specifically binds to the replication competent infectious Jaagsiekte sheep retrovirus (JSRV).

20 In yet another embodiment, the invention provides a method for inhibiting the binding of a JSRV to a cell comprising contacting the JSRV with an anti- JSRV- antibody.

25 The invention also provides a method for identifying a compound which binds to a Jaagsiekte sheep retrovirus (JSRV). The method includes incubating components comprising the compound and the JSRV under conditions sufficient to allow the components to interact; and measuring the binding or effect of binding of the compound to the JSRV. In one embodiment, the effect can be detected by measuring the infectivity of JSRV.

Also provided is a method for inhibiting the expression of Jaagsiekte sheep retrovirus (JSRV) in a cell comprising contacting the cell with an inhibiting effective amount of an antisense oligonucleotide that binds to a segment of an mRNA transcribed from the JSRV genome whereby the binding of the antisense to the mRNA segment inhibits JSRV gene expression.

BRIEF DESCRIPTION OF THE DRAWINGS

FIG. 1 shows the cloning of JSRV₂₁. The strategy used for the isolation of JSRV₂₁ is shown

FIG. 2 shows JSRV₂₁-based plasmid constructs and *in vitro* synthesis of viral particles. (a) Schematic representation of the genomic organization of the JSRV₂₁ provirus; standard retroviral notation is used. The proviral genome is typical of type B and type D retroviruses, with *pro* in a different open reading frame from *pol*. Note the presence of an accessory open reading frame (*orf-x*) overlapping *pol*. (b) pJSRV₂₁ and pCMV2JS₂₁ plasmid constructs. In pCMV2JS₂₁, the U3 region of the proximal LTR was replaced by the human CMV promoter.

FIG. 3 shows the buoyant-density analysis of JSRV₂₁. (a) Intact JSRV₂₁ particles prepared by transient transfection of 293T cells with pCMV2JS₂₁ were analyzed by isopycnic centrifugation in a 25 to 60% (wt/wt) sucrose gradient. Adjacent fractions were pooled, and exogenous RT activity was determined (solid lines). The densities of each fraction are shown in grams per milliliter (dashed lines). (b) JSRV₂₁ was treated with 0.1% Triton X-100 and analyzed as in panel a.

FIG. 4 shows a schematic representation of the genomic structure of the type D retroviruses of sheep. Premature stop codons are indicated by a vertical bar underlined by an asterisk. For convenience the *gag* open reading frame has been fixed at position -3 in all the sequences shown. The numbered bar at the bottom indicate distances in kilobases. The exogenous JSRV and ENTV show the canonical retroviral *gag*, *pro*, *pol* and *env* with *pro* in a different open reading frame from *pol* as in all type D and B retroviruses. An additional open reading frame (*orf-x*) overlapping *pol* is present in JSRV but it is interrupted by two stop codons in ENTV. enJS56A1 is the only one of the three endogenous loci cloned in this study to maintain full open reading frames in all the structural genes. EnJS59A1 has premature stop codons in *gag* and *pol* and an ample deletion in *env*. enJS5F16 has a deletion in *pol*.

FIG. 5 shows the alignment of the deduced amino acid sequence of *gag* of type D retrovirus of sheep. Alignment is shown of the exogenous JSRV₂₁

(AF105220), JSRV-SA (M80216), ENTV (Y16627) and the endogenous en5F16 and en56A1 that maintain an open reading frame along the whole *gag*. Dots refer to identical sequences while dashes indicate lack of sequence. Underlined are the variable region A and B (VRA and VRB). Note the proline rich region present in the VRA of the exogenous JSRVs and ENTV that is instead absent in the endogenous loci. In VRB, ENTV is more similar to JSRV than *enJSRVs*. Indicated is the putative major capsid region (CA) and the *HpaI* site used to generate exogenous-endogenous chimeras.

FIG. 6 shows the alignment of the deduced amino acid sequence of *env* of type D endogenous retroviruses of sheep. Alignment is shown of the exogenous JSRV₂₁ (AF105220), JSRV-SA (M80216), ENTV (Y16627) and the endogenous en5F16 and en56A1 that maintain an open reading frame along the whole *env*. Dots refer to identical sequences while dashes indicate lack of sequence. The boundaries between the surface (SU) and transmembrane (TM) are indicated. The variable region C (VRC) is underlined. Note the polymorphism between all the sequences in VRC.

FIG. 7 shows the construction of endogenous-exogenous chimeras for the identification of the enJS56A1 packaging defect. Schematic structure of the parental (JSRV₂₁ and enJS56A1) and chimeric plasmids. The restriction enzyme sites used for the cloning procedure are indicated. In pCMV2JS21 and in the various chimeric constructs expression is driven by the cytomegalovirus immediate-early promoter (CMV, indicated by an arrow).

FIG. 8 shows the alignment of the nucleotide sequence of the untranslated *gag* region of type-D retroviruses of sheep. Alignment is shown of the exogenous JSRV₂₁ (AF105220), JSRV-SA (M80216), ENTV (Y16627) and the endogenous en5F16, en59A1 and en56A1. The primer binding site (PBS) is underlined.

FIG. 9 shows a phylogenetic analysis of the type D retroviruses of sheep. Unrooted phylogenetic trees for the U3 (A), *env* (B) and *gag* and *pol* (C) has been estimated by neighbor joining. To show consistency all bootstrap values obtained with 1,000 replications of bootstrap sampling are shown. Sequences used for the analysis

are termed as in its original reference with the exception of Locus 1-6 which are indicated L1-L6 in (A). The GenBank accession numbers are: AF105220 (JSRV₂₁); M80216 (JSRV-SA); X95445-X95452 (endogenous Locus 1, 2, 3, 4, 5, 6 and exogenous type I and II LTR); Y16627 (ENTV); Y18301-Y18305 (JS7, 809T, 83RS28, 92K3); Z66531-Z66533 (enJSRV1, 2, 3); Z71304 (LTR-UK); (AF136224) enJS5F16; (AF136225) enJS59A1; AF153615 (enJS56A1). In all the estimated trees there are 5 distinct phylogenetic groups for the type-D retroviruses: *enJSRV-A*, *enJSRV-B* for the endogenous loci; the ENTV group and two groups for the exogenous JSRV, JSRV-I (African isolates) and JSRV-II (isolates from USA and UK).

FIG. 10 shows enJSRVs LTR activity in cell lines. The penJS56A1-luc, penJS5F16-luc and penJS59A1-luc plasmids were transfected into various cell lines as described herein. Cell lines used were derived from mouse differentiated lung epithelial cells (MLE-15 and mtCC1-2) and extrapulmonary tissues such as mouse fibroblasts (NIH-3T3), mouse kidney (TCMK) and sheep endometrium (LE). Luciferase activities of the various endogenous loci LTR relative to the activity of pJS21-luc, a reporter plasmid driven by the JSRV₂₁ LTR are shown. The activity of pJS21-luc in each cell line was set at 100 percent. Results shown are the average of 6-12 replicates.

FIG. 11 shows the transactivation of JSRV and *enJSRVs* LTR by HNF-3 α and HNF-3 β . pJS21-luc, penJS56A1-luc, penJS5F16-luc and penJS59A1-luc were co-transfected into NIH-3T3 cells (that do not efficiently support JSRV enhancer activity) along with expression plasmids for either HNF-3 α or β . Different amounts of the transcription factor expression plasmids were co-transfected with a set amount (200ng) of the reporter plasmid DNA. The amounts of luciferase activity for the different co-transfections are shown as fold activation of the reporter plasmid transfected with a plasmid having the CMV promoter but no HNF-3 insert.

DETAILED DESCRIPTION OF THE INVENTION

A novel viral genomic sequence of Jaagsiekte sheep retrovirus (JSRV) has been isolated and characterized herein. Exogenous JSRV sequences are present in the tumor tissues of SPA-affected (or experimentally infected) sheep but not in unaffected animals. Normal sheep have 15 to 20 copies of JSRV-related endogenous retroviruses, some of which are transcriptionally active. The tumor cells from the lungs of SPA-affected sheep are the main sites of JSRV replication, but viral DNA and RNA also can be detected in various lymphoid tissues, where the virus appears to infect a wide variety of lymphoid cell.

SPA strongly resembles human bronchiolo-alveolar carcinoma (BAC); both tumors have the same clinical, macroscopic, histopathologic, and ultrastructural features. BAC has many pathological and epidemiological characteristics that distinguish it from other types of human lung cancer, including adenocarcinoma. The incidence of BAC is rising, and it now represents up to a quarter of primary lung cancers in the United States. Most notably, lung cancer is the main cause of death from cancer in both men and women, but very few animal models are available. The common characteristics between human BAC and SPA suggest that SPA could be a unique experimental model and could offer novel insights into pulmonary carcinogenesis. SPA also is a significant veterinary problem in countries such as the United Kingdom, South Africa, and Spain. The cumulative lifetime risk for developing SPA approaches 25% in high-risk flocks in these countries.

To explore the role of JSRV in the etiology of SPA, and to identify related activities in BAC, the inventors have succeeded in molecularly cloning a JSRV provirus and assessed the infectivity and pathogenicity of this clone *in vivo*. The results established that JSRV is necessary and sufficient for induction of SPA. In addition, the invention provides a culture system for the production of JSRV and recombinant JSRV, as well as vaccines, diagnostics and recombinant vectors using JSRV. SPA represents a unique model for lung cancer, and studies on its aetiopathogenesis can provide further insight into the mechanisms of epithelial neoplasms.

Retroviruses are RNA viruses wherein the viral genome is RNA. When a host cell is infected with a retrovirus, the genomic RNA is reverse transcribed into a DNA intermediate which is integrated efficiently into the chromosomal DNA of infected cells. The integrated DNA intermediate is referred to as a provirus. The family Retroviridae are enveloped single-stranded RNA viruses that typically infect mammals, such as, for example, bovines, monkeys, sheep, and humans, as well as avian species. Retroviruses are unique among RNA viruses in that their multiplication involves the synthesis of a DNA copy of the RNA which is then integrated into the genome of the infected cell.

The Retroviridae family consists of three groups: the spumaviruses (or foamy viruses) such as the human foamy virus (HFV); the lentiviruses, as well as visna virus of sheep; and the oncoviruses (although not all viruses within this group are oncogenic). The term "lentivirus" is used in its conventional sense to describe a genus of viruses containing reverse transcriptase. The lentiviruses include the "immunodeficiency viruses" which include human immunodeficiency virus (HIV) type 1 and type 2 (HIV-1 and HIV-2) and simian immunodeficiency virus (SIV). The oncoviruses are further subdivided into groups A, B, C and D on the basis of particle morphology, as seen under the electron microscope during viral maturation. A-type particles represent the immature particles of the B- and D-type viruses seen in the cytoplasm of infected cells. These particles are not infectious. B-type particles bud as mature virion from the plasma membrane by the enveloping of intracytoplasmic A-type particles. At the membrane they possess a toroidal core of ~75 nm, from which long glycoprotein spikes project. After budding, B-type particles contain an eccentrically located, electron-dense core. The prototype B-type virus is mouse mammary tumor virus (MMTV). No intracytoplasmic particles can be observed in cells infected by C-type viruses. Instead, mature particles bud directly from the cell surface via a crescent "C"-shaped condensation which then closes on itself and is enclosed by the plasma membrane. Envelope glycoprotein spikes may be visible, along with a uniformly electron-dense core. Budding may occur from the surface plasma membrane or directly into intracellular vacuoles. The C-type viruses are the most commonly studied and include many of the avian and murine leukemia viruses (MLV). Bovine leukemia virus (BLV), and the human T-cell leukemia viruses types I

and II (HTLV-I/II) are similarly classified as C-type particles because of the morphology of their budding from the cell surface. However, they also have a regular hexagonal morphology and more complex genome structures than the prototypic C-type viruses such as the murine leukemia viruses (MLV). D-type particles resemble B-type particles in that they show as ring-like structures in the infected cell cytoplasm, which bud from the cell surface, but the virion incorporate short surface glycoprotein spikes. The electron-dense cores are also eccentrically located within the particles. Mason Pfizer monkey virus (MPMV) is the prototype D-type virus.

Retroviruses are defined by the way in which they replicate their genetic material. During replication the RNA is converted into DNA. Following infection of the cell a double- stranded molecule of DNA is generated from the two molecules of RNA which are carried in the viral particle by the molecular process known as reverse transcription. The DNA form becomes covalently integrated in the host cell genome as a provirus, from which viral RNAs are expressed with the aid of cellular and/or viral factors. The expressed viral RNAs are typically packaged into particles and released as infectious virion.

The retrovirus particle is composed of two identical RNA molecules. Each wild-type genome has a positive sense, single-stranded RNA molecule, which is capped at the 5' end and polyadenylated at the 3' tail. The diploid virus particle contains the two RNA strands complexed with gag proteins, viral enzymes (*pol* gene products) and host tRNA molecules within a "core" structure of gag proteins. Surrounding and protecting this capsid is a lipid bilayer, derived from host cell membranes and containing viral envelope (env) proteins. The env proteins bind to a cellular receptor for the virus and the particle typically enters the host cell via receptor-mediated endocytosis and/or membrane fusion.

After the outer envelope is shed, the viral RNA is copied into DNA by reverse transcription. This is catalyzed by the reverse transcriptase enzyme encoded by the *pol* region and uses the host cell tRNA packaged into the virion as a primer for DNA synthesis. In this way the RNA genome is converted into a DNA genome.

The double-stranded linear DNA produced by reverse transcription may, or may not, have to be circularized in the nucleus. The provirus now has two identical repeats at either end, known as the long terminal repeats (LTR). The termini of the two LTR sequences produces the site recognized by a pol product - the integrase protein - which catalyzes integration, such that the provirus is always joined to host DNA two base pairs (bp) from the ends of the LTRs. A duplication of cellular sequences is seen at the ends of both LTRs, reminiscent of the integration pattern of transposable genetic elements. Integration is thought to occur essentially at random within the target cell genome. However, by modifying the long-terminal repeats it is possible to control the integration of a retroviral genome.

Transcription, RNA splicing and translation of the integrated viral DNA is mediated by host cell proteins. Variously spliced transcripts are generated. In the case of the human retroviruses HIV-1/2 and HTLV-I/II viral proteins are also used to regulate gene expression. The interplay between cellular and viral factors is important in the control of virus latency and the temporal sequence in which viral genes are expressed.

Retroviruses can be transmitted horizontally and vertically. Efficient infectious transmission of retroviruses requires the expression on the target cell of receptors which specifically recognize the viral envelope proteins, although viruses may use receptor-independent, nonspecific routes of entry at low efficiency. In addition, the target cell type must be able to support all stages of the replication cycle after virus has bound and penetrated. Vertical transmission occurs when the viral genome becomes integrated in the germ line of the host. The provirus will then be passed from generation to generation as though it were a cellular gene. Hence endogenous proviruses become established which frequently lie latent, but which can become activated when the host is exposed to appropriate agents.

Sequence analysis showed that a JSRV₂₁, isolated as described below, possesses the hallmarks of integrated retroviral proviruses, such as the presence of a CA-TG dinucleotide pair present at the termini of the upstream and downstream viral LTRs, the loss of 2 nucleotides (nt) from the termini of the LTRs during integration,

and an apparent duplication of 6 nt of cellular flanking sequences (TGTGTC (SEQ ID NO:____)) at the integration site. The flanking cellular sequences in the JSRV₂₁ clone were 393 and 1,006 bp long and did not align with known cellular sequences (including proto-oncogenes).

In the early steps of infection, retroviruses deliver their nucleoprotein core into the cytoplasm of the target cell. Here, reverse transcription of the viral genome takes place while the core matures into a preintegration complex. The complex must reach the nucleus to achieve integration of the viral DNA into the host cell chromosomes. For simple retroviruses (oncoretroviruses), this step requires the dissolution of the nuclear membrane at mitotic prophase, most likely because the bulky size of the preintegration complex prevents its passive diffusion through the nuclear pores because there are no nuclear localization signals to facilitate active transport into the nucleus.

A JSRV₂₁ provirus is 7,834 bp long, and the viral genome (R to R) is 7,455 nt. JSRV₂₁ shows the characteristic genomic organization of type D and type B retroviruses, with *pro* in a different open reading frame from *pol* (FIG. 2a). JSRV₂₁ showed homology to JSRV-SA. The homology was 90% in the LTRs (89% in U3), 91% in *gag*, 96% in *pol*, and 91% in *env*. JSRV₂₁ is 7 bp shorter than JSRV-SA and in particular has a 5-bp deletion in U3 with respect to JSRV-SA. One difference between the coding regions of JSRV-SA and JSRV₂₁ was in the *pro* region: the *pro* open reading frame in JSRV₂₁ starts 53 nt downstream from the putative *pro* start in JSRV-SA; in particular, there are two stop codons in JSRV₂₁ at positions 1919 and 1931 that are not present in JSRV-SA. Thus, for JSRV₂₁, the translational frameshift that presumably occurs during synthesis of the gag-pro-pol polyprotein precursor must occur downstream of the stop codon at nt 1932. It is interesting that the *gag* protein sequences for these two viruses have 100% identity in the region shown, so that the differences in the *pro* sequences did not affect the overlapping *gag* gene product. The *orf-x* open reading frame first identified in JSRV-SA was conserved in pJSRV₂₁, suggesting that it plays a functional role. The nucleic acid sequence of JSRV₂₁ has accession number AF105220, which is hereby incorporated by reference in its entirety.

Animal retroviruses have provided great insights into steps in oncogenesis for both animal and human cancers. However, with the notable exception of murine mammary tumor virus, most oncogenic retroviruses typically induce tumors of the hematopoietic system. JSRV is unique among retroviruses in transforming lung epithelial cells (type II pneumocytes and Clara cells). The strong resemblance of human BAC and ovine SPA suggests that studies of JSRV oncogenesis provide new insights into the development of human BAC. SPA is a naturally occurring disease of an outbred animal species and therefore may be a particularly useful animal model for the human disease.

Interestingly, two other JSRV-related retroviruses of small ruminants, enzootic nasal tumor virus of sheep and goats, are associated with tumors of the ethmoid turbinates that arise from secretory epithelial cells. Thus, small-ruminant type D retroviruses as described herein offer novel insight into oncogenic mechanisms in secretory epithelial cells.

Other oncogenic retroviruses exert their pathogenic effects by carrying transforming genes (oncogenes) or by insertionally activating cellular proto-oncogenes. It is noteworthy that JSRV induces lung cancer in sheep quite rapidly: 4 months in these experiments and as quickly as 3 to 4 weeks in previous experiments with uncloned virus. Moreover, the pattern of the tumor cells was more consistent with multifocal disease. A histology of tissue showed the induction of SPA in JSRV₂₁-infected lambs. Lung tumor tissues from JSRV₂₁-infected lambs were fixed in neutral 10% formalin, embedded in paraffin, and sectioned by routine procedures. Hematoxylin and eosin-stains were used in the lung tumor sections. A low-magnification micrograph showed many neoplastic foci in the microscopic field. A high-magnification micrograph (magnification, $\times 372$; bar, 40 μm) of a neoplastic nodule with a clear papillary pattern showed myxoid tissue containing cells with elongated or round nuclei in the interstitium of the neoplastic tissue. A papillary proliferation was also seen occluding the lumen of a bronchiolus. Immunohistochemistry for JSRV CA antigen developed with an avidin-biotin peroxidase complex kit (ABC; Vector Laboratories) and a Carazzi's hematoxylin alone as counterstain showed a neoplastic focus indicative of JSRV CA antigen. No

staining was present in the cells infiltrating the tumor or in adjacent normal cells. A lung section from an uninoculated lamb was tested for JSRV CA antigen under conditions similar to those described above; there were no antigen-positive cells. By analogy to other retrovirus complexes that induce disease rapidly, it initially seemed possible that a defective acute transforming retrovirus carrying a viral oncogene was the cause of the SPA tumors. However, the cloned JSRV₂₁ can induce disease within the same time frame as field isolates. Thus, the oncogenic potential for SPA is contained within the JSRV₂₁ sequences, even though no obvious oncogenes with homology to cellular proto-oncogenes are present. On the other hand, insertional activation of proto-oncogenes is typically associated with multiple rounds of infection, high viral loads, and long incubation periods. Previous results suggest that JSRV oncogenesis may not fit this paradigm either. In animals with spontaneous or experimentally induced SPA, the only cells in which JSRV protein can be detected are the tumor cells themselves. In particular, in these animals, normal lung epithelial cells do not show detectable viral antigen. Also, in experimentally infected animals, viral DNA in circulating blood cells can be detected only by extremely sensitive nested PCR techniques, and there is no evidence for viral expression.

As described herein the JSRV genome carries an alternate open reading frame (orf-x) overlapping pol. This reading frame shows no homologies to any other known gene (viral or cellular). The fact that orf-x is conserved as an open reading frame for both the South African and British isolates of JSRV (JSRV-SA and JSRV₂₁) strongly suggests that it plays a role in viral replication, oncogenesis, or both.

As used herein, the term "isolated" means altered "by the hand of man" from its natural state; *i.e.*, if it occurs in nature, it has been changed or removed from its original environment, or both. For example, a naturally occurring polynucleotide or a polypeptide naturally present in a living animal in its natural state is not "isolated", but the same polynucleotide or polypeptide separated from the coexisting materials of its natural state is "isolated", as the term is employed herein. As part of or following isolation, a polynucleotide can be joined to other polynucleotides, such as for example DNAs, for mutagenesis studies, to form fusion proteins, and for propagation or expression of the polynucleotide in a host. The isolated polynucleotides, alone or joined

to other polynucleotides, such as vectors, can be introduced into host cells, in culture or in whole organisms. Such polynucleotides, when introduced into host cells in culture or in whole organisms, still would be isolated, as the term is used herein, because they would not be in their naturally occurring form or environment. Similarly, the polynucleotides and polypeptides may occur in a composition, such as a media formulation (solutions for introduction of polynucleotides or polypeptides, for example, into cells or compositions or solutions for chemical or enzymatic reactions).

Polynucleotide or nucleic acid sequence refers to a polymeric form of nucleotides. In some instances a polynucleotide refers to a sequence that is not immediately contiguous with either of the coding sequences with which it is immediately contiguous (one on the 5' end and one on the 3' end) in the naturally occurring genome of the organism from which it is derived. The term therefore includes, for example, a recombinant DNA which is incorporated into a vector; into an autonomously replicating plasmid or virus; or into the genomic DNA of a prokaryote or eukaryote, or which exists as a separate molecule (e.g., a cDNA) independent of other sequences. The polynucleotides of the invention can be ribonucleotides, deoxyribonucleotides, or modified forms of either nucleotide. In addition, the polynucleotide sequence involved in producing a polypeptide chain can include regions preceding and following the coding region (leader and trailer) as well as intervening sequences (introns) between individual coding segments (exons) depending upon the source of the polynucleotide sequence.

The term polynucleotide(s) generally refers to any polyribonucleotide or polydeoxyribonucleotide, which may be unmodified RNA or DNA or modified RNA or DNA. Thus, for instance, polynucleotides as used herein refers to, among others, single- and double-stranded DNA, DNA that is a mixture of single- and double-stranded regions, single- and double-stranded RNA, and RNA that is mixture of single- and double-stranded regions, hybrid molecules comprising DNA and RNA that may be single-stranded or, more typically, double-stranded or a mixture of single- and double-stranded regions.

In addition, a polynucleotide as used herein refers to triple-stranded regions comprising RNA or DNA or both RNA and DNA. The strands in such regions may be

from the same molecule or from different molecules. The regions may include all of one or more of the molecules, but more typically involve only a region of some of the molecules. One of the molecules of a triple-helical region often is an oligonucleotide.

In addition, the polynucleotides or nucleic acid sequences may contain one or more modified bases. Thus, DNAs or RNAs with backbones modified for stability or for other reasons are “polynucleotides” as that term is intended herein. Moreover, DNAs or RNAs comprising unusual bases, such as inosine, or modified bases, such as tritylated bases, to name just two examples, are polynucleotides as the term is used herein.

Nucleic acid sequences can be created which encode a fusion protein and can be operatively linked to expression control sequences. “Operatively linked” refers to a juxtaposition wherein the components so described are in a relationship permitting them to function in their intended manner. For example, a coding sequence is “operably linked” to another coding sequence when RNA polymerase will transcribe the two coding sequences into a single mRNA, which is then translated into a single polypeptide having amino acids derived from both coding sequences. The coding sequences need not be contiguous to one another so long as the expressed sequences ultimately process to produce the desired protein. An expression control sequence operatively linked to a coding sequence is ligated such that expression of the coding sequence is achieved under conditions compatible with the expression control sequences. As used herein, the term “expression control sequences” refers to nucleic acid sequences that regulate the expression of a nucleic acid sequence to which it is operatively linked. Expression control sequences are operatively linked to a nucleic acid sequence when the expression control sequences control and regulate the transcription and, as appropriate, translation of the nucleic acid sequence. Thus, expression control sequences can include appropriate promoters, enhancers, ribosomal binding sites, transcription terminators, a start codon (*i.e.*, ATG) in front of a protein-encoding gene, splicing signals for introns, maintenance of the correct reading frame of that gene to permit proper translation of the mRNA, and stop codons. The term “control sequences” is intended to include, at a minimum, components whose presence can influence expression, and can also include additional components whose presence is advantageous, for example, leader sequences and fusion partner sequences. Expression control sequences can include a promoter.

By "promoter" is meant minimal sequence sufficient to direct transcription. Also included in the invention are those promoter elements which are sufficient to render promoter-dependent gene expression controllable for cell-type specific, tissue-specific, or inducible by external signals or agents; such elements may be located in the 5' or 3' regions of the of the polynucleotide sequence. For example, the LTR regions of the JSRV of the present invention have a degree of specificity for pulmonary (e.g., lung) epithelial cells. Both constitutive and inducible promoters, are included in the invention (see e.g., Bitter *et al.*, *Methods in Enzymology* 153:516-544, 1987). For example, when cloning in bacterial systems, inducible promoters such as *pL* of bacteriophage, *plac*, *ptrp*, *ptac* (*ptrp-lac* hybrid promoter) and the like may be used. When cloning in mammalian cell systems, promoters derived from the genome of mammalian cells (e.g., metallothionein promoter) or from mammalian viruses (e.g., the retrovirus long terminal repeat; the adenovirus late promoter; the vaccinia virus 7.5K promoter) may be used. Promoters produced by recombinant DNA or synthetic techniques may also be used to provide for transcription of the nucleic acid sequences of the invention.

As described more fully below, a heterologous nucleic acid sequence or a fragment or portion of the JSRV genome of the invention may be inserted into a recombinant expression vector. A recombinant expression vector generally refers to a plasmid, virus or other vehicle known in the art that has been manipulated by insertion or incorporation of a nucleic acid sequences. For example, a recombinant expression vector of the invention includes the JSRV genomic sequence, or a fragment thereof, containing a heterologous polynucleotide sequence, or a fragment of the JSRV sequence (e.g., and LTR sequence of JSRV) linked to a sequence encoding a polynucleotide of interest in order to provide tissue specific regulation of the sequence of interest. The expression vector typically contains an origin of replication, one or more regulatory sequences, and can also contain specific genes which allow phenotypic selection of a transformed cell. Vectors suitable for use in the invention include, but are not limited to the T7-based expression vector for expression in bacteria (Rosenberg, *et al.*, *Gene* 56:125, 1987), the pMSXND expression vector for expression in mammalian cells (Lee and Nathans, *J. Biol. Chem.* 263:3521, 1988), baculovirus-derived vectors for expression in insect cells, cauliflower mosaic virus, CaMV; tobacco mosaic virus, TMV. The nucleic acid sequences of the invention can also include a localization sequence to

direct the indicator to particular cellular sites by fusion to appropriate organellar targeting signals or localized host proteins. For example, a polynucleotide encoding a localization sequence, or signal sequence, can be used as a repressor and thus can be ligated or fused at the 5' terminus of a polynucleotide encoding a polypeptide of the invention such that the localization or signal peptide is located at the amino terminal end of a resulting polynucleotide/polypeptide. The construction of expression vectors and the expression of genes in transfected cells involves the use of molecular cloning techniques also well known in the art. (See, for example, Sambrook *et al.*, Molecular Cloning --A Laboratory Manual, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, 1989, and Current Protocols in Molecular Biology, M. Ausubel *et al.*, eds., (Current Protocols, a joint venture between Greene Publishing Associates, Inc. and John Wiley & Sons, Inc., most recent Supplement)). These methods include *in vitro* recombinant DNA techniques, synthetic techniques and *in vivo* recombination/genetic recombination. (See also, Maniatis, *et al.*, Molecular Cloning A Laboratory Manual, Cold Spring Harbor Laboratory, N.Y., 1989).

In yeast, a number of vectors containing constitutive or inducible promoters may be used. For a review see, Current Protocols in Molecular Biology, Vol. 2, Ed. Ausubel, *et al.*, Greene Publish. Assoc. & Wiley Interscience, Ch. 13, 1988; Grant, *et al.*, "Expression and Secretion Vectors for Yeast," in Methods in Enzymology, Eds. Wu & Grossman, 1987, Acad. Press, N.Y., Vol. 153, pp.516-544, 1987; Glover, DNA Cloning, Vol. II, IRL Press, Wash., D.C., Ch. 3, 1986; and Bitter, "Heterologous Gene Expression in Yeast," Methods in Enzymology, Eds. Berger & Kimmel, Acad. Press, N.Y., Vol. 152, pp. 673-684, 1987; and The Molecular Biology of the Yeast *Saccharomyces*, Eds. Strathern *et al.*, Cold Spring Harbor Press, Vols. I and II, 1982. A constitutive yeast promoter such as *ADH* or *LEU2* or an inducible promoter such as *GAL* may be used ("Cloning in Yeast," Ch. 3, R. Rothstein In: DNA Cloning Vol.11, A Practical Approach, Ed. DM Glover, IRL Press, Wash., D.C., 1986). Alternatively, vectors may be used which promote integration of foreign DNA sequences into the yeast chromosome.

An alternative expression system which could be used to express a polypeptide (e.g., a polypeptide of JSRV) is an insect system. In one such system, *Autographa californica* nuclear polyhedrosis virus (AcNPV) is used as a vector to express foreign or

mutated polynucleotide sequences. The virus grows in *Spodoptera frugiperda* cells. The sequence encoding a protein of the invention may be cloned into non-essential regions (for example, the polyhedrin gene) of the virus and placed under control of an *AcNPV* promoter (for example the polyhedrin promoter). Successful insertion of the sequences coding for a protein of the invention will result in inactivation of the polyhedrin gene and production of non-occluded recombinant virus (*i.e.*, virus lacking the proteinaceous coat coded for by the polyhedrin gene). These recombinant viruses are then used to infect *S. frugiperda* cells in which the inserted gene is expressed, see Smith, *et al.*, *J. Virol.* **46**:584, 1983; Smith, U.S. Patent No. 4,215,051.

The vectors, including a recombinant JSRV sequence, of the invention can be used to transform a host cell. By transform or transformation is meant a permanent or transient genetic change induced in a cell following incorporation of new DNA (*i.e.*, DNA exogenous to the cell). Where the cell is a mammalian cell, a permanent genetic change is generally achieved by introduction of the DNA into the genome of the cell.

A transformed cell or host cell generally refers to a cell (*e.g.*, prokaryotic or eukaryotic) into which (or into an ancestor of which) has been introduced, by means of recombinant DNA techniques, a DNA molecule encoding a polypeptide of interest or a fragment thereof.

Transformation of a host cell with recombinant DNA may be carried out by conventional techniques as are well known to those skilled in the art. Where the host is prokaryotic, such as *E. coli*, competent cells which are capable of DNA uptake can be prepared from cells harvested after exponential growth phase and subsequently treated by the CaCl₂ method by procedures well known in the art. Alternatively, MgCl₂ or RbCl can be used. Transformation can also be performed after forming a protoplast of the host cell or by electroporation.

When the host is a eukaryote, methods of transfection or transformation with DNA include calcium phosphate co-precipitates, conventional mechanical procedures such as microinjection, electroporation, insertion of a plasmid or vector of the invention contained in liposomes, or virus vectors, as well as others known in the art, may be used. Eukaryotic cells can also be cotransfected with DNA sequences of the invention and a second foreign DNA molecule encoding a selectable marker, such as the herpes simplex

thymidine kinase gene. Another method is to use a eukaryotic viral vector, such as simian virus 40 (SV40) or bovine papilloma virus containing the JSRV sequence or a fragment thereof, to transiently infect or transform eukaryotic cells and express or replicate the sequence. (Eukaryotic Viral Vectors, Cold Spring Harbor Laboratory, Gluzman ed., 1982). Typically, a eukaryotic host will be utilized as the host cell. The eukaryotic cell may be a yeast cell (e.g., *Saccharomyces cerevisiae*), an insect cell (e.g., *Drosophila* sp.) or may be a mammalian cell such as equine, bovine, canine, feline, ovine, and include primate and human cells. Typically the cell will be a mammalian cell derived from the pulmonary system, including the lung, trachea or bronchia (e.g., tracheal or bronchial epithelial cell lines and primary cells).

Eukaryotic systems, and mammalian expression systems, allow for post-translational modifications of expressed mammalian proteins to occur. Eukaryotic cells which possess the cellular machinery for processing of the primary transcript, glycosylation, phosphorylation, and, advantageously secretion of the gene product should be used. Such host cell lines may include, but are not limited to, MLE-15, mtCC1-2, CHO, VERO, BHK, HeLa, COS, MDCK, Jurkat, HEK-293, and WI38.

Mammalian cell systems which utilize recombinant viruses or viral elements to direct expression may be engineered. For example, when using adenovirus expression vectors, a polynucleotide encoding a JSRV polypeptide may be ligated to an adenovirus transcription/ translation control complex, e.g., the late promoter and tripartite leader sequence. This chimeric sequence may then be inserted in the adenovirus genome by *in vitro* or *in vivo* recombination. Insertion in a non-essential region of the viral genome (e.g., region E1 or E3) will result in a recombinant virus that is viable and capable of expressing the polypeptide of interest or a fragment thereof in infected hosts (e.g., see Logan & Shenk, Proc. Natl. Acad. Sci. USA, 81:3655-3659, 1984). Alternatively, the vaccinia virus 7.5K promoter may be used. (e.g., see, Mackett, *et al.*, Proc. Natl. Acad. Sci. USA, 79:7415-7419, 1982; Mackett, *et al.*, J. Virol. 49:857-864, 1984; Panicali, *et al.*, Proc. Natl. Acad. Sci. USA 79:4927-4931, 1982). Of particular interest are vectors based on bovine papilloma virus which have the ability to replicate as extrachromosomal elements (Sarver, *et al.*, Mol. Cell. Biol. 1:486, 1981). Shortly after entry of this DNA into mouse cells, the plasmid replicates to about 100 to 200 copies per cell. Transcription of the inserted cDNA does not require integration of the plasmid into the

host's chromosome, thereby yielding a high level of expression. These vectors can be used for stable expression by including a selectable marker in the plasmid, such as the *neo* gene. Alternatively, the retroviral genome can be modified for use as a vector capable of introducing and directing the expression of a heterologous polynucleotide sequence encoding a therapeutic or non-therapeutic protein in host cells (Cone & Mulligan, Proc. Natl. Acad. Sci. USA, 81:6349-6353, 1984). High level expression may also be achieved using inducible promoters, including, but not limited to, the metallothioneine IIA promoter and heat shock promoters.

For long-term, high-yield production of recombinant proteins, stable expression is preferred. Rather than using expression vectors which contain viral origins of replication, host cells can be transformed with a JSRV polynucleotide or a polynucleotide encoding a JSRV polypeptide controlled by appropriate expression control elements (e.g., promoter, enhancer, sequences, transcription terminators, polyadenylation sites, *etc.*), and a selectable marker. The selectable marker in the recombinant vector confers resistance to the selection and allows cells to stably integrate the plasmid into their chromosomes and grow to form foci which in turn can be cloned and expanded into cell lines. For example, following the introduction of foreign DNA, engineered cells may be allowed to grow for 1-2 days in an enriched media, and then are switched to a selective media. A number of selection systems may be used, including, but not limited to, the herpes simplex virus thymidine kinase (Wigler, *et al.*, Cell, 11:223, 1977), hypoxanthine-guanine phosphoribosyltransferase (Szybalska & Szybalski, Proc. Natl. Acad. Sci. USA, 48:2026, 1962), and adenine phosphoribosyltransferase (Lowy, *et al.*, Cell, 22:817, 1980) genes can be employed in *tk*-, *hgprt*- or *aprt*- cells respectively. Also, anti-metabolite resistance can be used as the basis of selection for dhfr, which confers resistance to methotrexate (Wigler, *et al.*, Proc. Natl. Acad. Sci. USA, 77:3567, 1980; O'Hare, *et al.*, Proc. Natl. Acad. Sci. USA, 8:1527, 1981); *gpt*, which confers resistance to mycophenolic acid (Mulligan & Berg, Proc. Natl. Acad. Sci. USA, 78:2072, 1981; *neo*, which confers resistance to the aminoglycoside G-418 (Colberre-Garapin, *et al.*, J. Mol. Biol. 150:1, 1981); and *hygro*, which confers resistance to hygromycin (Santerre, *et al.*, Gene 30:147, 1984) genes. Recently, additional selectable genes have been described, namely *trpB*, which allows cells to utilize indole in place of tryptophan; *hisD*, which allows cells to utilize histinol in

place of histidine (Hartman & Mulligan, Proc. Natl. Acad. Sci. USA 85:8047, 1988); and ODC (ornithine decarboxylase) which confers resistance to the ornithine decarboxylase inhibitor, 2-(difluoromethyl)-DL-ornithine, DFMO (McConlogue L., In: Current Communications in Molecular Biology, Cold Spring Harbor Laboratory, ed., 1987).

The term "primer" as used herein refers to an oligonucleotide, whether natural or synthetic, which is capable of acting as a point of initiation of synthesis when placed under conditions in which primer extension is initiated or possible. Synthesis of a primer extension product which is complementary to a nucleic acid strand is initiated in the presence of nucleoside triphosphates and a polymerase in an appropriate buffer at a suitable temperature. For instance, if a nucleic acid sequence is inferred from a protein sequence, a primer generated to synthesize nucleic acid sequence encoding the protein sequence is actually a collection of primer oligonucleotides containing sequences representing all possible codon variations based on the degeneracy of the genetic code. One or more of the primers in this collection will be homologous with the end of the target sequence. Likewise, if a "conserved" region shows significant levels of polymorphism in a population, mixtures of primers can be prepared that will amplify adjacent sequences.

A polypeptide or protein refers to a polymer in which the monomers are amino acid residues which are joined together through amide bonds. When the amino acids are alpha-amino acids, either the L-optical isomer or the D-optical isomer can be used, the L-isomers being typical. A polypeptide of the invention includes an amino acid sequence encoded by a JSRV comprised of L- or D- amino acids and include modified sequences such as glycoproteins. Accordingly, the polypeptides of the invention are intended to cover naturally occurring proteins, as well as those which are recombinantly or synthetically synthesized. Polypeptide or protein fragments are also encompassed by the invention. Fragments can have the same or substantially the same amino acid sequence as the naturally occurring protein. A polypeptide or peptide having substantially the same sequence means that an amino acid sequence is largely, but not entirely, the same, but retains a functional activity of the sequence to which it is related. In general polypeptides of the invention include peptides, or full length protein, that contains substitutions, deletions, or insertions into the protein backbone, that would still have an approximately 70%-90% homology to the original protein over the

corresponding portion. A yet greater degree of departure from homology is allowed if like-amino acids, *i.e.* conservative amino acid substitutions, do not count as a change in the sequence

A polypeptide may be substantially related but for a conservative variation, such polypeptides being encompassed by the invention. A conservative variation denotes the replacement of an amino acid residue by another, biologically similar residue. Examples of conservative variations include the substitution of one hydrophobic residue such as isoleucine, valine, leucine or methionine for another, or the substitution of one polar residue for another, such as the substitution of arginine for lysine, glutamic for aspartic acids, or glutamine for asparagine, and the like. Other illustrative examples of conservative substitutions include the changes of: alanine to serine; arginine to lysine; asparagine to glutamine or histidine; aspartate to glutamate; cysteine to serine; glutamine to asparagine; glutamate to aspartate; glycine to proline; histidine to asparagine or glutamine; isoleucine to leucine or valine; leucine to valine or isoleucine; lysine to arginine, glutamine, or glutamate; methionine to leucine or isoleucine; phenylalanine to tyrosine, leucine or methionine; serine to threonine; threonine to serine; tryptophan to tyrosine; tyrosine to tryptophan or phenylalanine; valine to isoleucine to leucine. The term "conservative variation" also includes the use of a substituted amino acid in place of an unsubstituted parent amino acid provided that antibodies raised to the substituted polypeptide also immunoreact with the unsubstituted polypeptide.

Modifications and substitutions are not limited to replacement of amino acids. For a variety of purposes, such as increased stability, solubility, or configuration concerns, one skilled in the art will recognize the need to introduce, (by deletion, replacement, or addition) other modifications. Examples of such other modifications include incorporation of rare amino acids, dextra-amino acids, glycosylation sites, cytosine for specific disulfide bridge formation. The modified peptides can be chemically synthesized, or the isolated gene can be site-directed mutagenized, or a synthetic gene can be synthesized and expressed in bacteria, yeast, baculovirus, tissue culture and so on.

In one embodiment, the invention provides an isolated polynucleotide sequence corresponding to the isolated genome of JSRV. Polynucleotide sequences of the

invention include DNA, cDNA and RNA sequences. It is understood that all polynucleotides encoding all or a portion of a JSRV genome are included herein. Such polynucleotides include naturally occurring, synthetic, and intentionally manipulated polynucleotides. For example, a JSRV polynucleotide of the invention includes the JSRV sequence having accession number AF105220. In addition, a polynucleotide of the invention includes a fragment of the sequence having accession number AF105220 as well as sequences subjected to site-directed mutagenesis. The polynucleotides of the invention include sequences that are degenerate as a result of the genetic code. There are 20 natural amino acids, most of which are specified by more than one codon. Therefore, all degenerate nucleotide sequences are included in the invention so long as a protein encoded by a JSRV genome is functionally unchanged.

In addition, the present invention provides polynucleotide sequence encoding a recombinant JSRV vector of the present invention. The JSRV polynucleotide sequence can be incorporated into various viral particles.

The present invention also provides means for isolating and identifying related viral sequences or polynucleotide from other organisms, including humans. For example, one may probe a gene library with a natural or artificially designed probe using art recognized procedures (see, for example: Current Protocols in Molecular Biology, Ausubel F.M. *et al.* (Eds.) Green Publishing Company Assoc. and John Wiley Interscience, New York, 1989, 1992). It is appreciated by one skilled in the art that probes can be designed based on the degeneracy of the genetic code to a sequences corresponding to a polypeptide or polynucleotide of the invention.

In addition, sequencing algorithms can be used to measure homology or identity between known and unknown sequences. Such methods and algorithms are useful in identifying corresponding sequences present in other organisms. Homology or identity is often measured using sequence analysis software (e.g., Sequence Analysis Software Package of the Genetics Computer Group, University of Wisconsin Biotechnology Center, 1710 University Avenue, Madison, WI 53705). Such software matches similar sequences by assigning degrees of homology to various deletions, substitutions and other modifications. The terms "homology" and "identity" in the context of two or more nucleic acids or polypeptide sequences, refer to two or more sequences or subsequences

that are the same or have a specified percentage of amino acid residues or nucleotides that are the same when compared and aligned for maximum correspondence over a comparison window or designated region as measured using any number of sequence comparison algorithms or by manual alignment and visual inspection.

For sequence comparison, typically one sequence acts as a reference sequence, to which test sequences are compared. When using a sequence comparison algorithm, test and reference sequences are entered into a computer, subsequence coordinates are designated, if necessary, and sequence algorithm program parameters are designated. Default program parameters can be used, or alternative parameters can be designated. The sequence comparison algorithm then calculates the percent sequence identities for the test sequences relative to the reference sequence, based on the program parameters.

A "comparison window", as used herein, includes reference to a segment of any one of the number of contiguous positions selected from the group consisting of from 20 to 600, usually about 50 to about 200, more usually about 100 to about 150 in which a sequence may be compared to a reference sequence of the same number of contiguous positions after the two sequences are optimally aligned. Methods of alignment of sequence for comparison are well-known in the art. Optimal alignment of sequences for comparison can be conducted, *e.g.*, by the local homology algorithm of Smith & Waterman, *Adv. Appl. Math.* **2**:482 (1981), by the homology alignment algorithm of Needleman & Wunsch, *J. Mol. Biol.* **48**:443 (1970), by the search for similarity method of Pearson & Lipman, *Proc. Nat'l. Acad. Sci. USA* **85**:2444 (1988), by computerized implementations of these algorithms (GAP, BESTFIT, FASTA, and TFASTA in the Wisconsin Genetics Software Package, Genetics Computer Group, 575 Science Dr., Madison, WI), or by manual alignment and visual inspection.

One example of a useful algorithm is BLAST and BLAST 2.0 algorithms, which are described in Altschul *et al.*, *Nuc. Acids Res.* **25**:3389-3402 (1977) and Altschul *et al.*, *J. Mol. Biol.* **215**:403-410 (1990), respectively. Software for performing BLAST analyses is publicly available through the National Center for Biotechnology Information (<http://www.ncbi.nlm.nih.gov>). This algorithm involves first identifying high scoring sequence pairs (HSPs) by identifying short words of length W in the query sequence, which either match or satisfy some positive-valued threshold score T when aligned with

a word of the same length in a database sequence. T is referred to as the neighborhood word score threshold (Altschul *et al.*, *supra*). These initial neighborhood word hits act as seeds for initiating searches to find longer HSPs containing them. The word hits are extended in both directions along each sequence for as far as the cumulative alignment score can be increased. Cumulative scores are calculated using, for nucleotide sequences, the parameters M (reward score for a pair of matching residues; always >0). For amino acid sequences, a scoring matrix is used to calculate the cumulative score. Extension of the word hits in each direction are halted when: the cumulative alignment score falls off by the quantity X from its maximum achieved value; the cumulative score goes to zero or below, due to the accumulation of one or more negative-scoring residue alignments; or the end of either sequence is reached. The BLAST algorithm parameters W, T, and X determine the sensitivity and speed of the alignment. The BLASTN program (for nucleotide sequences) uses as defaults a wordlength (W) of 11, an expectation (E) of 10, M=5, N=-4 and a comparison of both strands. For amino acid sequences, the BLASTP program uses as defaults a wordlength of 3, and expectations (E) of 10, and the BLOSUM62 scoring matrix (see Henikoff & Henikoff, Proc. Natl. Acad. Sci. USA 89:10915 (1989)) alignments (B) of 50, expectation (E) of 10, M=5, N=-4, and a comparison of both strands.

The BLAST algorithm also performs a statistical analysis of the similarity between two sequences (see, *e.g.*, Karlin & Altschul, Proc. Natl. Acad. Sci. USA 90:5873 (1993)). One measure of similarity provided by BLAST algorithm is the smallest sum probability (P(N)), which provides an indication of the probability by which a match between two nucleotide or amino acid sequences would occur by chance. For example, a nucleic acid is considered similar to a references sequence if the smallest sum probability in a comparison of the test nucleic acid to the reference nucleic acid is less than about 0.2, more preferably less than about 0.01, and most preferably less than about 0.001.

Other algorithms for determining homology or identity include, for example, in addition to a BLAST program (Basic Local Alignment Search Tool at the National Center for Biological Information), ALIGN, AMAS (Analysis of Multiply Aligned Sequences), AMPS (Protein Multiple Sequence Alignment), ASSET (Aligned Segment Statistical Evaluation Tool), BANDS, BESTSCOR, BIOSCAN (Biological

Sequence Comparative Analysis Node), BLIMPS (BLocks IMProved Searcher), FASTA, Intervals & Points, BMB, CLUSTAL V, CLUSTAL W, CONSENSUS, LCONSENSUS, WCONSENSUS, Smith-Waterman algorithm, DARWIN, Las Vegas algorithm, FNAT (Forced Nucleotide Alignment Tool), Framealign, Framesearch, DYNAMIC, FILTER, FSAP (Fristensky Sequence Analysis Package), GAP (Global Alignment Program), GENAL, GIBBS, GenQuest, ISSC (Sensitive Sequence Comparison), LALIGN (Local Sequence Alignment), LCP (Local Content Program), MACAW (Multiple Alignment Construction & Analysis Workbench), MAP (Multiple Alignment Program), MBLKP, MBLKN, PIMA (Pattern-Induced Multi-sequence Alignment), SAGA (Sequence Alignment by Genetic Algorithm) and WHAT-IF. Such alignment programs can also be used to screen genome databases to identify polynucleotide sequences having substantially identical sequences. A number of genome databases are available, for example, a substantial portion of the human genome is available as part of the Human Genome Sequencing Project (J. Roach, http://weber.u.Washington.edu/~roach/human_genome_progress2.html) (Gibbs, 1995). At least twenty-one other genomes have already been sequenced, including, for example, *M. genitalium* (Fraser *et al.*, 1995), *M. jannaschii* (Bult *et al.*, 1996), *H. influenzae* (Fleischmann *et al.*, 1995), *E. coli* (Blattner *et al.*, 1997), and yeast (*S. cerevisiae*) (Mewes *et al.*, 1997), and *D. melanogaster* (Adams *et al.*, 2000). Significant progress has also been made in sequencing the genomes of model organism, such as mouse, *C. elegans*, *Arabidopsis sp.* and *D. melanogaster*. Several databases containing genomic information annotated with some functional information are maintained by different organization, and are accessible via the internet, for example, <http://www.tigr.org/tdb>; <http://www.genetics.wisc.edu>; <http://genome-www.stanford.edu/~ball>; <http://hiv-web.lanl.gov>; <http://www.ncbi.nlm.nih.gov>; <http://www.ebi.ac.uk>; <http://Pasteur.fr/other/biology>; and <http://www.genome.wi.mit.edu>.

A "substantially pure polypeptide" is typically pure when it is at least 60%, by weight, free from the proteins and naturally-occurring organic molecules with which it is naturally associated. Preferably, the preparation is at least 75%, more preferably at least 90%, and most preferably at least 99%, by weight, the polypeptide of interest. A substantially pure polypeptide includes substantially pure viral particles and may be obtained, for example, by extraction from a natural source (e.g., lung tissue or lung carcinoma tissue); by expression of a recombinant nucleic acid encoding or JSRV

genome; or by chemically synthesizing the protein. Purity can be measured by any appropriate method, *e.g.*, by column chromatography, polyacrylamide gel electrophoresis, or by HPLC analysis.

In addition to polypeptides of the invention, specifically disclosed herein is a DNA sequence for a jaagsiekte sheep retrovirus. DNA sequences of the invention can be obtained by several methods. For example, the DNA can be isolated using hybridization or computer-based techniques which are well known in the art. These include, but are not limited to: 1) hybridization of genomic libraries with probes to detect homologous nucleotide sequences; 2) antibody screening of expression libraries to detect cloned DNA fragments with shared structural features; 3) polymerase chain reaction (PCR) on genomic DNA using primers capable of annealing to the DNA sequence of interest; and 4) computer searches of sequence databases for similar sequences as described above.

The polynucleotide of the invention (*e.g.*, the JSRV polynucleotide sequence) includes complementary polynucleotide sequences, as well as splice variants thereof. When the sequence is RNA, the deoxyribonucleotides A, G, C, and T are replaced by ribonucleotides A, G, C, and U, respectively. Also included in the invention are fragments (portions) of the above-described nucleic acid sequences that are at least 15 bases in length, which is sufficient to permit the fragment to selectively hybridize to DNA that encodes a polypeptide sequence of the invention. "Selective hybridization" as used herein refers to hybridization under moderately stringent or highly stringent physiological conditions (See, for example, the techniques described in Maniatis *et al.*, 1989 Molecular Cloning A Laboratory Manual, Cold Spring Harbor Laboratory, N.Y., incorporated herein by reference), which distinguishes related from unrelated nucleotide sequences.

In nucleic acid hybridization reactions, the conditions used to achieve a particular level of stringency will vary, depending on the nature of the nucleic acids being hybridized. For example, the length, degree of complementarity, nucleotide sequence composition (*e.g.*, GC v. AT content), and nucleic acid type (*e.g.*, RNA v. DNA) of the hybridizing regions of the nucleic acids can be considered in selecting hybridization

conditions. An additional consideration is whether one of the nucleic acids is immobilized, for example, on a filter.

An example of progressively higher stringency conditions is as follows: 2 x SSC/0.1% SDS at about room temperature (hybridization conditions); 0.2 x SSC/0.1% SDS at about room temperature (low stringency conditions); 0.2 x SSC/0.1% SDS at about 42 °C (moderate stringency conditions); and 0.1 x SSC at about 68 °C (high stringency conditions). Washing can be carried out using only one of these conditions, e.g., high stringency conditions, or each of the conditions can be used, e.g., for 10-15 minutes each, in the order listed above, repeating any or all of the steps listed. However, as mentioned above, optimal conditions will vary, depending on the particular hybridization reaction involved, and can be determined empirically.

Oligonucleotides encompassed by the present invention are also useful as primers for nucleic acid amplification reactions. In general, the primers used according to the method of the invention embrace oligonucleotides of sufficient length and appropriate sequence which provides specific initiation of polymerization of a significant number of nucleic acid molecules containing the target nucleic acid under the conditions of stringency for the reaction utilizing the primers. In this manner, it is possible to selectively amplify the specific target nucleic acid sequence containing the nucleic acid of interest.

Amplified products may be detected by Southern blot analysis, without using radioactive probes. In such a process, for example, a small sample of DNA containing a very low level of a nucleotide sequence is amplified and analyzed via a Southern blotting technique known to those of skill in the art. The use of non-radioactive probes or labels is facilitated by the high level of the amplified signal.

Screening procedures which rely on nucleic acid hybridization make it possible to isolate any gene sequence from any organism, provided the appropriate probe is available. For example, it is envisioned that such probes can be used to identify other related or family members of the jaagsiekte sheep retrovirus. In accomplishing this, alignment algorithms (as described above) can be used to screen genome databases. Alternatively, oligonucleotide probes, which correspond to a part of the sequence encoding the protein in question, can be synthesized chemically. This requires that

short, oligopeptide stretches of amino acid sequence must be known. The DNA sequence encoding the protein can be deduced from the genetic code, however, the degeneracy of the code must be taken into account. It is possible to perform a mixed addition reaction when the sequence is degenerate. This includes a heterogeneous mixture of denatured double-stranded DNA. For such screening, hybridization is preferably performed on either single-stranded DNA or denatured double-stranded DNA. Hybridization is particularly useful in the detection of DNA clones derived from sources where an extremely low amount of mRNA sequences relating to the polypeptide of interest are present. In other words, by using stringent hybridization conditions directed to avoid non-specific binding, it is possible, for example, to allow the autoradiographic visualization of a specific cDNA clone by the hybridization of the target DNA to that single probe in the mixture which is its complete complement (Wallace, *et al.*, Nucl. Acid Res., 9:879, 1981).

When the entire sequence of amino acid residues of the desired polypeptide is not known, the direct synthesis of DNA sequences is not possible and the method of choice is use of cDNA sequences. Among the standard procedures for isolating cDNA sequences of interest is the formation of plasmid- or phage-carrying cDNA libraries which are derived from reverse transcription of mRNA which is abundant in donor cells that have a high level of genetic expression. When used in combination with polymerase chain reaction technology, even rare expression products can be cloned.

In the invention, a JSRV polynucleotide sequence may be inserted into a recombinant expression vector. The term "recombinant expression vector" refers to a plasmid, virus or other vehicle known in the art that has been manipulated by insertion or incorporation of a JSRV genetic sequence. Such expression vectors contain a promoter sequence which facilitates the efficient transcription of the inserted genetic sequence of the host. The expression vector typically contains an origin of replication, a promoter, as well as specific genes which allow phenotypic selection of the transformed cells. Vectors suitable for use in the present invention include those described above.

Methods, which are well known to those skilled in the art, can be used to construct expression vectors containing a JSRV polynucleotide or JSRV coding sequence and appropriate transcriptional/translational control signals. These methods

include *in vitro* recombinant DNA techniques, synthetic techniques, and *in vivo* recombination/genetic techniques. (See, for example, the techniques described in Maniatis *et al.*, 1989, Molecular Cloning A Laboratory Manual, Cold Spring Harbor Laboratory, N.Y.).

The genetic construct can be designed to provide additional benefits, such as, for example addition of C-terminal or N-terminal amino acid residues that would facilitate purification by trapping on columns or by use of antibodies. All those methodologies are cumulative. The choice as to the method of producing a particular construct can easily be made by one skilled in the art based on practical considerations: size of the desired peptide, availability and cost of starting materials, *etc.* All the technologies involved are well established and well known in the art. See, for example, Ausubel *et al.*, Current Protocols in Molecular Biology, Volumes 1 and 2 (1987), with supplements, and Maniatis *et al.*, Molecular Cloning, a Laboratory Manual, Cold Spring Harbor Laboratory (1989). Yet other technical references are known and easily accessible to one skilled in the art.

In another embodiment, the invention provides antibodies that bind to a JSRV viral particle (*e.g.*, env polypeptide) of the invention. Such antibodies are useful for research and diagnostics in the study and treatment of transmission of JSRV as well as related diseases (*e.g.*, lung carcinomas), and associated pathologies in general.

Such antibodies may be administered alone or contained in a pharmaceutical composition comprising antibodies against a JSRV polypeptide (*e.g.*, env antigen) and other reagents effective as modulators of the interaction of an JSRV env polypeptide with its ligand both *in vitro* and *in vivo*.

The term "epitope", as used herein, refers to an antigenic determinant on an antigen, such as an env polypeptide, to which the paratope of an antibody, such as an antibody that binds to a JSRV encoded polypeptide (*e.g.*, an env polypeptide) of the invention. Antigenic determinants usually consist of chemically active surface groupings of molecules, such as amino acids or sugar side chains, and can have specific three-dimensional structural characteristics, as well as specific charge characteristics.

Antibodies which bind to a polypeptide of the invention can be prepared using an intact polypeptide or fragments containing small peptides of interest as the immunizing antigen. The polypeptide or a peptide used to immunize an animal can be derived from translated cDNA or chemical synthesis which can be conjugated to a carrier protein, if desired. Such commonly used carriers which are chemically coupled to the peptide include keyhole limpet hemocyanin (KLH), thyroglobulin, bovine serum albumin (BSA), and tetanus toxoid. The coupled peptide is then used to immunize the animal (e.g., a mouse, a rat, or a rabbit).

If desired, polyclonal or monoclonal antibodies can be further purified, for example, by binding to and elution from a matrix to which the polypeptide or a peptide to which the antibodies were raised is bound. Those of skill in the art will know of various techniques common in the immunology arts for purification and/or concentration of polyclonal antibodies, as well as monoclonal antibodies (See for example, Coligan, *et al.*, Unit 9, Current Protocols in Immunology, Wiley Interscience, 1991, incorporated by reference).

It is also possible to use the anti-idiotype technology to produce monoclonal antibodies which mimic an epitope. For example, an anti-idiotypic monoclonal antibody made to a first monoclonal antibody will have a binding domain in the hypervariable region which is the "image" of the epitope bound by the first monoclonal antibody.

Antibodies of the invention include polyclonal antibodies, monoclonal antibodies, and fragments of polyclonal and monoclonal antibodies.

The preparation of polyclonal antibodies is well-known to those skilled in the art. See, for example, Green *et al.*, Production of Polyclonal Antisera, in Immunochemical Protocols (Manson, ed.), pages 1-5 (Humana Press 1992); Coligan *et al.*, Production of Polyclonal Antisera in Rabbits, Rats, Mice and Hamsters, in Current Protocols in Immunology, section 2.4.1 (1992), which are hereby incorporated by reference.

The preparation of monoclonal antibodies likewise is conventional. See, for example, Kohler & Milstein, *Nature*, 256:495 (1975); Coligan *et al.*, sections 2.5.1-2.6.7; and Harlow *et al.*, *Antibodies: A Laboratory Manual*, page 726 (Cold Spring Harbor Pub. 1988), which are hereby incorporated by reference. Briefly, monoclonal antibodies

can be obtained by injecting mice with a composition comprising an antigen, verifying the presence of antibody production by removing a serum sample, removing the spleen to obtain B lymphocytes, fusing the B lymphocytes with myeloma cells to produce hybridomas, cloning the hybridomas, selecting positive clones that produce antibodies to the antigen, and isolating the antibodies from the hybridoma cultures. Monoclonal antibodies can be isolated and purified from hybridoma cultures by a variety of well-established techniques. Such isolation techniques include affinity chromatography with Protein-A Sepharose, size-exclusion chromatography, and ion-exchange chromatography. See, *e.g.*, Coligan *et al.*, sections 2.7.1-2.7.12 and sections 2.9.1-2.9.3; Barnes *et al.*, Purification of Immunoglobulin G (IgG), in *Methods in Molecular Biology*, Vol. 10, pages 79-104 (Humana Press 1992). Methods of *in vitro* and *in vivo* multiplication of monoclonal antibodies is well-known to those skilled in the art. Multiplication *in vitro* may be carried out in suitable culture media such as Dulbecco's Modified Eagle Medium or RPMI 1640 medium, optionally replenished by a mammalian serum such as fetal calf serum or trace elements and growth-sustaining supplements such as normal mouse peritoneal exudate cells, spleen cells, bone marrow macrophages. Production *in vitro* provides relatively pure antibody preparations and allows scale-up to yield large amounts of the desired antibodies. Large scale hybridoma cultivation can be carried out by homogenous suspension culture in an airlift reactor, in a continuous stirrer reactor, or in immobilized or entrapped cell culture. Multiplication *in vivo* may be carried out by injecting cell clones into mammals histocompatible with the parent cells, *e.g.*, syngeneic mice, to cause growth of antibody-producing tumors. Optionally, the animals are primed with a hydrocarbon, especially oils such as pristane tetramethylpentadecane prior to injection. After one to three weeks, the desired monoclonal antibody is recovered from the body fluid of the animal.

Therapeutic applications for antibodies disclosed herein are also part of the present invention. For example, antibodies of the present invention may also be derived from subhuman primate antibody. General techniques for raising therapeutically useful antibodies in baboons can be found, for example, in Goldenberg *et al.*, International Patent Publication WO 91/11465 (1991) and Losman *et al.*, *Int. J. Cancer*, 46:310 (1990), which are hereby incorporated by reference.

Alternatively, an anti-JSRV antibody may be derived from a "humanized" monoclonal antibody. Humanized monoclonal antibodies are produced by transferring mouse complementarity determining regions from heavy and light variable chains of the mouse immunoglobulin into a human variable domain, and then substituting human residues in the framework regions of the murine counterparts. The use of antibody components derived from humanized monoclonal antibodies obviates potential problems associated with the immunogenicity of murine constant regions. General techniques for cloning murine immunoglobulin variable domains are described, for example, by Orlandi *et al.*, Proc. Nat'l Acad. Sci. USA, 86:3833 (1989), which is hereby incorporated in its entirety by reference. Techniques for producing humanized monoclonal antibodies are described, for example, by Jones *et al.*, Nature, 321:522 (1986); Riechmann *et al.*, Nature, 332:323 (1988); Verhoeyen *et al.*, Science, 239:1534 (1988); Carter *et al.*, Proc. Nat'l Acad. Sci. USA, 89:4285 (1992); Sandhu, Crit. Rev. Biotech., 12:437 (1992); and Singer *et al.*, J. Immunol., 150:2844 (1993), which are hereby incorporated by reference.

Antibodies of the invention also may be derived from human antibody fragments isolated from a combinatorial immunoglobulin library. See, for example, Barbas *et al.*, Methods: A Companion to Methods in Enzymology, Vol. 2, page 119 (1991); Winter *et al.*, Ann. Rev. Immunol. 12:433 (1994), which are hereby incorporated by reference. Cloning and expression vectors that are useful for producing a human immunoglobulin phage library can be obtained, for example, from STRATAGENE Cloning Systems (La Jolla, CA).

In addition, antibodies of the present invention may be derived from a human monoclonal antibody. Such antibodies are obtained from transgenic mice that have been "engineered" to produce specific human antibodies in response to antigenic challenge. In this technique, elements of the human heavy and light chain loci are introduced into strains of mice derived from embryonic stem cell lines that contain targeted disruptions of the endogenous heavy and light chain loci. The transgenic mice can synthesize human antibodies specific for human antigens, and the mice can be used to produce human antibody-secreting hybridomas. Methods for obtaining human antibodies from transgenic mice are described by Green *et al.*, Nature Genet., 7:13 (1994); Lonberg *et al.*, Nature, 368:856 (1994); and Taylor *et al.*, Int. Immunol., 6:579 (1994), which are hereby incorporated by reference.

Antibody fragments of the invention can be prepared by proteolytic hydrolysis of the antibody or by expression in *E. coli* of DNA encoding the fragment. Antibody fragments can be obtained by pepsin or papain digestion of whole antibodies by conventional methods. For example, antibody fragments can be produced by enzymatic cleavage of antibodies with pepsin to provide a 5S fragment denoted $F(ab')_2$. This fragment can be further cleaved using a thiol reducing agent, and optionally a blocking group for the sulphydryl groups resulting from cleavage of disulfide linkages, to produce 3.5S Fab' monovalent fragments. Alternatively, an enzymatic cleavage using pepsin produces two monovalent Fab' fragments and an Fc fragment directly. These methods are described, for example, by Goldenberg, U.S. patents No. 4,036,945 and No. 4,331,647, and references contained therein. These patents are hereby incorporated in their entireties by reference. See also Nisonhoff *et al.*, Arch. Biochem. Biophys., 89:230 (1960); Porter, Biochem. J., 73:119 (1959); Edelman *et al.*, Methods in Enzymology, Vol. 1, page 422 (Academic Press 1967); and Coligan *et al.* at sections 2.8.1-2.8.10 and 2.10.1-2.10.4.

Other methods of cleaving antibodies, such as separation of heavy chains to form monovalent light-heavy chain fragments, further cleavage of fragments, or other enzymatic, chemical, or genetic techniques may also be used, so long as the fragments bind to the antigen that is recognized by the intact antibody.

For example, Fv fragments comprise an association of V_H and V_L chains. This association may be noncovalent, as described in Inbar *et al.*, Proc. Nat'l Acad. Sci. USA, 69:2659 (1972). Alternatively, the variable chains can be linked by an intermolecular disulfide bond or cross-linked by chemicals such as glutaraldehyde. See, e.g., Sandhu, *supra*. Preferably, the F_v fragments comprise V_H and V_L chains connected by a peptide linker. These single-chain antigen binding proteins (sFv) are prepared by constructing a structural gene comprising DNA sequences encoding the V_H and V_L domains connected by an oligonucleotide. The structural gene is inserted into an expression vector, which is subsequently introduced into a host cell such as *E. coli*. The recombinant host cells synthesize a single polypeptide chain with a linker peptide bridging the two V domains. Methods for producing sFvs are described, for example, by Whitlow *et al.*, Methods: A Companion to Methods in Enzymology, Vol. 2, page 97 (1991); Bird *et al.*, Science,

242:423 (1988); Ladner *et al.*, U.S. patent No. 4,946,778; Pack *et al.*, *Bio/Technology*, 11:1271 (1993); and Sandhu, *supra*.

Another form of an antibody fragment is a peptide coding for a single complementarity- determining region (CDR). CDR peptides ("minimal recognition units") can be obtained by constructing genes encoding the CDR of an antibody of interest. Such genes are prepared, for example, by using the polymerase chain reaction to synthesize the variable region from RNA of antibody-producing cells. See, for example, Larrick *et al.*, *Methods: A Companion to Methods in Enzymology*, Vol. 2, page 106 (1991).

In one embodiment, the invention provides a method for modulating (e.g., inhibiting) the interaction of a JSRV env polypeptide with its ligand (either *in vitro* or *in vivo*) by administering to a cell or subject an effective amount of a composition which contains an env polypeptide, or biologically functional fragment thereof or an agent (e.g., an antibody, ribozyme, antisense molecule, or double-stranded interfering RNA molecules) that interacts with or inhibits expression of a JSRV polypeptide.

As used herein, an "effective amount" of a composition containing a JSRV - modulating agent is defined as that amount that is effective in modulating normal transduction or interaction of a JSRV in a subject or cell.

In another embodiment, the present invention provides a method for modulating expression of a JSRV polypeptide as well as methods for screening for agents which modulate JSRV gene expression. In this embodiment, a cell or subject is contacted with an agent suspected or known to have JSRV expression modulating activity. The change in JSRV gene expression is then measured as compared to a control or standard sample. The control or standard sample can be the baseline expression of the cell or subject prior to contact with the agent. An agent which modulates JSRV gene expression may be a polynucleotide, for example, the polynucleotide may be an antisense, a triplex agent, a ribozyme, or a double-stranded interfering RNA. For example, an antisense molecule may be directed to the structural gene region or to the promoter region (e.g., the LTR region) of JSRV. The agent may be an agonist, antagonist, peptide, peptidomimetic, antibody, or chemical.

It is envisioned that the invention can be used to treat pathologies associated with JSRV, including cell proliferative disorders, such as lung cancer. Therefore, the present invention encompasses methods for ameliorating a disorder associated with JSRV, including treating a subject having the disorder, at the site of the disorder, with an agent which modulates JSRV expression or its interaction with its ligand resulting in infection. Generally, the terms "treating", "treatment" and the like are used herein to mean affecting a subject, tissue or cell to obtain a desired pharmacologic and/or physiologic effect. The effect may be prophylactic in terms of completely or partially preventing a disease or sign or symptom thereof, and/or may be therapeutic in terms of a partial or complete cure for an infection or disease and/or adverse effect attributable to the infection or disease. "Treating" as used herein covers any treatment of, or prevention of a disease in an invertebrate, a vertebrate, a mammal, particularly a human, and includes: (a) preventing the disorder from occurring in a subject that may be predisposed to the disorder, but has not yet been diagnosed as having it; (b) inhibiting the disorder, *i.e.*, arresting its development; or (c) relieving or ameliorating the disorder, *i.e.*, cause regression of the disorder.

The invention includes various pharmaceutical compositions useful for treating or ameliorating symptoms attributable to a JSRV-associated disorder. The pharmaceutical compositions according to one embodiment of the invention are prepared by bringing an antibody against a JSRV polypeptide (*e.g.*, an env polypeptide), a drug, chemical or combination of chemicals or a JSRV-modulating agent into a form suitable for administration to a subject using carriers, excipients and additives or auxiliaries. Frequently used carriers or auxiliaries include magnesium carbonate, titanium dioxide, lactose, mannitol and other sugars, talc, milk protein, gelatin, starch, vitamins, cellulose and its derivatives, animal and vegetable oils, polyethylene glycols and solvents, such as sterile water, alcohols, glycerol and polyhydric alcohols. Intravenous vehicles include fluid and nutrient replenishers. Preservatives include antimicrobial, anti-oxidants, chelating agents and inert gases. Other pharmaceutically acceptable carriers include aqueous solutions, non-toxic excipients, including salts, preservatives, buffers and the like, as described, for instance, in Remington's Pharmaceutical Sciences, 15th ed. Easton: Mack Publishing Co., 1405-1412, 1461-1487 (1975) and The National Formulary XIV., 14th ed. Washington: American

Pharmaceutical Association (1975), the contents of which are hereby incorporated by reference. The pH and exact concentration of the various components of the pharmaceutical composition are adjusted according to routine skills in the art. See Goodman and Gilman's *The Pharmacological Basis for Therapeutics* (7th ed.).

The pharmaceutical compositions are preferably prepared and administered in dose units. Solid dose units are tablets, capsules and suppositories. For treatment of a subject, depending on activity of the compound, manner of administration, nature and severity of the disorder, age and body weight of the subject, different daily doses are necessary. Under certain circumstances, however, higher or lower daily doses may be appropriate. The administration of the daily dose can be carried out both by single administration in the form of an individual dose unit or else several smaller dose units and also by multiple administration of subdivided doses at specific intervals.

The pharmaceutical compositions according to the invention may be administered locally or systemically in a therapeutically effective dose. Amounts effective for this use will, of course, depend on the severity of the disease and the weight and general state of the subject. Typically, dosages used *in vitro* may provide useful guidance in the amounts useful for *in situ* administration of the pharmaceutical composition, and animal models may be used to determine effective dosages for treatment of particular disorders. Various considerations are described, *e.g.*, in Langer, *Science*, 249:1527, (1990); Gilman *et al.* (eds.) (1990), each of which is herein incorporated by reference.

“Administering” the pharmaceutical composition of the present invention may be accomplished by any means known to the skilled artisan. Preferably a “subject” refers to a mammal, most preferably a human, but may be any organism, including sheep or other domesticated animals.

An anti-JSRV antibody can be administered parenterally, enterically, by injection, rapid infusion, nasopharyngeal absorption, dermal absorption, rectally and orally. Pharmaceutically acceptable carrier preparations for parenteral administration include sterile or aqueous or non-aqueous solutions, suspensions, and emulsions. Examples of non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate. Carriers for

occlusive dressings can be used to increase skin permeability and enhance antigen absorption. Liquid dosage forms for oral administration may generally comprise a liposome solution containing the liquid dosage form. Suitable solid or liquid pharmaceutical preparation forms are, for example, granules, powders, tablets, coated tablets, (micro)capsules, suppositories, syrups, emulsions, suspensions, creams, aerosols, drops or injectable solution in ampule form and also preparations with protracted release of active compounds, in whose preparation excipients and additives and/or auxiliaries such as disintegrants, binders, coating agents, swelling agents, lubricants, flavorings, sweeteners and elixirs containing inert diluents commonly used in the art, such as purified water.

In another embodiment, the invention provides a method for identifying an agent which interacts with or modulates expression or activity of JSRV including incubating components comprising an agent and a cell or culture containing a replication competent JSRV, or a recombinant cell expressing a JSRV viral particle, under conditions sufficient to allow the agent to interact and determining the affect of the agent on the expression, activity, or infectivity of the gene, polypeptide, or JSRV, respectively. The term "affect", as used herein, encompasses any means by which gene expression or protein activity can be modulated, and includes measuring the interaction of the agent with the JSRV by physical means including, for example, fluorescence detection of the binding of a ligand to the receptor. Such agents can include, for example, polypeptides, peptidomimetics, chemical compounds, small molecules and biologic agents as described below.

Incubating includes conditions which allow contact between the test agent and a JSRV polypeptide, a cell expressing JSRV or a JSRV nucleic acid sequence. Contacting includes in solution and in solid phase. The test agent may optionally be a combinatorial library for screening a plurality of agents. Agents identified in the method of the invention can be further evaluated, detected, cloned, sequenced, and the like, either in solution or after binding to a solid support, by any method usually applied to the detection of a specific DNA sequence such as PCR, oligomer restriction (Saiki, *et al.*, *Bio/Technology*, 3:1008-1012, 1985), oligonucleotide ligation assays (OLAs) (Landegren, *et al.*, *Science*, 241:1077, 1988), and the like. Molecular techniques for DNA analysis have been reviewed (Landegren, *et al.*, *Science*, 242:229-237, 1988).

Thus, the method of the invention includes combinatorial chemistry methods for identifying chemical agents that bind to or affect JSRV gene expression or JSRV infectivity.

Areas of investigation are the development of therapeutic treatments. The screening identifies agents that provide modulation of JSRV gene function and/or infectivity in targeted organisms. Of particular interest are screening assays for agents that have a low toxicity or a reduced number of side effects for mammals, such as sheep and humans.

The term "agent" as used herein describes any molecule, *e.g.* protein or pharmaceutical, with the capability of altering or mimicking the physiological function or expression of a JSRV gene or a JSRV polypeptide. Generally, a plurality of assay mixtures are run in parallel with different agent concentrations to obtain a differential response to the various concentrations. Typically, one of these concentrations serves as a negative control, *i.e.* at zero concentration or below the level of detection.

In addition, cells or organisms which have a mutations in a JSRV polypeptide or polynucleotide sequence may be used as models to screen for agents which modulate disorders associated with the mutation.

In a further embodiment, the invention provides a method of detecting a JSRV, a JSRV polypeptide or a JSRV polynucleotide or diagnosing a JSRV-related disorder (*e.g.*, cancer) in a subject including contacting a cell component suspected of containing a JSRV polypeptide or a JSRV polynucleotide with a reagent which binds to the polypeptide or polynucleotide (herein after cell component). The cell component can be or contain a nucleic acid, such as DNA or RNA, or a protein. When the component is nucleic acid, the reagent is a nucleic acid probe or PCR primer. When the cell component is protein, the reagent is an antibody probe. The probes are detectably labeled, for example, with a radioisotope, a fluorescent compound, a bioluminescent compound, a chemiluminescent compound, a metal chelator or an enzyme. Those of ordinary skill in the art will know of other labels suitable for binding to an antibody or nucleic acid probe, or will be able to ascertain such, using routine experimentation. There are many different labels and methods of labeling known to those of ordinary skill in the art. Examples of the types of labels which can be used in the present invention

include enzymes, radioisotopes, colloidal metals, fluorescent compounds, chemiluminescent compounds, and bioluminescent compounds. In addition, the antibodies, polypeptides and polynucleotide sequences of the invention can be used to diagnosis a JSRV-related disorder.

A monoclonal antibody of the invention, directed toward a JSRV polypeptide (e.g., an env polypeptide) is useful for the *in vivo* and *in vitro* detection of antigen. The detectably labeled monoclonal antibody is given in a dose which is diagnostically effective. The term "diagnostically effective" means that the amount of detectably labeled monoclonal antibody is administered in sufficient quantity to enable detection of a JSRV, or a JSRV polypeptide antigen for which the monoclonal antibodies are specific.

The concentration of a detectably labeled monoclonal antibody administered to a subject should be sufficient such that the binding to those cells, body fluid, or tissue having a JSRV polypeptide that is detectable compared to the background. Further, it is desirable that the detectably labeled monoclonal antibody be rapidly cleared from the circulatory system in order to give the best target-to-background signal ratio.

For *in vivo* diagnostic imaging, the type of detection instrument available is a major factor in selecting a given radioisotope. The radioisotope chosen must have a type of decay which is detectable for a given type of instrument. Still another important factor in selecting a radioisotope for *in vivo* diagnosis is that the half-life of the radioisotope be long enough so that it is still detectable at the time of maximum uptake by the target, but short enough so that deleterious radiation with respect to the host is minimized. Ideally, a radioisotope used for *in vivo* imaging will lack a particle emission, but produce a large number of photons in the 140-250 key range, which may be readily detected by conventional gamma cameras.

For *in vivo* diagnosis, radioisotopes may be bound to immunoglobulin either directly or indirectly by using an intermediate functional group. Intermediate functional groups which often are used to bind radioisotopes which exist as metallic ions to immunoglobulins are the bifunctional chelating agents such as diethylenetriaminepentacetic acid (DTPA) and ethylenediaminetetraacetic acid (EDTA)

and similar molecules. Typical examples of metallic ions which can be bound to the monoclonal antibodies of the invention are ^{111}In , ^{97}Ru , ^{67}Ga , ^{68}Ga , ^{72}As , ^{89}Zr , and ^{201}Tl .

The monoclonal antibodies of the invention can also be labeled with a paramagnetic isotope for purposes of *in vivo* diagnosis, as in magnetic resonance imaging (MRI) or electron spin resonance (ESR). In general, any conventional method for visualizing diagnostic imaging can be utilized. Usually gamma and positron emitting radioisotopes are used for camera imaging and paramagnetic isotopes for MRI. Elements which are particularly useful in such techniques include ^{157}Gd , ^{55}Mn , ^{162}Dy , ^{52}Cr , and ^{56}Fe .

In another embodiment, nucleic acid probes can be used to identify a JSRV polynucleotide from a specimen obtained from a subject. Examples of specimens from which nucleic acid sequence encoding a retrovirus of the invention (e.g., JSRV) can be derived include insect, human, primate, swine, porcine, feline, canine, equine, murine, cervine, caprine, lupine, leporidine, opine and bovine species.

Oligonucleotide probes, which correspond to a part of the sequence encoding the protein in question, can be synthesized chemically. This requires that short, oligopeptide stretches of amino acid sequence must be known. The DNA sequence encoding the protein can be deduced from the genetic code, however, the degeneracy of the code must be taken into account. It is possible to perform a mixed addition reaction when the sequence is degenerate. This includes a heterogeneous mixture of denatured double-stranded DNA. For such screening, hybridization is preferably performed on either single-stranded DNA or denatured double-stranded DNA. Hybridization is particularly useful in the detection of cDNA clones derived from sources where an extremely low amount of mRNA sequences relating to the polypeptide of interest are present. In other words, by using stringent hybridization conditions directed to avoid non-specific binding, it is possible, for example, to allow the autoradiographic visualization of a specific cDNA clone by the hybridization of the target DNA to that single probe in the mixture which is its complete complement (Wallace, *et al.*, Nucl. Acid Res. 9:879, 1981).

In an embodiment of the invention, purified nucleic acid fragments containing intervening sequences or oligonucleotide sequences of 10-50 base pairs are radioactively

labeled. The labeled preparations are used to probe nucleic acids from a specimen by the Southern hybridization technique. Nucleotide fragments from a specimen, before or after amplification, are separated into fragments of different molecular masses by gel electrophoresis and transferred to filters that bind nucleic acid. After exposure to the labeled probe, which will hybridize to nucleotide fragments containing target nucleic acid sequences, binding of the radioactive probe to target nucleic acid fragments is identified by autoradiography (see *Genetic Engineering*, 1, ed. Robert Williamson, Academic Press, (1981), 72-81). Alternatively, nucleic acid from the specimen can be bound directly to filters to which the radioactive probe selectively attaches by binding nucleic acids having the sequence of interest. Specific sequences and the degree of binding is quantitated by directly counting the radioactive emissions.

Where the target nucleic acid is not amplified, detection using an appropriate hybridization probe may be performed directly on the separated nucleic acid. In those instances where the target nucleic acid is amplified, detection with the appropriate hybridization probe would be performed after amplification.

For the most part, the probe will be detectably labeled with an atom or inorganic radical, most commonly using radionuclides, but also heavy metals can be used. Conveniently, a radioactive label may be employed. Radioactive labels include ^{32}P , ^{125}I , ^{3}H , ^{14}C , ^{111}In , ^{99}Tc , or the like. Any radioactive label may be employed which provides for an adequate signal and has sufficient half-life. Other labels include ligands, which can serve as a specific binding pair member for a labeled ligand, and the like. A wide variety of labels routinely employed in immunoassays can readily be employed in the present assay. The choice of the label will be governed by the effect of the label on the rate of hybridization and binding of the probe to a nucleotide sequence. It will be necessary that the label provide sufficient sensitivity to detect the amount of a nucleotide sequence available for hybridization.

The manner in which the label is bound to the probe will vary depending upon the nature of the label. For a radioactive label, a wide variety of techniques can be employed. Commonly employed is nick translation with an a ^{32}P -dNTP or terminal phosphate hydrolysis with alkaline phosphatase followed by labeling with radioactive ^{32}P employing ^{32}P -NTP and T4 polynucleotide kinase. Alternatively, nucleotides can be

synthesized where one or more of the elements present are replaced with a radioactive isotope, *e.g.*, hydrogen with tritium. If desired, complementary labeled strands can be used as probes to enhance the concentration of hybridized label.

Standard hybridization techniques for detecting a nucleic acid sequence are known in the art. The particular hybridization technique is not essential to the invention. Other hybridization techniques are described by Gall and Pardue, *Proc. Natl. Acad. Sci.* 63:378, 1969); and John, *et al.*, *Nature*, 223:582, 1969). As improvements are made in hybridization techniques they can readily be applied in the method of the invention.

The amount of labeled probe present in the hybridization solution will vary widely, depending upon the nature of the label, the amount of the labeled probe that can reasonably bind to the filter, and the stringency of the hybridization. Generally, substantial excess over stoichiometric concentrations of the probe will be employed to enhance the rate of binding of the probe to the fixed target nucleic acid.

Currently a number of retroviral vectors used for human gene therapy are replication-defective and must be produced in "packaging cells," which contain integrated wild type virus genome sequences and thus provide all of the structural elements necessary to assemble viruses (*e.g.*, the *gag*, *pol*, and *env* gene products), but cannot encapsidate their own wild type virus genomes due to a deletion of the packaging signal sequence (*psi*). Replication-defective virus vectors created by removal of the viral structural genes and replacement with therapeutic genes are introduced into the packaging cells; so long as these vectors contain the *psi* signal, they can take advantage of the structural proteins provided by the cells and be encapsidated into virion. However, after infection of a target cell, the vectors are incapable of secondary horizontal infections of adjacent cells due to the deletion of the essential viral genes.

Accordingly, in one embodiment of the invention a replication incompetent JSRV vector is provided. The replication incompetent JSRV vector has one or more sequences associated with *gag*, *pol*, or *env* gene products mutated, deleted or otherwise rendered non-functional. In addition, the replication incompetent JSRV can include a heterologous polynucleotide sequence. The heterologous polynucleotide

sequence can encode a protein of interest, a therapeutic protein, a marker or any other sequence commonly used in protein delivery or therapeutic treatments. The heterologous nucleic acid sequence is operably linked to a regulatory nucleic acid sequence. As used herein, the term "heterologous" nucleic acid sequence refers to a sequence that originates from a foreign species, or, if from the same species, it may be substantially modified from its original form. Alternatively, an unchanged nucleic acid sequence that is not normally expressed in a cell is a heterologous nucleic acid sequence. The term "operably linked" refers to functional linkage between the regulatory sequence and the heterologous nucleic acid sequence. Typically, the heterologous sequence is linked to a promoter, resulting in a chimeric gene. The heterologous nucleic acid sequence is preferably under control of either the viral LTR promoter-enhancer signals or of an internal promoter, and retained signals within the retroviral LTR can still bring about efficient integration of the vector into the host cell genome.

In another embodiment, a JSRV packaging system is provided. The packaging system includes a defective JSRV, as described above (e.g., lacking a functional env, pol, gag, or combination thereof), and a host cell containing functional JSRV env, pol, gag or a combination thereof. The JSRV complement sequence present in the packaging cell line allow encapsidation of the defective JSRV into virions. Examples of packaging systems, e.g., lentiviral packaging systems are known in the art. Accordingly, one of skill in the art can modify the packaging systems for use with the JSRV of the invention. In addition, it is contemplated that transient co-transfection of packaging plamsids (e.g., plasmids containing gag, pol, env, or combination thereofs) and vector plasmid into the same cell (e.g., a 293T cell) can be used to propagate a defective JSRV of the invention.

The use of replication-defective vectors has been an important safeguard against the uncontrolled spread of virus, as replication-competent retroviruses have been shown to cause malignancies in primates (Donahue *et al.*, *J. Exp. Med.*, 1992, 176:1124-1135). However, replication-defective retroviral vectors are produced from the packaging cells at titers on the order of only 10^{6-7} colony-forming units (cfu) per ml, which is barely adequate for transduction *in vivo*. In fact, clinical trials for gene

therapy of glioblastoma multiforme, a highly malignant brain tumor, have encountered major problems in achieving adequate levels of tumor cell transduction, and despite promising initial results in animal studies (Culver *et al.*, *Science*, 1992, 256:1550-1552). In order to increase transduction levels as much as possible, instead of using a single shot of virus-containing supernatant, the virus packaging cell line PA317 itself was injected into the brain tumors to constitutively produce retrovirus vectors carrying the HSV-tk gene (Oldfield *et al.*, *Human Gene Therapy*, 1993, 4:39-69). Subsequently, the protocol was further modified to include a debulking procedure followed by multiple injection sites, as it was found that the virus vectors did not diffuse far enough from the site of initial injection. Despite these modifications, the transduction efficiency has been estimated to less than 1% of the tumor cell mass and any significant tumor destruction is presumed to be due to the potent "bystander" effect of the HSV-tk/ganciclovir treatment. Thus efficient transduction of cancer cells in a solid tumor mass represents a major problem for cancer gene therapy.

As mentioned above, the integrated DNA intermediate is referred to as a provirus. Prior gene therapy or gene delivery systems use methods and retroviruses that require transcription of the provirus and assembly into infectious virus while in the presence of an appropriate helper virus or in a cell line containing appropriate sequences enabling encapsidation without coincident production of a contaminating helper virus. It is contemplated, however, that due to the specificity of the JSRV genome and its regulation within specific tissues a helper virus is not required for the production of the recombinant retrovirus of the invention for gene delivery or therapy.

The retroviral genome and the proviral DNA of the present invention have at least the following genes: the gag, the pol, and the env, which are flanked by two long terminal repeat (LTR) sequences containing cis-acting sequences such as *psi*. The *gag* gene encodes the internal structural (matrix, capsid, and nucleocapsid) proteins; the *pol* gene encodes the RNA-directed DNA polymerase (reverse transcriptase), protease and integrase; and the *env* gene encodes viral envelope glycoproteins. The 5' and 3' LTRs serve to promote transcription and polyadenylation of the virion RNAs. The LTR contains all other cis-acting sequences necessary for viral replication.

Adjacent to the 5' LTR are sequences necessary for reverse transcription of the genome (the tRNA primer binding site) and for efficient encapsidation of viral RNA into particles (the *psi* site). If the sequences necessary for encapsidation (or packaging of retroviral RNA into infectious virion) are missing from the viral genome, the result is a *cis* defect which prevents encapsidation of genomic viral RNA. This type of modified vector is what has typically been used in prior gene delivery systems (*i.e.*, systems lacking elements which are required for encapsidation of the virion).

In a first embodiment, the invention provides a recombinant retrovirus capable of infecting a non-dividing cell, a dividing cell, or a cell having a cell proliferative disorder. The recombinant replication competent retrovirus of the present invention comprises a polynucleotide sequence having a viral GAG, a viral POL, a viral ENV, a heterologous polynucleotide and LTRs having sequences (or fragments thereof) as set forth in accession no. AF105220. For example, non-dividing cells of the lung can be infected using a modified JSRV comprising, for example, env and LTR's from JSRV, and additional sequence from lentiviral vectors known in the art.

The heterologous nucleic acid sequence is operably linked to a regulatory nucleic acid sequence. As used herein, the term "heterologous" nucleic acid sequence or "transgene" refers to a sequence that does not normally exist in the wild-type retrovirus or a sequence that originates from a foreign species, or, if from the same species, it may be substantially modified from its original form. Alternatively, an unchanged nucleic acid sequence that is not normally expressed in a cell is a heterologous nucleic acid sequence.

Depending upon the intended use of the retroviral vector of the present invention any number of heterologous polynucleotide or nucleic acid sequences may be inserted into the retroviral vector. For example, for *in vitro* studies commonly used marker genes or reporter genes may be used, including, antibiotic resistance and fluorescent molecules (*e.g.*, GFP). Additional polynucleotide sequences encoding any desired polypeptide sequence may also be inserted into the vector of the present

invention. Where *in vivo* delivery of a heterologous nucleic acid sequence is sought both therapeutic and non-therapeutic sequences may be used. For example, the heterologous sequence can encode a therapeutic molecule including antisense molecules or ribozymes directed to a particular gene associated with a cell proliferative disorder, the heterologous sequence can be a suicide gene (e.g., HSV-tk or PNP), or a therapeutic protein (e.g., Factor IX). Other therapeutic proteins applicable to the present invention are easily identified in the art (see for example, R. Crystal, *Science* 270:404-410 (1995)). Thus, the recombinant virus of the invention is capable of transferring a heterologous sequence or transgene into a target cell.

The term "regulatory nucleic acid sequence" refers collectively to promoter sequences, polyadenylation signals, transcription termination sequences, upstream regulatory domains, origins of replication, internal ribosome entry sites ("IRES"), enhancers, and the like, which collectively provide for the replication, transcription and translation of a coding sequence in a recipient cell. Not all of these control sequences need always be present so long as the selected coding sequence is capable of being replicated, transcribed and translated in an appropriate host cell. One skilled in the art can readily identify regulatory nucleic acid sequence from public databases and materials. Furthermore, one skilled in the art can identify a regulatory sequence that is applicable for the intended use, for example, *in vivo*, *ex vivo*, or *in vitro*.

The heterologous sequence is typically linked to a promoter, resulting in a chimeric gene. The heterologous nucleic acid sequence is preferably under control of either the viral LTR promoter-enhancer signals or of an internal promoter, and retained signals within the retroviral LTR can still bring about efficient integration of the vector into the host cell genome. Accordingly, the recombinant retroviral vectors of the invention, the desired sequences, genes and/or gene fragments can be inserted at several sites and under different regulatory sequences. For example, a site for insertion can be the viral enhancer/promoter proximal site (*i.e.*, 5' LTR-driven gene locus). Alternatively, the desired sequences can be inserted into a regulatory sequence distal to the 5' LTR (*e.g.*, an IRES sequence 3' to the *gag* gene). Other distal sites include viral promoter sequences, where the expression of the desired sequence or

sequences is through splicing of the promoter proximal cistron, an internal heterologous promoter as SV40 or CMV, or an internal ribosome entry site (IRES).

An example of a heterologous polynucleotide sequence which may be used in accordance with the invention include green fluorescent protein (GFP) or a selectable marker gene. Marker genes are utilized to assay for the presence of the vector, and thus, to confirm infection and integration. Typical selection genes encode proteins that confer resistance to antibiotics and other toxic substances, *e.g.*, histidinol, puromycin, hygromycin, neomycin, methotrexate, and other reporter genes known in the art. Other heterologous sequences include, for example, suicide genes, such as PNP and HSV-thymidine kinase, polynucleotide sequences that encode an antisense molecule, or polynucleotides sequences that encode a ribosome.

It can be advantageous to have at one's disposal more efficacious gene therapy vectors capable, in particular, of producing several proteins of interest efficiently. However, the presence of several promoters within the same vector very often manifests itself in a reduction or even a loss of expression over time. This is due to a well-known phenomenon of interference between promoter sequences. In this context, the publication of International Application WO93/03143 proposes a solution to this problem which consists in employing an IRES. It describes a dicistronic retroviral vector for the expression of two genes of interest placed under the control of the same promoter. For example, the presence of a picornavirus IRES site between these genes permits the production of the expression product originating from the second gene of interest by internal initiation of the translation of the dicistronic mRNA (see Morgan *et al.*, Nucleic Acids Research, 20:(6) 1293-1299 (1992)).

Normally, the entry of ribosomes into messenger RNA takes place via the cap located at the 5' end of all eukaryotic mRNAs. However, there are exceptions to this universal rule. The absence of a cap in some viral mRNAs suggests the existence of alternative structures permitting the entry of ribosomes at an internal site of these RNAs. To date, a number of these structures, designated IRES on account of their function, have been identified in the 5' noncoding region of uncapped viral mRNAs, such as that, in particular, of picornaviruses such as the poliomyelitis virus (Pelletier

et al., 1988, Mol. Cell. Biol., 8, 1103-1112) and the EMCV virus (encephalo-myocarditis virus (Jang *et al.*, J. Virol., 1988, 62, 2636-2643).

In another embodiment, a targeting polynucleotide sequence is included as part of the recombinant retroviral vector of the present invention. Preferably, the targeting ligand is operably linked to the env protein of the retrovirus, creating a chimeric retroviral env protein. The viral GAG, viral POL and viral ENV proteins can be derived from any suitable retrovirus (e.g., MLV or lentivirus-derived) (Han *et al.*, Proc Natl Acad Sci USA, 1995, 92(21):9747-51). In another embodiment, the viral ENV protein is non-retrovirus-derived (e.g., CMV or VSV).

The recombinant retrovirus of the invention is to effective for targeting expression in pulmonary tissue or a particular cell pulmonary cell type. In addition, other modification to the JSRV can be made to allow targeting to other cell types, including, for example, smooth muscle cells, hepatic cells, renal cells, fibroblasts, keratinocytes, mesenchymal stem cells, bone marrow cells, chondrocyte, epithelial cells, intestinal cells, neoplastic cells and others known in the art) such that the modified JSRV genome (e.g., modified to contain a heterologous sequence) is delivered to a target non-dividing, a target dividing cell, or a target cell having a cell proliferative disorder.

Targeting can be achieved in two ways. The first way directs the retrovirus to a target cell by preferentially binding to cells having a molecule on the external surface of the cell. This method of targeting the recombinant JSRV utilizes expression of a targeting ligand on the coat of the recombinant JSRV to assist in targeting the virus to cells or tissues that have a receptor or binding molecule which interacts with the targeting ligand on the surface of the retrovirus. After infection of a cell by the virus, the virus injects its nucleic acid into the cell and the retrovirus genetic material can integrate into the host cell genome. The second method for targeting uses cell- or tissue- specific LTR to preferentially promote expression and transcription of the viral genome in a targeted cell which actively utilizes the regulatory elements, as described more fully below. The transferred retrovirus genetic material is then transcribed and translated into proteins within the host cell.

By inserting a heterologous nucleic acid sequence of interest into the viral vector of the invention, along with another gene which encodes, for example, the ligand for a receptor on a specific target cell, the vector is now target specific. Viral vectors can be made target specific by attaching, for example, a sugar, a glycolipid, or a protein (Han *et al.*, Proc Natl Acad Sci USA, 1995, 92(21):9747-51). Targeting can be accomplished by using an antibody to target the viral vector. Those of skill in the art will know of, or can readily ascertain, specific polynucleotide sequences which can be inserted into the viral genome or proteins which can be attached to a viral envelope to allow target specific delivery of the viral vector containing the nucleic acid sequence of interest.

Thus, the present invention, includes in one embodiment, a chimeric env protein comprising a retroviral env protein operably linked to a targeting polypeptide. The targeting polypeptide can be a cell specific receptor molecule, a ligand for a cell specific receptor, an antibody or antibody fragment to a cell specific antigenic epitope or any other ligand easily identified in the art which is capable of binding or interacting with a target cell. Examples of targeting polypeptides or molecules include bivalent antibodies using biotin-streptavidin as linkers (Etienne-Julian *et al.*, J. Of General Virol., 73:3251-3255, 1992); Roux *et al.*, Proc. Natl. Acad. Sci USA 86:9079-9083, 1989), recombinant virus containing in its envelope a sequence encoding a single-chain antibody variable region against a hapten (Russell *et al.*, Nucleic Acids Research, 21:1081-1085, 1993)), cloning of peptide hormone ligands into the retrovirus envelope (Kasahara *et al.*, Science, 266:1373-1376, 1994), chimeric EPO/env constructs (Kasahara *et al.*, 1994), single-chain antibody against the low density lipoprotein (LDL) receptor in the ecotropic MLV envelope, resulting in specific infection of HeLa cells expressing LDL receptor (Somia *et al.*, Proc. Natl. Acad. Sci USA, 92:7570-7574, 1995), and Dornberg and co-workers (Chu and Dornburg, J. Virol 69:2659-2663, 1995) have reported tissue-specific targeting of spleen necrosis virus (SNV), an avian retrovirus, using envelopes containing single-chain antibodies directed against tumor markers.

The invention provides a method of producing a recombinant JSRV capable of infecting a target cell comprising transfecting a suitable host cell with the following: a modified JSRV comprising a polynucleotide sequence encoding a viral gag, a viral - pol and a viral env, a heterologous polynucleotide sequence, operably linked to a regulatory nucleic acid sequence, and recovering the recombinant virus.

Accordingly, the invention provides replication incompetent JSRV vectors and replication competent JSRV vectors that do not require helper virus or additional nucleic acid sequence or proteins in order to propagate and produce virion. For example, the nucleic acid sequences of the JSRV as set forth in accession no. AF105220 encodes, for example, a group specific antigen and reverse transcriptase, (and integrase and protease-enzymes necessary for maturation and reverse transcription), respectively, as discussed above. A JRSV vector contains a gag and pol which can be modified from known gag proteins of other retroviral vectors. In addition, the nucleic acid genome of the JSRV vector of the present invention includes a sequence encoding a viral envelope (ENV) protein. The env gene can be derived from any retroviruses. The env may be an amphotropic envelope protein which allows transduction of cells of human and other species or can be species specific. Further, it may be desirable to target the JSRV vector by linkage of the envelope protein with an antibody or a particular ligand for targeting to a receptor of a particular cell-type. As mentioned above, retroviral vectors can be made target specific by inserting, for example, a glycolipid, or a protein. Targeting is often accomplished by using an antibody to target the retroviral vector to an antigen on a particular cell-type (e.g., a cell type found in a certain tissue, or a cancer cell type). Those of skill in the art will know of, or can readily ascertain without undue experimentation, specific methods to achieve delivery of a retroviral vector to a specific target. Examples of retroviral-derived env genes include, but are not limited to: Moloney murine leukemia virus (MoMuLV), Harvey murine sarcoma virus (HaMuSV), murine mammary tumor virus (MuMTV), gibbon ape leukemia virus (GaLV), human immunodeficiency virus (HIV) and Rous Sarcoma Virus (RSV). Other env genes such as Vesicular stomatitis virus (VSV) (Protein G), cytomegalovirus envelope (CMV), or influenza virus hemagglutinin (HA) can also be used.

In another embodiment, the present invention provides JSRV vectors that are target specific due to LTR tissue specificity. Accordingly, in one embodiment, the present invention provides a JSRV having tissue-specific LTR elements at the 5' and 3' end of the retroviral genome.

The LTRs of JSRV allow for preferential expression in pulmonary tissues and cell types. Accordingly, the JSRV LTR's are capable of driving transcription of a gene in one tissue while remaining largely "silent" in other tissue types. It will be understood, however, that tissue-specific LTRs may have a detectable amount of "background" or "base" activity in those tissues where they are silent. The degree to which a promoter is selectively activated in a target tissue can be expressed as a selectivity ratio (activity in a target tissue/activity in a control tissue). In this regard, a tissue specific LTR useful in the practice of the present invention typically has a selectivity ratio of greater than about 3. Preferably, the selectivity ratio is greater than about 15.

Tissue-specific LTRs or regulatory elements may be derived, for example, from genes or viruses that are differentially expressed in different tissues. For example, a variety of promoters have been identified which are suitable for up regulating expression in cardiac tissue. Included, for example, are the cardiac I-myosin heavy chain (AMHC) promoter and the cardiac I-actin promoter. Other examples of tissue-specific regulatory elements include, tissue-specific promoters, such as milk-specific (whey), pancreatic (insulin or elastase), actin promoter in smooth muscle cells or neuronal (myelin basic protein) promoters. Through the use of promoters, such as milk-specific promoters, recombinant retroviruses may be isolated directly from the biological fluid of the progeny.

In addition, numerous gene therapy methods, that take advantage of retroviral vectors, for treating a wide variety of diseases are well-known in the art (see, e.g., U.S. Pat. Nos. 4,405,712 and 4,650,764; Friedmann, 1989, *Science*, 244:1275-1281; Mulligan, 1993, *Science*, 260:926-932, R. Crystal, 1995, *Science* 270:404-410, each of which are incorporated herein by reference in their entirety). An increasing number

of these methods are currently being applied in human clinical trials (Morgan, R., 1993, BioPharm, 6(1):32-35; see also, The Development of Human Gene Therapy, Theodore Friedmann, Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 1999. ISBN 0-87969-528-5, which is incorporated herein by reference in its entirety). The safety of these currently available gene therapy protocols can be substantially increased by using JSRV vectors of the present invention. For example, where the retroviral vector infects a non-targeted cell (e.g., a non-pulmonary cell type), the retroviral genome will integrate but will not be transcribed. However, when the retroviral vector containing a tissue specific LTR or regulatory element infects a targeted cell the active tissue specific promoter will result in transcription and translation of the viral genome.

The phrase "non-dividing" cell refers to a cell that does not go through mitosis. Non-dividing cells may be blocked at any point in the cell cycle, (e.g., G0/G1, G1/S, G2/M), as long as the cell is not actively dividing. For *ex vivo* infection, a dividing cell can be treated to block cell division by standard techniques used by those of skill in the art, including, irradiation, aphidocolin treatment, serum starvation, and contact inhibition. However, it should be understood that *ex vivo* infection is often performed without blocking the cells since many cells are already arrested (e.g., stem cells). For example, a recombinant JSRV vector of the invention is capable of infecting a non-dividing cell, regardless of the mechanism used to block cell division or the point in the cell cycle at which the cell is blocked. Examples of pre-existing non-dividing cells in the body include neuronal, muscle, liver, certain epithelial cells (e.g., skin), heart, lung, and bone marrow cells, and their derivatives.

By "dividing" cell is meant a cell that undergoes active mitosis, or meiosis. Such dividing cells include stem cells, skin cells (e.g., fibroblasts and keratinocytes), gametes, and other dividing cells known in the art. Of particular interest and encompassed by the term dividing cell are cells having cell proliferative disorders, such as neoplastic cells. The term "cell proliferative disorder" refers to a condition characterized by an abnormal number of cells. The condition can include both hypertrophic (the continual multiplication of cells resulting in an overgrowth of a cell population within a tissue) and hypotrophic (a lack or deficiency of cells within a

tissue) cell growth or an excessive influx or migration of cells into an area of a body. The cell populations are not necessarily transformed, tumorigenic or malignant cells, but can include normal cells as well. Cell proliferative disorders include disorders associated with an overgrowth of connective tissues, such as various fibrotic conditions, including scleroderma, arthritis and liver cirrhosis. Cell proliferative disorders include neoplastic disorders such as head and neck carcinomas. Head and neck carcinomas would include, for example, carcinoma of the mouth, esophagus, throat, larynx, thyroid gland, tongue, lips, salivary glands, nose, paranasal sinuses, nasopharynx, superior nasal vault and sinus tumors, esthesioneuroblastoma, squamous cell cancer, malignant melanoma, sinonasal undifferentiated carcinoma (SNUC) or blood neoplasia. Also included are carcinoma's of the regional lymph nodes including cervical lymph nodes, prelaryngeal lymph nodes, pulmonary juxtaesophageal lymph nodes and submandibular lymph nodes (Harrison's Principles of Internal Medicine (eds., Isselbacher, *et al.*, McGraw-Hill, Inc., 13th Edition, pp1850-1853, 1994). Other cancer types, include, but are not limited to, lung cancer, colon-rectum cancer, breast cancer, prostate cancer, urinary tract cancer, uterine cancer lymphoma, oral cancer, pancreatic cancer, leukemia, melanoma, stomach cancer and ovarian cancer.

The present invention also provides gene therapy for the treatment of cell proliferative disorders. Such therapy would achieve its therapeutic effect by introduction of an appropriate therapeutic polynucleotide sequence (e.g., antisense, ribozymes, suicide genes), into cells of subject having the proliferative disorder. Delivery of polynucleotide constructs can be achieved using the recombinant retroviral vector of the present invention.

In addition, the therapeutic methods (e.g., the gene therapy or gene delivery methods) as described herein can be performed *in vivo* or *ex vivo*. It may be preferable to remove the majority of a tumor prior to gene therapy, for example surgically or by radiation.

Thus, the invention provides a recombinant retrovirus capable of infecting a non-dividing cell, a dividing cell or a neoplastic cell comprising a JSRV GAG; POL;

ENV; a heterologous nucleic acid sequence operably linked to a regulatory nucleic acid sequence; and cis-acting nucleic acid sequences necessary for packaging, reverse transcription and integration.

The invention also provides a method of nucleic acid transfer to a target cell to provide expression of a particular nucleic acid sequence (e.g., a heterologous sequence). Therefore, in another embodiment, the invention provides a method for introduction and expression of a heterologous nucleic acid sequence in a target cell comprising infecting the target cell with a recombinant JSRV vector containing a heterologous sequence and expressing the heterologous nucleic acid sequence in the target cell. As mentioned above, the target cell can be any cell type including dividing, non-dividing, neoplastic, immortalized, modified and other cell types recognized by those of skill in the art, so long as they are capable of infection by a retrovirus. Simply measuring expression of a detectable marker after contacting the cell with a recombinant JSRV of the invention is sufficient to ascertain infectivity. An example of a detectable marker is GFP. Examples of therapeutic heterologous sequence include sequence which modify the expression of chloride channels that are defective in cystic fibrosis by providing replacement sequence or sequence which modify or inhibit expression of the defective sequences (e.g., antisense sequences).

It may be desirable to modulate the expression of a gene in a cell by the introduction of a nucleic acid sequence (e.g., the heterologous nucleic acid sequence) by the method of the invention, wherein the nucleic acid sequence give rise, for example, to an antisense or ribozyme molecule. The term "modulate" envisions the suppression of expression of a gene when it is over-expressed, or augmentation of expression when it is under-expressed. Where a cell proliferative disorder is associated with the expression of a gene, nucleic acid sequences that interfere with the gene's expression at the translational level can be used. This approach utilizes, for example, antisense nucleic acid, ribozymes, or triplex agents to block transcription or translation of a specific mRNA, either by masking that mRNA with an antisense nucleic acid or triplex agent, or by cleaving it with a ribozyme.

Antisense nucleic acids are DNA or RNA molecules that are complementary to at least a portion of a specific mRNA molecule (Weintraub, *Scientific American*, 262:40, 1990). In the cell, the antisense nucleic acids hybridize to the corresponding mRNA, forming a double-stranded molecule. The antisense nucleic acids interfere with the translation of the mRNA, since the cell will not translate a mRNA that is double-stranded. Antisense oligomers of about 15 nucleotides are preferred, since they are easily synthesized and are less likely to cause problems than larger molecules when introduced into the target cell. The use of antisense methods to inhibit the *in vitro* translation of genes is well known in the art (Marcus-Sakura, *Anal.Biochem.*, 172:289, 1988).

The antisense nucleic acid can be used to block expression of a mutant protein or a dominantly active gene product, such as amyloid precursor protein that accumulates in Alzheimer's disease. Such methods are also useful for the treatment of Huntington's disease, hereditary Parkinsonism, and other diseases. Of particular interest are the blocking of genes associated with cell-proliferative disorders. Antisense nucleic acids are also useful for the inhibition of expression of proteins associated with toxicity.

Use of an oligonucleotide to stall transcription is known as the triplex strategy since the oligomer winds around double-helical DNA, forming a three-strand helix. Therefore, these triplex compounds can be designed to recognize a unique site on a chosen gene (Maher, *et al.*, *Antisense Res. and Dev.*, 1(3):227, 1991; Helene, C., *Anticancer Drug Design*, 6(6):569, 1991).

Ribozymes are RNA molecules possessing the ability to specifically cleave other single-stranded RNA in a manner analogous to DNA restriction endonucleases. Through the modification of nucleotide sequences which encode these RNAs, it is possible to engineer molecules that recognize specific nucleotide sequences in an RNA molecule and cleave it (Cech, *J.Amer.Med. Assn.*, 260:3030, 1988). A major advantage of this approach is that, because they are sequence-specific, only mRNAs with particular sequences are inactivated.

It may be desirable to transfer a nucleic acid encoding a biological response modifier. Included in this category are immunopotentiating agents including nucleic acids encoding a number of the cytokines classified as "interleukins". These include, for example, interleukins 1 through 12. Also included in this category, although not necessarily working according to the same mechanisms, are interferons, and in particular gamma interferon (γ -IFN), tumor necrosis factor (TNF) and granulocyte-macrophage-colony stimulating factor (GM-CSF). Other polypeptides include, for example, angiogenic factors and anti-angiogenic factors. It may be desirable to deliver such nucleic acids to bone marrow cells or macrophages to treat enzymatic deficiencies or immune defects. Nucleic acids encoding growth factors, toxic peptides, ligands, receptors, or other physiologically important proteins can also be introduced into specific target cells.

For diseases due to deficiency of a protein product, gene transfer could introduce a normal gene into the affected tissues for replacement therapy, as well as to create animal models for the disease using antisense mutations. For example, it may be desirable to insert a factor which requires oxygen or ambient air for activation such that it is expressed preferentially in the pulmonary tissue using the JSRV vector of the invention.

The present invention also provides gene therapy for the treatment of cell proliferative or immunologic disorders. Such therapy would achieve its therapeutic effect by introduction of an antisense or dominant negative encoding polynucleotide into cells having the proliferative disorder, wherein the polynucleotide binds to and prevents translation or expression of a gene associated with a cell-proliferative disorder. Delivery of heterologous nucleic acids useful in treating or modulating a cell proliferative disorder (e.g., antisense polynucleotides) can be achieved using a JSRV vector of the present invention.

In another embodiment, the invention provides a method of treating a subject having a cell proliferative disorder. The subject can be any mammal, and is preferably a human. The subject is contacted with a recombinant replication competent or incompetent JSRV vector of the present invention. The contacting can

be *in vivo* or *ex vivo*. Methods of administering the JSRV vector of the invention are known in the art and include, for example, systemic administration, topical administration, intraperitoneal administration, intra-muscular administration, as well as administration directly at the site of a tumor or cell-proliferative disorder and other routes of administration known in the art.

Thus, the invention includes various pharmaceutical compositions useful for treating a cell proliferative disorder, preferably a pulmonary proliferative disorder. The pharmaceutical compositions according to the invention are prepared by bringing a JSRV vector containing a heterologous polynucleotide sequence useful in treating or modulating a cell proliferative disorder according to the present invention into a form suitable for administration to a subject using carriers, excipients and additives or auxiliaries. Frequently used carriers or auxiliaries include magnesium carbonate, titanium dioxide, lactose, mannitol and other sugars, talc, milk protein, gelatin, starch, vitamins, cellulose and its derivatives, animal and vegetable oils, polyethylene glycols and solvents, such as sterile water, alcohols, glycerol and polyhydric alcohols. Intravenous vehicles include fluid and nutrient replenishers. Preservatives include antimicrobial, anti-oxidants, chelating agents and inert gases. Other pharmaceutically acceptable carriers include aqueous solutions, non-toxic excipients, including salts, preservatives, buffers and the like, as described, for instance, in Remington's Pharmaceutical Sciences, 15th ed. Easton: Mack Publishing Co., 1405-1412, 1461-1487 (1975) and The National Formulary XIV., 14th ed. Washington: American Pharmaceutical Association (1975), the contents of which are hereby incorporated by reference. The pH and exact concentration of the various components of the pharmaceutical composition are adjusted according to routine skills in the art. See Goodman and Gilman's The Pharmacological Basis for Therapeutics (7th ed.).

In some instances it may be advantageous to deliver and express a JSRV sequence of the invention locally (*e.g.*, within a particular tissue or cell type). For example, local expression of JSRV in certain lung tissues of an animal. The nucleic sequence may be directly delivered to the tissue and cells, for example. Such delivery methods are known in the art and include electroporation, viral vectors and direct DNA uptake.

For example, one type of nucleic acid delivery vehicle comprises liposomal transfection vesicles, including both anionic and cationic liposomal constructs. The use of anionic liposomes requires that the nucleic acids be entrapped within the liposome. Cationic liposomes do not require nucleic acid entrapment and instead may be formed by simple mixing of the nucleic acids and liposomes. The cationic liposomes avidly bind to the negatively charged nucleic acid molecules, including both DNA and RNA, to yield complexes which give reasonable transfection efficiency in many cell types. See, Farhood *et al.* (1992) *Biochem. Biophys. Acta.* 1111:239-246, the disclosure of which is incorporated herein by reference. A particularly preferred material for forming liposomal vesicles is lipofectin which is composed of an equimolar mixture of dioleylphosphatidyl ethanolamine (DOPE) and dioleyloxypropyl-triethylammonium (DOTMA), as described in Felgner and Ringold (1989) *Nature* 337:387-388, the disclosure of which is incorporated herein by reference.

It is also possible to combine delivery systems. For example, Kahn *et al.* (1992), *supra.*, teaches that a retroviral vector may be combined in a cationic DEAE-dextran vesicle to further enhance transformation efficiency. It is also possible to incorporate nuclear proteins into viral and/or liposomal delivery vesicles to even further improve transfection efficiencies. See, Kaneda *et al.* (1989) *Science* 243:375-378, the disclosure of which is incorporated herein by reference.

Another targeted delivery system for polynucleotides is a colloidal dispersion system. Colloidal dispersion systems include macromolecule complexes, nanocapsules, microspheres, beads, and lipid-based systems including oil-in-water emulsions, micelles, mixed micelles, and liposomes. The preferred colloidal system of this invention is a liposome. Liposomes are artificial membrane vesicles which are useful as delivery vehicles *in vitro* and *in vivo*. It has been shown that large unilamellar vesicles (LUV), which range in size from 0.2-4.0 μm can encapsulate a substantial percentage of an aqueous buffer containing large macromolecules. RNA, DNA and intact virions can be encapsulated within the aqueous interior and be delivered to cells in a biologically active form (Fraley, *et al.*, *Trends Biochem. Sci.*, 6:77, 1981). In addition to mammalian cells,

liposomes have been used for delivery of polynucleotides in plant, yeast and bacterial cells. In order for a liposome to be an efficient gene transfer vehicle, the following characteristics should be present: (1) encapsulation of the genes of interest at high efficiency while not compromising their biological activity; (2) preferential and substantial binding to a target cell in comparison to non-target cells; (3) delivery of the aqueous contents of the vesicle to the target cell cytoplasm at high efficiency; and (4) accurate and effective expression of genetic information (Mannino, *et al.*, *Biotechniques*, 6:682, 1988).

The composition of the liposome is usually a combination of phospholipids, particularly high-phase-transition-temperature phospholipids, usually in combination with steroids, especially cholesterol. Other phospholipids or other lipids may also be used. The physical characteristics of liposomes depend on pH, ionic strength, and the presence of divalent cations.

Examples of lipids useful in liposome production include phosphatidyl compounds, such as phosphatidylglycerol, phosphatidylcholine, phosphatidylserine, phosphatidylethanolamine, sphingolipids, cerebrosides, and gangliosides. Particularly useful are diacylphosphatidyl-glycerols, where the lipid moiety contains from 14-18 carbon atoms, particularly from 16-18 carbon atoms, and is saturated. Illustrative phospholipids include egg phosphatidylcholine, dipalmitoylphosphatidylcholine and distearoylphosphatidylcholine.

The targeting of liposomes has been classified based on anatomical and mechanistic factors. Anatomical classification is based on the level of selectivity, for example, organ-specific, cell-specific, and organelle-specific. Mechanistic targeting can be distinguished based upon whether it is passive or active. Passive targeting utilizes the natural tendency of liposomes to distribute to cells of the reticulo-endothelial system (RES) in organs which contain sinusoidal capillaries. Active targeting, on the other hand, involves alteration of the liposome by coupling the liposome to a specific ligand such as a monoclonal antibody, sugar, glycolipid, or protein, or by changing the composition or size of the liposome in order to achieve targeting to organs and cell types other than the naturally occurring sites of localization.

The surface of the targeted delivery system may be modified in a variety of ways. In the case of a liposomal targeted delivery system, lipid groups can be incorporated into the lipid bilayer of the liposome in order to maintain the targeting ligand in stable association with the liposomal bilayer. Various linking groups can be used for joining the lipid chains to the targeting ligand. In general, the compounds bound to the surface of the targeted delivery system will be ligands and receptors which will allow the targeted delivery system to find and "home in" on the desired cells. A ligand may be any compound of interest which will bind to another compound, such as a receptor.

The agents useful in the method of the invention can be administered, for *in vivo* application, parenterally by injection or by gradual perfusion over time. Administration may be intravenously, intraperitoneally, intramuscularly, subcutaneously, intracavity, or transdermally. For *in vitro* studies the agents may be added or dissolved in an appropriate biologically acceptable buffer and added to a cell or tissue.

Preparations for parenteral administration include sterile aqueous or non-aqueous solutions, suspensions, and emulsions. Examples of non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate. Aqueous carriers include water, alcoholic/aqueous solutions, emulsions or suspensions, including saline and buffered media. Parenteral vehicles include sodium chloride solution, Ringer's dextrose, dextrose and sodium chloride, lactated Ringer's intravenous vehicles include fluid and nutrient replenishers, electrolyte replenishers (such as those based on Ringer's dextrose), and the like. Preservatives and other additives may also be present such as, for example, antimicrobials, anti-oxidants, chelating agents and inert gases and the like.

In one embodiment, the invention provides a pharmaceutical composition useful for inducing an immune response to a JSRV or related retrovirus in an animal comprising an immunologically effective amount of a JSRV or JSRV antigen (e.g., env protein) in a pharmaceutically acceptable carrier. The term "immunogenically effective amount," as used in describing the invention, is meant to denote that amount of antigen which is necessary to induce in an animal the production of an immune response to a JSRV or JSRV antigen. Env protein(s) are particularly useful in

sensitizing the immune system of an animal such that, as one result, an immune response is produced which ameliorates the effect of an infection by a JSRV or related viral particle.

The JSRV or JSRV antigen (e.g. env protein) can be administered parenterally by injection, rapid infusion, nasopharyngeal absorption, dermal absorption, and orally. Pharmaceutically acceptable carrier preparations for parenteral administration include sterile or aqueous or non-aqueous solutions, suspensions, and emulsions. Examples of non-aqueous solvents are propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable organic esters such as ethyl oleate. Carriers for occlusive dressings can be used to increase skin permeability and enhance antigen absorption. Liquid dosage forms for oral administration may generally comprise a liposome solution containing the liquid dosage form. Suitable forms for suspending the liposomes include emulsions, suspensions, solutions, syrups, and elixirs containing inert diluents commonly used in the art, such as purified water. Besides the inert diluents, such compositions can also include adjuvants, wetting agents, emulsifying and suspending agents, and sweetening, flavoring, and perfuming agents.

It is also possible for the antigenic preparations containing the JSRV or JSRV protein of the invention to include an adjuvant. Adjuvants are substances that can be used to nonspecifically augment a specific immune response. Normally, the adjuvant and the antigen are mixed prior to presentation to the immune system, or presented separately, but into the same site of the animal being immunized. Adjuvants can be loosely divided into several groups based on their composition. These groups include oil adjuvants (for example, Freund's Complete and Incomplete), mineral salts (for example, $AlK(SO_4)_2$, $AlNa(SO_4)_2$, $AlNH_4(SO_4)_2$, silica, alum, $Al(OH)_3$, $Ca_3(PO_4)_2$, kaolin, and carbon), polynucleotides (for example, poly IC and poly AU acids), and certain natural substances (for example, wax D from *Mycobacterium tuberculosis*, as well as substances found in *Corynebacterium parvum*, *Bordetella pertussis*, and members of the genus *Brucella*).

In another embodiment, a method of inducing an immune response to an infectious JSRV in an animal is provided. Many different techniques exist for the

timing of the immunizations when a multiple immunization regimen is utilized. It is possible to use the antigenic preparation of the invention more than once to increase the levels and diversity of expression of the immune response of the immunized animal. Typically, if multiple immunizations are given, they will be spaced two to four weeks apart. Subjects in which an immune response to JSRV or a related retrovirus is desirable include sheep, swine, cattle and humans.

Generally, the dosage of JSRV or a JSRV protein administered to an animal will vary depending on such factors as age, condition, sex and extent of disease, if any, and other variables which can be adjusted by one of ordinary skill in the art.

The antigenic preparations of the invention can be administered as either single or multiple dosages and can vary from about 10 ug to about 1,000 ug for the antigen per dose, more preferably from about 50 ug to about 700 ug antigen per dose, most preferably from about 50 ug to about 300 ug antigen per dose.

It should be understood, that JSRV is typically administered in an inactive form in order to induce the immune response. Inactive forms of JSRV can include heat inactivated forms, as well as recombinant forms that lack the ability to replicate without a helper cell system, as described herein.

The following Examples are intended to illustrate, but not to limit the invention. While such Examples are typical of those that might be used, other procedures known to those skilled in the art may alternatively be utilized.

EXAMPLES

EXAMPLE 1

ISOLATION AND CLONING OF JSRV

Molecular cloning. Molecular cloning of JSRV proviral DNA was carried out using standard molecular biology and cloning techniques. The strategy is shown in Fig. 1. High-molecular-weight genomic DNA was isolated from a lung tumor collected from an adult sheep with naturally acquired SPA. The genomic DNA was digested to completion with *Xba*I (an enzyme believed not to cut within JSRV DNA

on the basis of the York *et al.* sequence), ligated to *Xba*I-digested Dash II phage vector (Stratagene), and packaged into phage particles by using Gigapack III gold-packaging extracts (Stratagene). The resulting phage library (750,000 PFU) was divided into 15 sublibraries, and each sublibrary was independently amplified. DNA was extracted from an aliquot of each sublibrary and subjected to PCR for JSRV provirus by using a JSRV U3-specific hemi-nested PCR (U3 hn-PCR) to discriminate between exogenous JSRV and endogenous JSRV-related proviruses. Of the 15 sublibraries, 3 were positive for exogenous JSRV sequences. The positive sublibraries also were tested for the presence of exogenous JSRV by PCR amplification of a portion of the *gag* region followed by digestion of the PCR product with *Sca*I. The *gag Sca*I site is a molecular marker for exogenous JSRV. Sublibrary 2 was then plated onto bacterial agar plates and subjected to hybridization of plaque lifts with two ³²P-labelled probes on replica filters: a JSRV long terminal repeat (LTR)-specific probe and a *gag*-specific probe. Under the hybridization conditions used, these probes hybridized with both endogenous and exogenous JSRV sequences. Primary plaques positive for both LTR and *gag* probes were picked, and DNA was extracted from a portion and screened for the presence of exogenous JSRV sequences by U3 hn-PCR. Exogenous JSRV-positive primary plaque picks were further purified by dilution and plating for isolated plaques on bacterial lawns, followed by hybridization with both LTR and *env* probes. A recombinant phage carrying a seemingly full-length JSRV provirus was subcloned into pBluescript (Stratagene) to give pJSRV₂₁. Both strands of p JSRV₂₁ were completely sequenced with an automated liquid fluorescence sequencer.

Isolation of JSRV₂₁. As described above, an integrated copy of JSRV provirus from DNA isolated from an animal with a spontaneous case of SPA was obtained. A lambda phage library from a lung tumor of an animal with SPA was screened by combining classical plaque hybridizations involving JSRV DNA probes with sib selection procedures. The sib selection involved PCR amplifications that could distinguish exogenous JSRV from multicopy endogenous JSRV-related sequences present in the sheep genome. This combination of techniques was useful because the available JSRV hybridization probes cross-hybridized with the endogenous JSRV-related sequences. The cloning strategy resulted in the isolation of a full-length

exogenous JSRV proviral clone (JSRV₂₁). The insert from this clone was subcloned into a plasmid to give p JSRV₂₁. The nucleotide sequence of JSRV₂₁ has been deposited in GenBank under accession no. AF105220.

Plasmid pCMV2JS₂₁ was generated by replacing the U3 region in the upstream LTR of pJSRV21 with the human cytomegalovirus (CMV) immediate-early promoter by methods known in the art (Sambrook, J., E. F. Fritsch, and T. Maniatis. 1989. *Molecular cloning: a laboratory manual*, 2nd ed. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y.). The CMV promoter was obtained by PCR amplification from the pCDNA3 plasmid (Invitrogen) with primers CMVNotIf (AAAGGGTTGCGGCCGATGTAC GGGCCAGATATAC (SEQ ID NO:____)) and CMV-r2 (CAGAGAGCTCTGC TTATATAGACCTCCCAC (SEQ ID NO:____)) and the Pfu Turbo polymerase (Stratagene) under PCR conditions as suggested by the manufacturer. The resulting PCR product was cut with *NotI* and then ligated to an amplified portion of JSRV₂₁ spanning position 13 in the U3 to +618 in gag. This portion of JSRV₂₁, which includes R, U5, and the beginning of gag, was amplified by PCR with primers JS21-R (GCATTGTAATAAAGCAGAGTATCAGCC (SEQ ID NO:____)) and JS21663-r (GGAACCAAGGGCAAACCTCCTCAATAATGAA (SEQ ID NO:____)) and the Pfu Turbo polymerase as above. The ligation reaction mixture was reamplified by PCR with primers CMVNotIf and JS21663-r, and the resulting product was digested with *NotI* and *PacI* and inserted into *NotI*-*PacI*-digested JSRV₂₁ to give pCMV2JS₂₁ (FIG. 2).

Sequence analysis showed that JSRV₂₁ possesses the hallmarks of integrated retroviral proviruses, such as the presence of a CA-TG dinucleotide pair present at the termini of the upstream and downstream viral LTRs, the loss of 2 nucleotides (nt) from the termini of the LTRs during integration, and an apparent duplication of 6 nt of cellular flanking sequences (TGTGTC (SEQ ID NO:____)) at the integration site. The flanking cellular sequences in the JSRV21 clone were 393 and 1,006 bp long and did not align with known cellular sequences (including proto-oncogenes).

JSRV₂₁ provirus is 7,834 bp long, and the viral genome (R to R) is 7,455 nt. JSRV₂₁ shows the characteristic genomic organization of type D and type B retroviruses, with pro in a different open reading frame from pol (Fig. 2a). These results were consistent with the genomic organization of JSRV deduced by York *et al.* for JSRV-SA. JSRV₂₁ showed overall 93% homology to JSRV-SA. The homology was 90% in the LTRs (89% in U3), 91% in *gag*, 96% in *pol*, and 91% in *env*. JSRV₂₁ is 7 bp shorter than JSRV-SA and in particular has a 5-bp deletion in U3 with respect to JSRV-SA. One difference between the suspected coding region of JSRV-SA and JSRV₂₁ was in the *pro* region: the *pro* open reading frame in JSRV₂₁ starts 53 nt downstream from the putative *pro* start in JSRV-SA; in particular, there are two stop codons in JSRV₂₁ at positions 1919 and 1931 that are not present in JSRV-SA. Thus, for JSRV₂₁, the 1 translational frameshift that presumably occurs during synthesis of the *gag*-*pro*-*pol* polyprotein precursor must occur downstream of the stop codon at nt 1932. The *gag* protein sequences for these two viruses have 100% identity in the region shown, so that the differences in the *pro* sequences did not affect the overlapping *gag* gene product. The *orf-x* open reading frame first identified in JSRV-SA was conserved in pJSRV21, suggesting that it plays a functional role.

The presence of the *Scal* site at position 1726 in *gag* and the nucleotide sequence of the U3 indicated that JSRV₂₁ has the molecular markers of an exogenous JSRV and that it was not an endogenous JSRV-related provirus.

In vitro transfections. 293T cells were grown in Dulbecco minimum essential medium supplemented with 10% fetal bovine serum in 10-cm tissue culture dishes at 37°C under 5% CO₂. The cells were transfected with 45 µg of pCMV2JS₂₁ DNA by using the CalPhos mammalian transfection kit (Clonetech) as recommended by the manufacturer. Medium was replaced after 12 to 16 h with 5 ml of fresh medium. The medium was then harvested at 24, 48, and 72 h after the first medium change. The medium was filtered through a 0.45-µm-pore-size filter, and virus was pelleted by ultracentrifugation through a double layer of glycerol (25 and 50%, vol/vol) at 100,000 × g for 1 h at 4°C. The viral pellet was resuspended in TNE buffer (100 mM NaCl, 10 mM Tris, 1 mM EDTA) at a 300-fold-higher concentration with respect to the initial supernatant and stored at -140°C until further use.

Western blotting. Western blotting was performed on 15- μ l aliquots of concentrated JSRV₂₁ particles obtained from 293T cells transiently transfected with pCMV2JS₂₁. A rabbit antiserum to JSRV major capsid protein (CA) was used essentially as described previously (Palmarini *et al.* 1995. *J. Gen. Virol.* **76**:2731-2737; Sharp and Herring. 1983. *J. Gen. Virol.* **64**:2323-2327), except that an enhanced chemiluminescence detection system (Supersignal; Pierce) was used as recommended by the manufacturer. Concentrated lung fluid collected from an animal with a natural case of SPA was prepared as described previously (Palmarini *et al.* 1995. *J. Gen. Virol.* **76**:2731-2737; Sharp and Herring. 1983. *J. Gen. Virol.* **64**:2323-2327) and used as a positive control.

In vivo DNA transfections. All the lambs used in this study were obtained from a maedi-visna virus-free flock raised at the Moredun Research Institute. Three newborn lambs were inoculated intratracheally with pJSRV₂₁ DNA complexed with a cationic lipid (GL-67) formulated with the neutral colipid DOPE in a molar ratio of 1:2. GL-67-DOPE was prepared as described in Lee *et al.* 1996. *Hum. Gene Ther.* **7**:1701-1717. For each transfected animal, a total of 1 mg of pJSRV₂₁ DNA was complexed with GL-67-DOPE at the suggested molar ratio and diluted to a final volume of 5 ml with distilled water. Five animals kept in the high-security unit were used as uninoculated controls.

Peripheral blood mononuclear cells (PBMCs) were collected from transfected or control lambs at various times postinoculation (Table 1) and stored at -70°C. Two inoculated lambs and two uninoculated controls were killed 38 weeks postinoculation, and samples of lungs, mediastinal lymph nodes, spleens, and kidneys were collected. The tissues were split into two portions: the first portion was snap-frozen in liquid nitrogen and stored at -70°C for subsequent isolation of nucleic acids; the remainder was fixed in 10% neutral buffered formalin, processed routinely in an automatic tissue processor, embedded in paraffin wax, and sectioned into 4- to 6- μ m-thick slices. Genomic DNA was prepared as described above.

PCR analysis. The presence of JSRV proviral DNA in PBMCs and tissues collected from the *in vivo*-transfected animals and from uninoculated control animals

was investigated by the use of a JSRV U3 hn-PCR as described in Palmarini *et al.* 1996. *J. Gen. Virol.* **77**:2991-2998, except that for each sample, five 500-ng replicates of DNA were used (2.5 µg in total) and the samples were considered positive when one or more PCR replicate was positive. In each PCR assay, 5 to 10 500-ng replicates of calf thymus DNA were subjected to JSRV-specific U3 hn-PCR as additional negative controls.

***In vivo* infections.** Four newborn lambs were inoculated intratracheally with 1 ml each of concentrated supernatant collected from 293T cells transiently transfected with pCMV2JS₂₁. The inoculum was diluted in phosphate-buffered saline (5 ml (final volume)) immediately before use. Two lambs were inoculated with phosphate-buffered saline alone and were kept as uninoculated controls. All the lambs were killed 4 months postinoculation, and tissues were treated as for the *in vivo*-transfected animals.

Assays for exogenous JSRV provirus in lungs and lung tumors of inoculated and control animals included exogenous virus-specific PCR in the U3 region of the LTR and testing for an exogenous virus-specific ScaI site in an LTR-gag hn-PCR product.

Histologic examination and immunohistochemistry. Lung sections (4 to 6 µm thick) were stained with hematoxylin and eosin and examined by light microscopy for tumor lesions. Sections were also examined for the presence of JSRV major capsid protein by immunohistochemistry as described in Palmarini *et al.* 1995. *J. Gen. Virol.* **76**:2731-2737, except that an antigen retrieval step was included by microwaving the sections at 800 W twice for 7 min. SPA tumor tissue was used as a positive control.

***In vivo* DNA transfection of pJSRV₂₁.** To test the infectivity of the JSRV₂₁ provirus, *in vivo* DNA transfection was performed in sheep. Three newborn black-face lambs were inoculated intratracheally with pJSRV₂₁ DNA complexed with a cationic lipid (GL-67-DOPE) that favors transfection of lung cells. PBMCs were collected at various times postinoculation (2 to 22 weeks), and the presence of JSRV provirus and transcripts was assessed by U3 hn-PCR (Table 1). All three lambs showed detectable JSRV sequences at various times postinoculation. The levels of

JSRV DNA in PBMCs from inoculated lambs were low, as judged by the fraction of replicate PCR products that scored positive. However, they were similar to the levels of JSRV DNA detected in PBMCs from lambs experimentally inoculated with concentrated SPA lung fluid. These results indicated that pJSRV₂₁ contained an infectious JSRV provirus. On the other hand, when two inoculated animals were sacrificed at 9 months postinfection, no SPA lesions were observed in the lungs by macroscopic or histologic examinations. JSRV antigens were not detected by immunohistochemistry for JSRV CA antigen in the lungs of the inoculated animals; only the highly sensitive U3 hn-PCR allowed the detection of JSRV provirus in the lungs of one inoculated animal and in the mediastinal lymph nodes and PBMCs of another (Table 1). As controls, PBMCs from five uninoculated control animals were tested by U3 hn-PCR, and they were always negative (none of five replicates were positive for each animal). In addition, two uninoculated animals were sacrificed and lung, mediastinal lymph node, spleen, and kidney samples were tested by U3 hn-PCR; they were also negative. In each PCR assay, 5 to 10 500-ng replicates of calf thymus DNA were subjected to JSRV-specific U3 hn-PCR as additional negative controls, and they were always negative.

TABLE 1. JSRV U3 hn-PCR on samples from *in vivo*-transfected lambs
Presence of JSRV provirus^a:

<u>Lamb</u>	<u>Antemortem^b</u>			<u>Postmortem^c in:</u>			
	<u>6wk</u>	<u>12wk</u>	<u>22wk</u>	<u>PBMC</u>	<u>Lungs</u>	<u>MLN^d</u>	<u>Spleen</u>
<u>Kidney</u>							
71	4/5	1/5	1/5	ND ^e	ND	ND	ND
73	4/5	1/5	1/5	0/5	5/5	0/5	0/5
74	5/5	4/5	1/5	0/5	0/5	1/5	0/5

^a Number of positive reactions/total number of replicate reactions on 500 ng of DNA.

^b Weeks postinfection. PBMC were used for these experiments.

^c Animals were sacrificed for postmortem analysis at 38 weeks postinfection.

^d MLN, mediastinal lymph nodes.

^c ND, not done.

Synthesis of JSRV particles *in vitro*. Because no *in vitro* culture systems were available for JSRV, attempts were made to recover virus particles by direct transfection of a derivative of pJSRV₂₁ containing a simian virus 40 origin of replication into highly transfectable human 293T cells. This did not result in the production of detectable virus in the culture supernatants. It seemed possible that the JSRV LTR was not active in 293T cells, and so the U3 region of the upstream LTR in pJSRV₂₁ was replaced with the human CMV immediate-early promoter, which is highly active in these cells (Fig. 2b). The CMV promoter was positioned so that the resulting RNA transcript would be very similar to wild-type JSRV RNA. When the resulting plasmid (pCMV2JS₂₁) was transfected into 293T cells, substantial amounts of JSRV₂₁ virus were released into the supernatant. Western blot analysis for JSRV CA protein indicated that the amount of virions produced from transfected 293T cells was comparable to that present in lung fluid from SPA-affected sheep. Moreover, the fact that the supernatants from transfected 293T cells showed CA protein of the mature (cleaved) size strongly suggested that normal virion morphogenesis and polyprotein cleavage (presumably mediated by functional JSRV protease) took place. Enzymatically active RT could also be detected in the 293T cell supernatants by standard exogenous assays.

Analysis of JSRV₂₁ buoyant density. Approximately 700 μ l of concentrated JSRV₂₁ particles was analyzed by isopycnic centrifugation on a linear 25 to 60% (wt/wt) continuous sucrose gradient in an SW41 rotor (Beckman) at 25,000 rpm for 16 h at 4°C. Fractions of approximately 450 μ l were collected, and their density was determined by refractometry. Consecutive fractions were pooled two at a time and diluted with 10 ml of TNE buffer, and virus was recovered by centrifugation in an SW41 rotor at 35,000 rpm for 1 h at 4°C. Viral pellets were resuspended in 20 μ l of TNE buffer and used in a conventional exogenous RT assay with poly(rA)-oligo(dT). For analysis of viral cores, 700 μ l of concentrated JSRV was treated with a final concentration of 0.1% (vol/vol) Triton X-100 for 8 min at room temperature prior to density gradient analysis.

Supernatants from pCMV2JS₂₁-transfected 293T cells were analyzed by isopycnic centrifugation in sucrose density gradients. Supernatants from transfected cells contained RT activity that could be measured by an exogenous RT assay with poly(rA)-oligo(dT) as the template primer. RT assays across the sucrose gradient indicated a peak of RT activity with a buoyant density of approximately 1.15 g/ml (Fig. 3a). This was consistent with the buoyant density of retroviruses in general, although it was slightly lower than that reported for JSRV (1.16 to 1.18 g/ml) when the virus was isolated directly from the lung secretions of SPA-affected animals. Treatment of the 293T supernatants with 0.1% Triton X-100 prior to centrifugation shifted the RT peak to 1.218 to 1.238 g/ml, consistent with the release of viral cores (Fig. 3b) and suggesting that complete viral particles had been synthesized. Supernatants from mock-transfected 293T cells showed no RT activity.

Experimental induction of SPA. Four newborn black-face lambs were inoculated intratracheally with concentrated JSRV₂₁ stocks obtained from transfected 293T cells. At 4 months postinoculation, one of the animals showed clinical signs of respiratory distress suggestive of SPA. All four animals were sacrificed at this time.

At necropsy, the lungs of the clinically affected lamb showed gross pathological changes typical of SPA. They were both considerably enlarged and heavier than normal due to extensive lesions in the dependent areas of the cranial, medial, and caudal lobes. The lesions had a reddish translucent appearance and were well demarcated from the unaffected dorsal areas of the lungs, although some isolated small foci were scattered throughout the lungs. At the margins of the lesions, small reddish white nodules, approximately 3 to 5 mm in diameter, were observed. Transverse sections of the affected areas were clearly consolidated, and a moderate amount of clear, foamy fluid exuded from the cut surface and airways, as seen in naturally occurring and experimentally transmitted SPA. A few small foci with similar features also were observed in the caudal lobes of a second lamb. Histologic examination revealed the presence of multifocal neoplastic foci in both of these animals. Lesions comprised many small intra-alveolar and bronchiolar papilliform proliferations of cuboidal or prismatic epithelial cells. Some of these neoplastic nodules had an interstitial myxoid or fibrotic appearance. Alveoli adjacent to tumor

nodules contained a small number of alveolar macrophages. The above lesions were consistent with previously described features of SPA. To test if the tumors expressed JSRV protein, immunohistochemistry with an antiserum raised against JSRV CA protein was carried out. The tumor cells showed readily detectable staining for JSRV CA protein (reddish brown stain), while the surrounding normal tissue was negative for viral protein. As expected, two uninoculated control lambs showed no signs of disease, and at necropsy their lungs showed no signs of macroscopic or histologic SPA lesions, as well as no immunoreactive material.

To further test if the tumors in the JSRV₂₁-inoculated lambs resulted from exogenous viral infection, tumor tissue DNA was tested from the infected animals for the presence of exogenous JSRV₂₁ DNA sequences. PCR was carried out with primers from the U3 region of the LTR that are specific for exogenous JSRV. Lung tissues from both of the infected lambs with SPA lesions and from one of the infected animals that did not show SPA were positive for exogenous JSRV LTR sequences. As expected, no exogenous JSRV sequences were amplified from lung DNA from the uninoculated controls. To further confirm the presence of exogenous JSRV sequences in tumor DNA, an exogenous JSRV-specific *Scal*I site present in the *gag* region was measured by performing hn-PCR that favors amplification of exogenous JSRV sequences on tissue DNAs followed by digestion of the PCR product with *Scal*I. DNA from the tumor tissues of both lambs that developed SPA showed evidence of exogenous JSRV, as indicated by the appearance of more rapidly migrating *Scal*I cleavage products in the gel. These results indicated that both tumors induced by JSRV₂₁ infection contained exogenous JSRV sequences from the LTR and *gag* regions. This further supported the conclusion that JSRV₂₁ induced the SPA lesions in the infected animals.

It should be emphasized that the infectious JSRV₂₁ was obtained by transient transfection of pCMV2JS₂₁ plasmid DNA into human 293T cells. While the virus obtained by this technique is infectious and should be identical to that obtained from infected ovine tumor tissues (since the RNA transcribed in the transfected 293T cells is identical to genomic JSRV₂₁ RNA), there was an additional advantage. It has been shown that uninfected sheep cells carry several copies of highly related endogenous

JSRV DNA but that human DNA does not contain cross-hybridizing sequences. Thus, the potential for recombination between the exogenous JSRV₂₁ genome and ovine endogenous JSRV-related viruses during generation of JSRV₂₁ virus stocks was eliminated. Moreover, the fact that the virus was obtained by a transient transfection further minimized the likelihood of any low-level genetic interaction between the JSRV₂₁ genome and potential distantly related (nonhybridizing) endogenous viruses of humans.

Another area of interest is the strict association of JSRV expression with cells of the lungs. *In vivo*, JSRV infects several cell types, but viral antigens can be detected in great abundance only in the epithelial tumor cells of the lungs. To investigate whether the JSRV LTR contains enhancers specific for the cells in which the tumor originates (type II pneumocytes, Clara cells, and/or a common precursor) the experiments below were performed.

EXAMPLE 2
THE LONG TERMINAL REPEATS OF JAAGSIEKTE SHEEP
RETROVIRUS (JSRV) ARE PREFERENTIALLY ACTIVATED IN TYPE II
PNEUMOCYTES

Cell cultures. The cell lines used in this study, tissue, cells and animal species from which they originate and the source, reference or ATCC catalog number are listed in Table 2. Cells were grown at 37°C with 5% CO₂. MLE-15 cell line (provided by J. Whitsett), MLE-12, JS-7 and primary fetal lamb lung (FLL) cells were grown in RPMI 1640 (Gibco BRL), 2% fetal bovine serum (FBS), 0.5 % insulin-transferrin-sodium selenite (ITS) (Sigma) modified with the addition of 5mg/l transferrin, 10 mM Hepes, 1X10⁻⁸ M β-estradiol and 1X10⁻⁸ M Hydrocortisone. 293T cell line, OAT, CP-MRI, OA1, mtCC1-2 (provided by Dr. F. DeMayo), IC-21 and 3T3 were grown in DMEM (ATCC) and 10% FBS. IC-21 and ABI-2 were grown in RPMI 1640 (Gibco BRL) and 10% FBS. FOP, ST3, CP-ATCC, C2C12 and TCMK cell line were grown in DMEM (ATCC), 1X non-essential aminoacids (Cellgro) and 10% FBS. F9 cell line was grown in DMEM (ATCC), 7X10⁻⁶ M mercaptoethanol, 1X non-essential aminoacids and 10% FBS. BV2 and A549 cell lines were grown in F-12K (Gibco, BRL) and 10% FBS. H441 and H358 cell lines were grown in RPMI

1640 (Gibco BRL) adjusted to contain 1.5 g/l sodium bicarbonate, 4.5 g/l glucose and 10 mM Hepes with 10%FBS.

Table 2. Cell lines

Cell Lines	Species of origin	Tissue/cell type	ATCC #/ Reference
A549	Human	Lung carcinoma	CCL-185
H441	Human	Bronchioloalveolar carcinoma	HTB-174
H358	Human	Bronchioloalveolar carcinoma	CRL-5807
293T	Human	Embryonic Kidney	Lebrowsky <i>et al.</i>
OA1	Sheep	Brain fibroblasts	CRL-6538
OAT	Sheep	Sheep testis	CRL-6546
FLL	Sheep	Primary fetal lamb	MRI*
JS7	Sheep	Bronchioloalveolar carcinoma	Jassim
CP-MRI	Sheep	Choroid plexus	MRI*
CP-ATCC	Sheep	Choroid plexus	CRL-1700
MtCC1-2	Mouse	Clara cells	Magdaleno <i>et al.</i>
BV2	Mouse	Microglia	Tenner A*
F9	Mouse	Testicular carcinoma	CRL-1720
FOP	Mouse	Mammary carcinoma	
IC-21	Mouse	Peritoneal macrophages	TIB-186
MHS	Mouse	Alveolar macrophages	CRL-2019
C2C12	Mouse	Myoblasts	CRL-1772
ABI-2	Mouse	Hybridoma	HB-33
MLE-12	Mouse	Lung epithelial	CRL-2110
TCMK	Mouse	Mouse Kidney	CCL-139
3T3	Mouse	Mouse embryo	CCL-92
MLE-15	Mouse	Type II pneumocytes	Wikenheiser <i>et al.</i>
ST3	Mouse	Thymus stroma	Brightman <i>et al.</i>

Oligonucleotides. For the electrophoretic mobility shift assays (EMSA) the following double stranded oligonucleotide probe were used: JS₂₁wt(-267/-247) (TGC~~GGGGG~~ACGAC CCGTGAA (SEQ ID NO:____)) and JS₂₁mt(-267/-247) (TGC~~GGG~~TTACGACCCGTGAA (SEQ ID NO:____)); mutated nucleotides are shown in bold). JS₂₁wt(-266/-247) corresponds to position -266 to -247 of the U3 of JSRV₂₁ and includes an NF- κ B-like binding site (underlined). JS₂₁mt(-266/-247) has three nucleotides changes (in bold) with respect to JS₂₁wt(-267/-247) to alter the NF- κ B-like site. Oligonucleotide probes for the consensus sequence of NF- κ B were purchased from Geneka as positive controls.

Plasmids. Plasmids pGL3-control, pGL3-promoter and pGL3-basic where purchased from Promega. pGL3-control expresses the firefly luciferase gene (*luc*) under the control of the SV40 promoter and enhancer regions; pGL3-promoter expresses the *luc* gene under an SV40 promoter while pGL3-basic is devoided of eukaryotic promoter and enhancer regions. Plasmid pMLV-luc was obtained by inserting the whole LTR of Moloney-murine leukemia virus (M-MuLV) into pGL3-basic by PCR-based cloning techniques. PCRs were performed using the *Pfu-Turbo* polymerase (Stratagene) as recommended by the manufacturers. The LTR of M-MLV was amplified from plasmid p63.2. Plasmid pCMV-luc was derived by inserting the *HindIII-BamHI* fragment of pGL3-basic containing the *luc* gene and the poly(A) signal into pCDNA3.1 (Invitrogen).

The LTR of JSRV₂₁ were amplified from pJSRV₂₁ and inserted into the *MluI* and *BglII* site of pGL3-basic. The resulting plasmid was called pJS21-luc. The derivatives of pJS21-luc described below were all cloned into the *MluI* and *BglII* sites of pGL3-basic.

Progressive 5' deletions of pJS21-luc were generated by PCR cloning. All the various constructs (including those described below) were checked by nucleotide sequencing and/or restriction digestion.

The linker-scanning mutant pJS21(Δ -209/-167)-luc contains the whole JSRV LTR with the exception of a portion of the U3 encompassing nucleotides -209 and -166. Plasmid pJS21U3R-luc is composed of the U3 and R region of the pJS21 LTR.

Plasmid pJS21U5(+63)-luc is truncated in position +63 in the U5. Plasmid pNFKBm-luc was obtained by amplification of pJS21-luc with primers 3LTR-*BglII* and NFKBm-*MluI*. Primer NFKBm-*MluI* has incorporated in its sequence the desired mutation of the NF- κ B-like binding site present at position -262 of pJS21-luc (GGG \rightarrow TTT).

Plasmid pMLVp-luc was obtained by inserting the proximal promoter region of M-MLV (from -150 in the U3 until the end of U5) into pGL3-basic. Plasmid pMLVp+JSe was derived by inserting the JSRV₂₁ enhancers in the U3 region between -40 and -267 in front of pMLVp-luc. Plasmid pSVp+JSe was derived by inserting the U3 region of JSRV₂₁ between -51 and -267 into pGL3-promoter.

Plasmid pJSp+SVe has the SV40 enhancer driving the expression of the JSRV proximal promoter region starting at -51 in the U3 and includes the R and U5 region of the JSRV LTR. pJSp+SVe was derived by inserting the SV40 enhancer region from pGL3-control into pJS21(-51)-luc.

For the transactivation experiments the following expression plasmids were used. Plasmid pBETNFI-B1f expressing the NFI-A1.1 isoform driven by the chicken β -actin promoter and the control plasmid pBET containing only the β -actin promoter were provided by C. Bachurski and were originally developed by T. Tamura. Plasmids pCMV-TTFI, expressing the thyroid transcription factor (TTF-I) was originally made by R. Di Lauro and provided by G. Suske (Philipps-Universität, Marburg, Germany); pCMV-HNF3 α and pCMV-HNF3 β expressing the hepatocyte nuclear factor (HNF) 3 α and β were originally developed by R.H. Costa and provided by G. Suske as was pEVR2-Sp1, expressing the Sp-1 transcription factor under the control of the CMV promoter. To adjust the luciferase values for transfection efficiency and lysate preparations the following plasmids were used: pCMV- β gal expressing the β -galactosidase gene under the control of the CMV promoter; pRL-tk (Promega) expressing the *renilla* luciferase under the control of the herpes simplex thymidine kinase promoter and pRL-null (Promega) a promoterless plasmid containing the *renilla* luciferase gene.

Transient transfections and luciferase assays. Transient transfections were performed on 2-4 X 10⁵ cells plated on six well plates (Falcon) approximately 24 hours prior to transfection. For each well, 2 µg in total of plasmid DNA (1 µg of reporter plasmid and 1 µg of pCMV-βgal to adjust for transfection efficiency) and 6 µl of Fugene (Boehringer) were used as recommended by the manufacturers. In selected cell lines (MLE-15, mtCC1-2, 3T3, TCMK, ST3, CP-MRI and CP-ATCC) experiments were performed using the dual luciferase reporter system (Promega) (0.5 µg of reporter plasmid and 0.5 µg or 50ng of pRL-tk or pRL-null) and the activity of pJS21-luc was compared to that one of different neutral promoters (pGL3-control, pMLV-luc, pCMV-luc, pGL3-basic). For the transactivation experiments 200ng of pJS21-luc, 1 to 200ng of transactivating plasmid (or control plasmid containing the same promoter as the transactivating plasmid) and 100 ng of pRL-null was used. After 48 h, transfected cells were washed with PBS, lysed with 400 µl/well of 1 X Reporter Lysis Buffer (Promega), and frozen at -20°C. Luciferase assays were performed on 20 µl of the cleared lysate by rapid addition of Luciferase Assay Reagent (Promega) and light output was integrated over 10 sec at room temperature using a Monolight 2010 luminometer (Analytical Luminescence Laboratory). Luciferase activity was normalized for transfection efficiency and cell extract preparation by either assaying 50 µl of each lysate for β-galactosidase activity using the Luminescent β-galactosidase Genetic Reporter System II (Clontech) as recommended by the manufacturers, or measuring the *renilla* luciferase activity driven by pRL-tk and pRL-null in the Dual Luciferase System (Promega) as recommended by the manufacturers. The relative activity of pGL3-control adjusted for transfection efficiency was set to 100 for the experiments aimed to compare the activity of pJS21-luc across different cell lines.

In selected cell lines the activity of pJS21-luc was compared to different "neutral" promoters (pGL3-control, pCMV-luc, pMLV-luc or pGL3-basic) using either pCMV-βgal or pRL-tk or pRL-null to adjust for transfection efficiency.

All the transfections were performed at least 6 independent times and results are presented as the mean value for each sample. Values were determined at extract concentrations where the luciferase assays were in the linear range.

Analysis of Putative Transcription Factor Binding Sites. Analysis of putative transcription factors binding elements were done by computer analysis using the MatInspector v2.2 (Genomatix).

Nuclear extracts, electrophoretic mobility shift assays (EMSA). Nuclear extracts were prepared from TCMK and MLE-15 cell lines by established procedures with minor modifications (Dignam *et al.* 1983. Nucleic Acids Res. 11:1475-1489). The salt concentration of the extraction buffer was 1.2 M KCl; the final concentration was adjusted to 300 mM KCl. 3T3 cell line nuclear extract was purchased from Geneka. EMSAs were performed using the Nushift Kit (Geneka) as recommended by the manufacturer. Five μ g of nuclear extracts were incubated with 0.5ng 32 P end-labeled oligonucleotides probes for 20 minutes at 4°C with or without a 100-fold excess of cold competitor. For antibody-supershift-interference assays an anti-NF- κ B p50 (Geneka) or an anti-NF- κ B p52 (SantaCruz) rabbit polyclonal antibody was used by incubating nuclear extracts and antibodies for 20 min at 4°C. Bound and free probes were separated by nondenaturing electrophoresis in a 5% polyacrilamide gel.

Type II pneumocytes/Clara cells support preferential expression of the JSRV LTR. To determine the transcriptional activity of the JSRV LTR, transient transfection assays in different cell lines using a construct containing the firefly luciferase gene driven by the LTR of JSR21 (pJSRV21-luc) were performed. In each cell line, the relative activity of pJS21-luc was determined with respect to a promoter/enhancer plasmid (pGL3-control) containing a “neutral” promoter/enhancer (SV40, acted in many cell types) driving the same reporter gene. In all cases, co-transfections with a second reporter plasmid expressing a different reporter gene (e.g. pCMV- β gal expressing the β -galactosidase) also served to normalize transfection efficiencies between different experiments. Initial experiments were performed on

the MLE-15 line, which is a mouse cell line originating from lung tumors generated in transgenic mice harboring the SV40 large T antigen under the transcriptional control of the promoter/enhancer region from the human surfactant protein see (SP-C) gene (Wikenheiser, *et al.* 1993. Proc Natl Acad Sci U S A. 90:11029-11033). mtCC1-2 is a cell line derived from Clara cells from transgenic mice in a similar fashion but with the SV40 promoter under the transcriptional control of the CC10 promoter/enhancer (Magdaleno *et al.* 1997. Am J Physiol. 272:L1142-L1151). The activity of the JSRV LTR in lung cell lines vs. non lung cell lines such as those originating from testicular carcinoma, mammary carcinoma, mouse kidney cells, myoblasts, *etc.* (see table 1) were compared.

The relative activity of pGL3-control adjusted for transfection efficiency (by the co-transfected pCMV- β gal) was set to 100. The highest relative luciferase values for pJS21-luc were obtained in MLE-15, mtCCL-2 and MLE-12 with 429%, 109 %, and 16% of the activities of pGL3-control in the respective cell lines. Among the non-pulmonary cell lines, pJS21-luc showed the highest level of activity in 3T3 cells (11 percent). These results suggested that the JSRV LTR is preferentially expressed in cell lines derived from differentiated epithelial cells of the lungs.

Additional cell lines derived from sheep and humans were tested. Generally low activity was observed, even though the tested cell lines were derived from lung epithelial cells, including those that originated from human patients with bronchiolo-alveolar carcinoma (A549, H358 and H441 and the JS-7 cell line derived from a SPA tumor from a sheep. The fact that these BAC/SPA-derived cell lines showed relatively low expression of pJS21-luc may have been due to the fact that the cell lines generally have lost differentiation properties typical of BAC/SPA tumors and/or lung epithelial cells. The non-epithelial cell line that supported the highest levels of pJS21-luc activity was a sheep choroid plexus cell line (CP-PRI) obtained from the Moredun Research Institute, however, another sheep choroid plexus cell line obtained from the American type culture collection (CP-ATTC) supported expression of pJS21-luc very inefficiently.

To confirm the results in which pGL3-control (SV40 promoter/enhancer) was used as the reference neutral promoter/enhancer, the luciferase assays was repeated in selected murine and ovine cell lines using the Moloney murine leukemia virus (M-MuLV) LTR, the cytomegalovirus (CMV) immediate early promoter, or pGL3-basic (SV40 promoter but no enhancer) as "neutral" promoter/enhancer's. Transfection efficiency was adjusted with either pCMV- β gal (experiment series #1) or pRL-tk (experiment series #2) and the relative activity of the neutral promoter was set to 100.

In another set of experiments (#3 and 4), the relative activity of pJS21-luc was compared among the selected cell lines indicated above by comparing the straight ratios between the firefly luciferase values (induced by pJS21-luc transfected at 0.5 μ g/well) and the *renilla* luciferase values used to normalize for transfection efficiency by using either pRL-tk or pRL-null (used at 50 ng/well).

Cell lines studied included MLE-15 and mtCC1-2 cells because they support high expression of pJS21-luc; 3T3 cells were the non-lung epithelial cells that supported the highest levels of pJS21-luc expression, while TCMK and St3 gave the lowest levels of expression. The ovine CP-MRI and CP-ATCC lines were also tested to compare murine and ovine cell lines. The results are shown in table 3.

In sets # 1 and 2, the relative activities of pJS21-luc in the different cell lines relative to the four "neutral" promoter/enhancer's are shown. Depending on the reference promoter/enhancer, there was variation in the relative strength of the JSRV LTR in the different cell lines. For instance, the activity of pJS21-luc in MLE-15 cells was approximately 200-fold greater than the SV40 promoter/enhancer, while it was 20-50-fold more active than the M-MuLV LTR in the same cell line. Nevertheless, among all the murine cell lines MLE-15 and mtCC1-2 consistently showed the highest activities regardless of the comparison "neutral" promoter/enhancer. In sets # 3 and 4, where pJS21-luc was co-transfected with *renilla* luciferase expression plasmids driven by either the HSV-tk or pRL-null the results were also consistent with the results of sets 1 and 2, in that the MLE-15 and mtCC1-2 cells consistently showed the highest levels of pJS21-luc activity. Overall, the results supported the implications that the two murine lung epithelial-derived cell

lines supported the highest transcriptional activity of the JSRV LTR.

Table 3 also shows expanded studies of the relative activities of pJS21-luc in the two sheep choroid plexus cell lines, CP-MRI and CP-ATTC. These two lines generally showed higher activities of pJS21-luc activity than the non-lung epithelial murine cell lines and in some cases also respect the lung murine cell lines, which might reflect higher activity of the JSRV LTR in ovine than murine cell lines. It was also noteworthy that overall the CP-MRI cells supported higher pJS21-luc activity than the CP-ATCC cells, consistent with the initial results. Similar experiments in which the concentrations of the co-transfected control plasmids were reduced, in order to rule out the possibility that promoter/enhancer elements on the co-transfected plasmids were titrating cellular transcription factors were performed. Essentially the same results as shown in table 3 were obtained.

The JSRV enhancers are particularly active in MLE-15 cells. To map transcriptional control elements in the JSRV LTR, a series of overlapping 5' truncations to two pJS21-luc were prepared. These truncations progressively eliminated four regions from the U3 region of the LTR: i) a distal region (-208 to -266); ii) a central distal region (-167 to -208); iii) a central proximal region (-51 to -167). The promoter proximal region of the LTR was considered to be from position 0 to -51. The deletions were then tested for transcriptional activity by transfection into various murine and ovine cell lines. The activities of the deletions are shown as folds of activation relative to pJS21(-37)-luc, a plasmid containing the JSRV LTR truncated and position -37. This plasmid would contain the putative basal promoter elements of the JSRV LTR, including the TATA box (position -23), as well as the R and U5 regions. The results showed that the central and distal elements were able to enhance transcriptional activity of the basal JSRV promoter in the murine MLE-15 and mtCC1-2 cell lines, with the strongest evidence for enhancer activity in MLE-15 cells. On the other hand, the other murine cell lines showed little evidence for enhancer activity for the JSRV LTR, with at most a two-fold difference between the full length pJS21-luc and the basal pJS21(-37)-luc. These results were very consistent with the results and table 3, in that the two lung epithelial cell lines that showed the highest level of transcriptional activity for the JSRV LTR also showed evidence for functional enhancer elements.

The results allowed localization of enhancer activity within the JSRV LTR for MLE-15 and mtCC1-2 cells. In particular, in MLE-15, approximately 40 percent of the enhancer activity was associated with elements between positions -51 and -240, while the remaining 60 percent was associated with the distal elements between -240 and -267. An internal deletion of the JSRV LTR (pJS21[Δ -209/-166]) was generated lacking the central distal elements, and had approximately 40 percent of activity in MLE-15 cells. This was consistent with the importance of the central distal elements of the JSRV LTR for enhancer activity in these cells.

When the sheep cell lines were tested with the truncation series, only the CP-MRI cells showed substantial evidence for enhancer activity. This was consistent with the higher JSRV LTR activity in those cells (table 3).

The contribution of elements downstream from the transcriptional start site (e.g., R and U5) for the activity of the JSRV LTR were also tested. The U5 region appears to contain elements necessary for optimal expression, since deletion of the U5 region from pJS21-luc (construct pJS21U3R-luc) had 20-50 percent activity relative to pJS21-luc in all murine cell lines tested (MLE-15, mtCC1-2, 3T3 and TCMK). Addition of the first 63 nucleotides of U5 to this construct (pJS21[+63]-luc) fully or partially restored activity to the same levels of pJS21-luc activity in 3T3 and TCMK cells, but these nucleotides did not increase expression to the high levels of expression observed in MLE-15 or mtCC1-2 cells. Deletion of both R and U5 sequences from pJS21-luc reduced transcriptional activity to the background level given by pGL3-basic. Further studies will be required to elucidate the roles of R and U5 sequences in JSRV LTR-driven transcription.

Interaction between promoter and enhancer elements for optimal expression from the JSRV LTR. Both distal and central elements in the U3 region of the JSRV LTR contribute to optimal expression. It seemed that the most likely explanation was that the JSRV LTR contains enhancer elements that are particularly active in lung epithelial-derived cells. The JSRV enhancer elements (position -51 to -260) were examined to determine if it could confer cell-specificity to heterologous promoters. A series of luciferase reporter constructs were generated in which the JSRV enhancers were inserted in front of the basal SV40 or M-MuLV promoters. These constructs were tested for activity in MLE-15, 3T3 and TCMK cells. The activity of pJSp (or pSV-p or pMLV-p) after normalization for transfection efficiency with pCMV- β gal was taken as unit and compared to the activity of the various JS21 deletion mutants or the constructs containing heterologous promoters and heterologous enhancers. The JSRV enhancers were able to enhance expression from the SV40 and M-MuLV promoters in MLE-15 cells. Also, the JSRV enhancers were unable to enhance expression from the same promoters and TCMK cells, where there was little evidence for enhancer activity. In the case of 3T3 cells, results were somewhat unexpected, in that the JSRV enhancers were able to enhance expression of the SV40 and M-MuLV promoters; this enhancement was greater than the difference between the basal JSRV promoter and the full length JSRV LTR in these cells (pJSp vs pJSp+JSe, left panel).

Thus in 3T3 cells, the JSRV enhancers apparently are active, but they are more efficient at activating transcription from the heterologous SV40 and M-MuLV promoters than from the basal JSRV promoter. Similar results were obtained when a slightly larger portion of the JSRV LTR (-32 to -266) was placed in front of the basal SV40 promoter.

The fact that the JSRV enhancers combined with the JSRV basal promoter showed less enhancement in 3T3 cells than when they were placed in front of the heterologous promoters raised the possibility that the JSRV promoter may not be active in 3T3 (and/or TCMK) cells. To investigate this, a chimeric luciferase reporter construct in which the SV40 enhancers were placed in front of the basal JSRV promoter (pJSp+SVe) were prepared and its activity tested relative to the basal JSRV promoter and the full length JSRV LTR. The results indicated that the SV40 enhancers are able to activate expression of the basal JSRV promoter in all three cell lines. Thus the low expression of the native JSRV LTR in 3T3 cells (or TCMK cells) cannot be attributed to lack of basal promoter activity. These results suggest that high-level expression of the JSRV LTR in MLE-15 cells are the result (at least in part), not only to active enhancer and basal promoter elements, but appropriate interaction between these elements. Indeed, in MLE-15 cells the SV40 enhancers are less efficient at activating the basal JSRV promoter than are the JSRV enhancers, while in 3T3 and TCMK cells the converse is true.

The JSRV LTR response to cellular transcription factors involved in expression of lung surfactant proteins. In light of the demonstration that the JSRV LTR is preferentially active in lung epithelial-derived cell lines, the U3 region of the JSRV LTR was examined for potential binding sites for transcription factors known to be important for expression of genes in these cells. In particular, there are two putative HNF-3 binding sites; members of the HNF-3/forkhead family of nuclear transcription factors have been shown to be important in the regulation of surfactant gene expression (Margana and Bogaram. 1997. J Biol Chem. 272:3083-3090; Whitsett and Glasser. 1998. Biochim Biophys Acta. 1408:303-311; Hay and Crystal. 1997. Lung-specific gene expression, p. 277-304. In R. G. Crystal and J. B. West and E. R. Weibel and P. J. Barnes (ed.), *The Lung: scientific foundations*, 2nd ed, vol. 1.

Lippincott-Raven, Philadelphia). It has also been reported that other transcription factors such as NF-1, SP-1 and members of the octamer family cooperate with HNF-3/forkhead proteins in lung-specific expression, and these binding elements are also present in the JSRV LTR.

To test if putative binding elements in the JSRV LTR were important for expression, 3T3 cells were co-transfected with pJS21-luc along with expression plasmids for a series of transcription factors: TTF-1, HNF-3 alpha, HNF-3 beta, SP-1, HFH-8, and NF-1. The activation of JS21-luc by the various transcription factors was calculated by comparing the relative activity of pJS21-luc co-transfected with either a plasmid expressing the tested transcription factor driven by the CMV promoter or a plasmid with the CMV promoter alone. Transfection efficiency was normalized using pRL-null.

When the different amounts of the transcription factor expression plasmids were co-transfected with a standard amount of pJS21-luc, HNF-3 α and HNF-3 β luciferase expression was stimulated in a dose-dependent fashion. In contrast, HFH-8, another member of the HNF-3/forkhead family, did not activate expression of the JSRV LTR. It is interesting to note that HNF-3 α and HNF-3 β are expressed in type II pneumocytes and Clara cells, while HFH-8 expression is restricted to the epithelium and fibroblasts of the alveolar sac. It was also interesting that the JSRV LTR did not respond to co-transfection with the TTF-1 expression plasmid.

An NF κ B binding site is important for expression of the JSRV LTR.

Approximately one-half of the enhancer activity of the JSRV LTR in MLE-15 and mtCC1-2 cells could be attributed to elements in the distal region (-239 to -266). This region contains an NF κ B-like binding site with one mismatch (5'-GGGACGACC-3' (SEQ ID NO: ____)) from the canonical NF κ B consensus binding sequence (5'-GGG κ PPuNNPyPyCC-3' (SEQ ID NO: ____)). To test if this binding site was important for the enhancer activity in the distal region of the JSRV LTR, a version of pJS21-luc was generated in which the NF κ B-like site was mutated (pNF κ Bm-luc). The activity of pNF κ Bm-luc was compared to pJS21-luc in various cell lines and the relative

activity of pJS21-luc was set as 100.

Mutation of the NF κ B-like site from the JSRV LTR reduced transcriptional activity in MLE-15 and mtCC1-2 cells while it did not affect the level of expression in the other murine cell lines. Thus these results support the idea that the NF κ B-like elements is important for the high-level expression of the JSRV LTR in lung epithelial-derived cells, while it is not important for the low-level expression in non-lung epithelial cells. It was interesting that the only cell line in which mutation of the NF κ B-like site showed a negative effect was the CP-MRI cells, which also show the highest expression of the JSRV LTR.

In view of the importance of the NF κ B-like site for expression of the JSRV LTR in MLE-15 and mtCC1-2 cells, experiments were performed to test for the presence of nuclear factors that could bind to this sequence by electrophoretic mobility shift assays. Four major complexes of different mobilities could be detected in extracts from the MLE-15 cells when incubated with a labeled oligonucleotide containing the wild-type NF κ B-like sequence, and these complexes could all be competed with excess wild-type oligonucleotide. When the same nuclear extracts were incubated with a mutant oligonucleotide corresponding to the mutation in pNF κ Bm-luc, two of the wild-type complexes were absent (the slowest and the most rapidly migrating ones) while two complexes were still detected. The complexes bound by the wild-type but not the mutant oligonucleotides seemed most likely to represent factors important in expression of the JSRV LTR. Experiments were performed to determine the presence of the NF κ B site-binding proteins in 3T3 and TCMK cells, which do not support high-level expression of the JSRV LTR. Somewhat surprisingly, these cells also generated complexes that co-migrated with the complexes unique to wild-type oligonucleotide from MLE-15 cells. Thus the factor or factors that bind to the JSRV NF κ B-like sequences may be ubiquitously expressed.

Antibodies to the p50 and p52 members of the NF κ B proteins complex were used in attempts to supershift or inhibit complex formation in nuclear extracts from MLE 15 cells. However neither antibody showed inhibition or a supershift of any of

the complexes. Thus the proteins that bind to the NF κ B-like site in the JSRV LTR may be previously unidentified NF κ B-like proteins, or unrelated factors. It should be noted that the NF κ B-like site also overlaps with an Ik-2-like binding site for Ikaros-related proteins. The Ikaros gene is expressed typically in hematopoietic cells, and there have not yet been reports of expression in differentiated lung cells.

These experiments demonstrate that JSRV long terminal repeats are preferentially activated in type II pneumocytes and Clara cells. This is supported by i) demonstrating that in transient transfection assays the JSRV LTR shows a preferential activation in mouse cell lines derived from type II pneumocytes (MLE-15) and Clara cells (mtCC1-2); ii) analysis of deletion mutants of pJS21-luc showed that the JSRV₂₁ enhancers are able to strongly activate the JSRV₂₁ proximal promoter in MLE-15; iii) the U3 of JSRV₂₁ contains putative enhancer binding motifs for transcription factors such as HNF-3, which have been involved in lung specific expression of the surfactant proteins and of the Clara cell protein CC10; iv) transactivation experiments demonstrated that HNF-3 is able to enhance the basal activity of pJS21-luc.

These data point to the LTRs as a determinant of the JSRV tropism for type II pneumocytes and Clara cells. The restriction in expression of JSRV in cell types other than type II pneumocytes and Clara cells, both *in vivo* and *in vitro*, is probably due to the lack of lung-specific transcription factors (or the presence of transcription repressors) which are necessary for the JSRV LTR to be activated. This also explains the difficulty to obtain a convenient tissue culture system for the propagation of JSRV. The most suitable substrate for JSRV replication *in vitro* would be type II pneumocytes and Clara cells isolated from sheep lungs.

Elements of the JSRV LTR located both upstream and downstream the TATA box seem to cooperate and be essential for optimal functionality and cell-specificity of the JSRV LTR. In promoter activation experiments we have shown that the JSRV enhancers (central and distal elements) are able to activate heterologous promoters (such as SV40 and MLV) but optimal (and cell-specific) activation is achieved only with the homologous JSRV promoter. It is also observed that deletion of the whole U5 or a portion of it reduces drastically pJS21-luc expression suggesting that

sequences downstream the transcriptional start site might have a role in JSRV transcription. However R and U5 are not by themselves capable of conferring tissue-specificity because a construct with the proximal elements of the JSRV U3, R and U5 (pJS21(-51)-luc) was activated by SV40 enhancers also in cell lines such as TCMK where the JSRV enhancers and the JSRV LTR showed to be poorly active. Further studies are necessary to establish the role of R and U5 in the JSRV LTR transcription. The R and U5 region might be necessary merely as a spacer for the JSRV promoter. On the other hand, R has been shown to be important for transcription not only in human and primate lentiviruses through the interaction between the tat protein and the TAR but also in other retroviruses such as murine leukemia viruses, mouse mammary tumor viruses, bovine leukemia viruses and the reticuloendotheliosis virus group member chicken syncytial virus.

Table 3. Comparison of the relative luciferase activity of pJS21-luc in selected cell lines by using different reference promoters and/or co-transfected plasmids to adjust for transfection efficiency.

Cell Lines	Set # 1				Set # 2				Set#3	Set#4
	SV	CMV	MLV	Basic	SV	CMV	MLV	Basic	JS21/ pRLTK	JS21/ pRLnull
MLE-15	22	9.7	22.8	11.2	187.2	52.1	50	11.6	77.2	56.1
	3									
mtCC1-2	51.	15.2	22.7	12.4	90	93.6	76.3	5.6	62.9	29.9
	3									
3T3	5.9	2.4	7.8	4.5	5.9	46	24	3.9	16.3	5.4
TCMK	1	1	1	1	1	1	1	1	1	1
ST3	2.9	3.1	14.3	0.8	6.5	15	34.7	1	11.6	6.8
CP-MRI	7.1	6.6	4	13.2	29.2	46.2	34	9.4	26.8*	76.5*
CP-ATCC	4.3	4.3	3.2	6.1	6.6	10.4	9.9	5.4	24	13

EXAMPLE 3
CHARACTERIZATION OF JAAGSIEKTE SHEEP RETROVIRUS-
RELATED ENDOGENOUS RETROVIRUSES OF SHEEP

Molecular cloning. The construction of a high molecular weight genomic DNA lambda phage library derived from an OPC lung tumour DNA is described above. The library was divided into 15 sub-library and each sub-library was independently amplified. Aliquots of the 15 sublibraries were screened for the presence of exogenous JSRV proviruses by using a JSRV U3-specific hemi-nested PCR (U3 hn-PCR). The sub-libraries negative for exogenous JSRV were further screened for the presence of *enJSRVs*. In particular sublibrary #5 and #6 were plated onto bacterial agar plates and subjected to hybridization of plaque lifts with two ³²P-labelled probes on replica filters: a *gag*-specific probe and an *env*-specific probe. Under the hybridization conditions used, these probes hybridized with both endogenous and exogenous JSRV sequences. Primary plaques positive for both probes were picked and further purified by dilution and plating for isolated plaques on bacterial lawns, followed by hybridization with both *gag* and *env* probes. The presence of exogenous JSRV was ruled out by LTR exogenous-specific PCR and by the lack of the exogenous specific *Scal*I restriction site in *gag*. Three recombinant phages carrying three distinct *enJSRVs* loci were subcloned into pBlueScript (Stratagene) to give penJS56A1, penJS59A1 and penJS51F6. Both strands of the three clones were completely sequenced on an ABI Prism 310 Genetic Analyser (Perkin-Elmer), using a BigDye Terminator DNA cycle sequencing kit (PE Applied Biosystems) as recommended by the manufacturer.

Computer analysis of sequence data. Sequences were analyzed using DNASTAR 1.59 software package (DNASTAR, Inc.) and DNA Strider 1.2. Sequences alignments were performed using ClustalW 1.8. Phylogenetic analysis was performed calculating the genetic distances between sequence pairs by the DNADIST program in PHYLIP version 3.5. Neighbor-joining trees were estimated by NEIGHBOR program and a bootstrap analysis using 1,000 bootstrap replications.

Plasmids. Plasmid pCMV2JS21 is a construct derived from the JSRV₂₁ infectious molecular clone where the viral genes are under the control of the cytomegalovirus immediate-early promoter as describe above. Plasmid pCMV2en56A1 was derived by replacing the 5' LTR of pen56A1 with the CMV, R and U5 of pCMV2JS₂₁ by standard molecular techniques. Chimeric constructs

between pCMV2JS₂₁ and pCMV2en56A1 were obtained taking advantage of the *HpaI* and *BamHI* restriction sites present respectively in *gag* (position 1274 of JSRV₂₁) and at the end of *pol* (position 5265 of JSRV₂₁, 135bp before the end of the *pol* reading frame and 56 bp before the start codon of *env*) in both constructs. Plasmid pGPxEe has *gag* and *pol* of pCMV2JS₂₁ and *env* from pCMV2en56A1 while plasmid pGPeEx has the *gag* and *pol* from pCMV2en56A1 and the *env* from pCMV2JS₂₁. Plasmid pGePEx has the majority of *gag* from pCMV2en56A1 and *pol* and *env* from pCMV2JS₂₁ while pGxPEe on the contrary has the first two-thirds of *gag* from the exogenous pCMV2JS₂₁ and the rest of the genome from pCMV2en56A1.

The LTR of penJS5F16, penJS56A1 and penJS59A1 were cloned into pGL3-basic (Promega) by standard PCR cloning techniques. The resulting plasmids (pen5F16-luc, pen56A1-luc and pen59A1-luc) have the firefly luciferase gene under the control of the various endogenous LTR. pJS21-luc has instead the LTR of JSRV₂₁ which drives the firefly luciferase gene. pRL-null (Promega), a promoterless plasmid with the *renilla* luciferase gene was used to adjust the transfection efficiency in the luciferase assays described below.

Plasmids pCMV-HNF3 α and pCMV-HNF3 β , expressing the hepatocyte nuclear factor (HNF) 3 α and β (provided by R.H. Costa, University of Illinois, Chicago) were used in transactivation experiments.

Cell cultures. MLE-15 cell line, a mouse type II pneumocytes-derived cell line (provided by J. Whitsett), was grown in RPMI 1640 (Gibco BRL), 2% FBS, 0.5 % ITS (Sigma) modified with the addition of 5mg/l transferrin, 10 mM Hepes, 1X10⁻⁸ M β -estradiol and 1X10⁻⁸ M Hydrocortisone. Human 293T cell line, mtCC1-2, derived from mouse Clara cells (provided by F. DeMayo), and NIH-3T3 (ATCC#CCL-92) were grown in DMEM (ATCC) and 10% FBS. TCMK (ATCC#CCL-139) cell line (derived from mouse kidney) were grown in DMEM (ATCC), 1X non-essential amino acids (Cellgro) and 10% FBS. The LE cell line (provided by T. Spencer) derives from sheep endometrium epithelium and was grown in F12-K (Gibco BRL) 10% FBS. All the cell lines were grown in an incubator at 37°C with 5% CO₂.

Transient transfections and luciferase assays. Transient transfections were performed on 2-4 X 10⁵ cells plated on six well plates (Falcon) approximately 24 hours prior to transfection. For each well, 500ng of reporter plasmid and 50ng of pRL-null were used with 6 µl of Fugene (Boehringer) as recommended by the manufacturers. Experiments were done in 12 replicates. Cells were lysed 48 h after transfection using the dual luciferase reporter system (Promega) protocol in a TD 20/20 luminometer (Turner Design) as recommended by the manufacturer. The values of the various endogenous LTR reporters were compared to the activity of pJS21-luc which was taken as 100%.

For the transactivation experiments, 200ng of pJS21-luc, 1 to 200ng of transactivating plasmid (or control plasmid containing the same promoter as the transactivating plasmid) and 50 ng of pRL-null have been used in NIH-3T3 cells. The activation of JS21-luc by HNF-3 expression plasmids was calculated by comparing the relative activity of pJS21-luc co-transfected with either pCMVHNF-3α (or pCMVHNF-3β) or a plasmid with the CMV promoter alone. Transfection efficiency was normalized as above using pRL-null.

For the production of viral particles, 293T cells were transfected with pCMV2JS21 or pCMV2en56A1 (or the various chimeras), and viral particles were collected from concentrated supernatants as described above.

Western blotting. Western blotting of concentrated 293T supernatants for the detection of JSRV major capsid protein were performed as described above.

Tissue Samples. Tissue samples used for *in situ* hybridizations were collected during the necropsy of a healthy sheep. Tissues analyzed were lungs, liver, kidney, spleen, uterus, intestine/jejunal Peyer's patches, mediastinal lymph nodes, pre-crural lymph nodes, jejunal lymph nodes. Samples were fixed in 10% neutral buffered formalin, processed routinely in an automatic tissue processor, embedded in paraffin wax and sectioned (5-7 µm).

In situ hybridization. Deparaffinized, rehydrated, and deproteinated tissue sections were hybridized with radiolabeled antisense or sense cRNA probe generated

from linearized plasmid template (DD54) by *in vitro* transcription with [α -³⁵S]UTP (3000 Ci/nmol; Amersham-Pharmacia). DD54 contains 436 bp from the *env* region of *enJSRVs* and is 96 to 98% identical to enJS56A1 and enJS5F16. Autoradiographs of slides were prepared using Kodak BioMax MR film exposed for 16 h.

Autoradiography was performed using Kodak NTB-2 liquid photographic emulsion. Slides were kept at 4 °C for 1 week, developed in Kodak D-19 developer, counterstained with Harris' modified hematoxylin in acetic acid (Fisher), dehydrated through a graded series of alcohol to xylene, and cover-slipped. Photomicrographs were taken under brightfield and darkfield illumination using a Carl Zeiss Axioplan2 photomicroscope fitted with a Hamamatsu chilled 3CCD color camera.

Nucleotide sequences accession numbers. Sequences of pen56A1, pen5F16 and pen59A1 have been deposited in GenBank with the following accession numbers AF153615, AF136224 and AF136225.

From the cloning procedure described above three full length endogenous proviral loci termed enJS56A1, enJS5F16 and enJS59A1 were obtained. The length of the proviruses was 6915bp for enJS5F16, 7939bp for enJS56A1 and 6695bp for enJS59A1. The genomic structure of the three loci is schematically presented in Fig. 4.

All three endogenous loci have an upstream and a downstream LTR, hallmark of complete proviruses. In the U3 region of the LTR there were major differences respect to the exogenous JSRV. The LTR of the endogenous loci are also longer with respect to the exogenous JSRV and ENTV and the difference in length is all given by the U3 region. The length of U3 of the endogenous loci varies between 301 (enJS59A1) to 319 bp (enJS56A1 and enJS5F16) while for the exogenous JSRV is 272 and only 250bp for ENTV. The U3 region of enJSRV5F16 and enJSRV56A1 were 98% identical between each other and 85% respect enJSRV59A1. The endogenous loci showed approximately 74% identity respect the JSRV₂₁ U3 while R and U5 were highly homologous among the endogenous loci and respect JSRV₂₁. The upstream and downstream LTRs of enJSRV5F16 are identical while those of enJSRV56A1 and enJSRV59A1 display two and four base changes.

All the three endogenous loci have a conserved tRNA^{lys}_{1,2} primer binding site (PBS) which is the same used by the exogenous JSRV and ENTV. The *gag* gene shows an intact open reading frame in enJSRV56A1 and enJSRV5F16 while a single bp insertion creates a frameshift with a downstream termination codon at position 820 of the enJSRV59A1 provirus. The whole Gag is 98.2% identical in the endogenous clones. The Gag polyprotein is highly conserved between the endogenous and exogenous viruses (94 to 95% identity) with the exception of a short region corresponding to the matrix (MA) of JSRV₂₁ between nt 624 and 661 that shows a proline-rich motif where there is no real homology (Fig. 5) between the endogenous clones and the exogenous JSRV. Interestingly this region shows also some polymorphism between JSRV and ENTV where there is only 50% identity at the amino acid level compared to the 95.8% identity for the whole Gag. We termed this region VRA (variable region A) for the type D retroviruses of sheep. Downstream the VRA (50 aa residues) there is another region that shows polymorphism between endogenous and exogenous viruses; we termed this region VRB. It is interesting to note that ENTV in VRB, seem to be more closely related to the endogenous loci than to the exogenous JSRV.

The *pro* region shows an uninterrupted open reading frame and it is highly homologous among all the three endogenous clones. A very high homology it is shown also between the endogenous clones and the exogenous JSRV₂₁ (95 to 99.7% identity). The dUTPase motifs found in the 5' half of the *pro* gene of JSRV are conserved in the endogenous loci.

pol shows major defects in enJS5F16 and enJS59A1: in enJS5F16 there are two large deletions of 154 and 872 bp while a point mutation in enJS59A1 creates a stop codon (position 4071 of the provirus sequence).

In enJS56A1 there is a two bp deletion respect the exogenous JSRV at the 3' end of the gene (corresponding at the integrase region) that results in a theoretical polypeptide 14 aa shorter respect the exogenous product and with the last 33 amino acid with no homology with the exogenous amino acid sequence. The Pol

polyproteins of enJS56A1 and JSRV₂₁ are 97.8% identical (this value exclude the last 33aa of the endogenous locus).

The *orf-x* region which overlap *pol* is an uninterrupted open reading frame in enJSRV59A1. In enJSRV5F16 there is an ample truncation as a consequence of the deletion in *pol* while in enJSRV56A1 there is a stop codon 39bp before the stop codon of the JSRV₂₁ *orf-x*.

The *env* gene is deleted in enJSRV59A1 while it is a fully open reading frame in enJS5F16 and enJS56A1. This region is 98% identical at the aminoacidic level between the two endogenous loci and around 92% identical between endogenous and exogenous JSRV₂₁ sequences. In the last 67 aa of Env (in the TM region) there is another region of high divergency between endogenous and exogenous sequences (57 to 59% aa identity). This region has been shown to be also high variable between JSRV type I (composed of isolates from the African continent) and JSRV type 2 (from the UK and USA) sequences. This region was termed VRC. VRC shows to be highly variable also between exogenous JSRV and ENTV sequences (Fig. 6).

Of the three endogenous loci cloned enJS56A1 has uninterrupted open reading frames in all the structural genes. The only apparent defects of enJS56A1 are a premature stop codon in the *orf-x* and a two bp deletion respect the exogenous JSRV at the 3' end of the *pol* gene (corresponding to the integrase region) that results in a theoretical polypeptide 14 aa shorter respect the exogenous product and with the last 33 amino acids with no homology with the exogenous amino acid sequence. The *orf-x* is not necessary for viral particle formation and infectivity *in vitro*.

In order to test whether the enJS56A1 has the potential to express viral particles a construct was generated where transcription is driven by the cytomegalovirus immediate-early promoter (termed pCMV2en56A1) (Fig. 7). In pCMV2en56A1 the upstream LTR of penJS56A1 has been replaced with the CMV, the R and U5 regions from pCMV2JS₂₁. pCMV2JS₂₁ is a derivative of pJSRV₂₁ where the CMV immediate-early promoter drives JSRV transcription and it has been a useful tool to produce JSRV infectious virus *in vitro* by transiently transfecting 293T

cells and collecting viral particles in the resulting supernatant. 293T cells were transfected in parallel with pCMV2JS21 and with pCMV2en56A1 and their supernatants harvested at 24, 48 and 72h post-transfection. The resultant pools were ultracentrifuged over a double cushion of glycerol and the pellets subjected to SDS-PAGE/ western blotting using a rabbit antiserum towards the major capsid protein of JSRV. A band of 26 kDa was observed in the concentrated supernatants of pCMV2JS₂₁ transfected cells, as expected, but no band was detected in the pCMV2en56A1 supernatants. This indicates that enJS56A1 is unable to form virus particles. To localize the region/s responsible for this defect chimeric constructs were made between pCMV2JS₂₁ and pCMV2en56A1 (Fig.7) as described herein. pGPxEe has *gag* and the majority of *pol* from the exogenous JSRV₂₁ and the 3' 180 bp of *pol* and the entire *env* from enJS56A1; pGPeEx is the opposite chimera with *gag* and the majority of *pol* from the endogenous locus and *env* from JSRV₂₁. pGePEx has instead the first 2/3 of *gag* from the endogenous enJS56A1 and the rest of the genome from pCMV2JS21 and pGxPEe is the opposite chimera with *gag* endogenous and *pol* and *env* endogenous. pGPxEe was able to produce viral particles. A western blot of 300-fold-concentrated supernatant from 293T transiently transfected with the constructs showed a positive signal from lung fluid, pCMV2JS₂₁ and pGPxEe suggesting that the defect for packaging for enJS56A1 is contained upstream the *HpaI* site in *gag*. The 26 kDa protein is indicated; the defect for viral packaging is not therefore due to the slippage of the 3' portion of the *pol* open reading frame that is after the *BamHI* site used to make this chimera. Conversely neither pGPeEx or pGePEx were able to produce viral particles while pGxPEe did produce viral particles. The defect for packaging is therefore localized in the first two/thirds of *gag*, upstream the *HpaI* site (position 1274 of JSRV₂₁); interestingly this is where the two variable regions, VRA and VRB, are contained. However any single amino acid change outside this regions or polymorphism in the untranslated *gag* (Fig. 8) might also determine the packaging defect of enJS56A1.

Phylogenetic analysis and evolution. Unrooted neighbor-joining phylogenetic trees to assess the phylogenetic relationship between the three endogenous loci that were cloned and other known sequences of endogenous and exogenous type D retroviruses of sheep were generated. A tree for the U3 region, one for *env* and one for

gag and *pol* (Fig 9a to c) were generated. In each tree it is possible to distinguish three major branches: one for the endogenous loci, one for the exogenous ENTV and one for the exogenous JSRV sequences confirming previous analysis performed with limited *gag* sequences. The exogenous JSRV are further divided into two branches corresponding to sequences derived from the UK or from Africa and the USA. In all the generated trees the enJS59A1 branches apart from the other two endogenous loci cloned in this study and from most of the previous endogenous sequences generated by PCR-cloning.

The endogenous type D retroviruses loci seem to be quite young from the evolutionary point of view. An estimate of the time of integration in the sheep germline of these elements can be made by taking into account the variability between 5' and 3' LTR of a single locus. The intragenomic changes reflect changes that have accumulated since the time of integration in the sheep germline since it can be safely assumed that these LTRs were identical at the time of integration and were then subjected to non-coding regions or pseudogenes mutation rates. In other words, intragenomic variability of the LTRs can be used as a molecular clock to estimate time of integration. Thus, the integration events of enJSRV56A1 and enJSRV59A1 happened approximately 0.9 and 1.8 millions years ago using the average value of 4.85×10^{-9} substitutions per nucleotide site per year relative to pseudogenes. enJS5F16 might have integrated less than 500000 years ago. These numbers are subject to a margin of error and do not take into account the possibility of gene conversion.

From the constructed trees (Fig. ____), the endogenous loci can be divided in at least two phylogenetic groups: *enJSRV-A*, *enJSRV-B*. Another one or two groups might arise (e.g., proviruses where the sequences locus 5 and 6 were derived might form a group separate from *enJSRV-A*) but complete proviral sequences need to be obtained in order to fully classify these elements.

Expression of *enJSRVs* in vivo. To evaluate the expression of *enJSRVs* *in vivo* *in situ* hybridization was performed in a panel of tissues collected from healthy sheep. The DD54 probe that contains 436bp of the *env* gene and it is 96-98% identical to enJS56A1 and enJS5F16 *env* was used. DD54 was derived in a study aimed to isolate

messengers differentially expressed in the uterine epithelium. Indeed the luminal epithelium and the glandular epithelium of the uterus was where a very strong hybridization signal was detected. Cells in the lamina propria of the gut also showed some positivity and some positive signal above background was detected in the bronchiolar epithelium in the lungs. The alveolar epithelium did not show signal above background. Very weak signal above background or no signal above background was detected in the liver, kidney, spleen, tonsils and peripheral lymph nodes.

As discussed above, the long terminal repeat of JSRV are preferentially expressed in cell lines derived from the epithelial cells of the lungs (type II pneumocytes and Clara cells). To assess whether the pulmonary tropism is common between the exogenous and endogenous viruses reporter assays were performed with luciferase expressing constructs driven by the JSRV₂₁ LTR (pJS21-luc) or by the LTR of each one of the three endogenous loci (enJS56A1-luc, enJS5F16-luc and enJS59A1-luc). Results are expressed as % luciferase activity respect pJS21-luc (=100%) after adjustment for transfection efficiency by measuring the *renilla* luciferase values induced by the co-transfected pRL-null.

These experiments were performed in five different cell lines: MLE-15 (a mouse cell line derived from type II pneumocytes), mtCC1-2 (derived from mouse Clara cells), TCMK (derived from mouse kidney), NIH-3T3 (mouse embryo fibroblasts) and LE cells (a sheep cell line derived from the endometrial epithelium). JS21-luc had the highest relative luciferase activity in MLE-15 and mtCC1-2; NIH-3T3 had an intermediate level of JS21-luc expression while TCMK had low expression of pJS21-luc, as described above. The LE cells were chosen because of a previously reported study where *enJSRV*'s transcripts *in vivo* have been shown in the epithelium of the endometrium. As it is schematically shown in Fig. 10, the endogenous LTRs had a much lower luciferase activity respect pJS21-luc in the lung derived cell lines MLE-15 and mtCC1-2. The activity of the endogenous LTRs ranged from 7 to 11% (respect pJS21-luc) in MLE-15 cells and from 17 to 24% in mtCC1-2. However in TCMK, 3T3 and LE cells the activity of the endogenous LTR clones

were in the great majority of cases comparable (45% to 115%) with the activity of pJS21-luc.

This result suggest that the pulmonary tropism of JSRV has been probably acquired during the evolution and that the JSRV-like exogenous virus that gave origin to the *enJSRVs* elements did not show the tropism for the differentiated epithelial cells of the lungs that it is shown by the contemporary JSRV.

In addition, the endogenous clones were transactivated by HNF-3. HNF-3 which is a transcription factor which has been shown to play a major role in the lung-specific transcription. JSRV LTR have two hypothetical HNF-3 responsive elements and are transactivated in 3T3 cells by HNF-3. In the transactivation experiments shown in Fig.11, none of the endogenous LTR clones responded to HNF-3 α or HNF-3 β while the exogenous JSRV was activated by both HNF-3 α and β as expected.

Three loci of type D endogenous retroviruses of sheep (*enJSRVs*) were clones and showed their proviral structure, phylogeny and pattern of expression. All the three loci have fully open reading frames for at least one or more of the structural genes. In particular, enJS56A1 is an apparently full length provirus with open reading frames for *gag*, *pol* and *env*. enJS56A1 is however unable to make viral particles and by the construction of viral chimeras between the exogenous JSRV₂₁ and enJS56A1 we were able to identify the first two/third of *gag* of enJS56A1 as the main region where the defect for particle formation lies. For the first time two short regions in *gag* (VRA and VRB) where major differences between endogenous and exogenous type-D retroviruses of sheep are localized were identified. In VRA, in particular, is contained a proline-rich region in both JSRV and ENTV that it is absent in the endogenous loci. A third region that is divergent between exogenous and endogenous sequences is localized in the carboxy terminal portion of the transmembrane (TM) protein (that we termed VRC). Interestingly, in these variable regions there is also an high polymorphism between JSRV and ENTV. Future studies might need to further investigate VRA, VRB and VRC to evaluate if they influence the pathogenicity and/or tropism of the oncogenic exogenous viruses.

With the exception of these three variable regions, the endogenous loci are remarkable similar to their exogenous counterparts in all the genes; a strong polymorphism is instead localized in the U3 where the retroviral promoter and enhancers are located. The JSRV LTR has been shown to be a main determinant of viral tropism for the epithelial cells of the lungs, as described above. By *in situ* hybridization, it was shown that the strongest expression of *enJSRVs* seem to be localized in the luminal epithelium and in the glandular epithelium of the uterus. High expression of these elements along the genital tract might have been necessary for integration in the germ cells allowing in this way the generation of endogenous viruses. Weaker expression was detected in the lamina propria the gut and in the bronchial epithelium of the lung but no signal above background was detected in the alveolar epithelium.

By reporter assays it was shown that the LTR of the three cloned endogenous loci do not share the same lung-tropism of the exogenous JSRV. This suggests that JSRV has developed its lung tropism during the evolution as an exogenous virus. In other words the exogenous virus that integrated into the sheep germline to give origin to the endogenous loci did not show strong pulmonary tropism. This hypothesis is reinforced by the fact that the LTR of the various *enJSRVs*, on the contrary of the JSRV LTR, are not transactivated by HNF-3, a transcription factor involved in lung-specific gene expression.

Based on the analysis of the variability between 5' and 3' LTR of the same locus is estimated that the time of integration for *enJS56A1* and *enJS59A1* was between 0.9 and 1.8 million years ago while *enJS5F16* might have integrated even less than 500000 years ago. This is of course an estimation. Hecht *et al* showed that sheep (plus the wild members of the genus *Ovis*) and goats (plus the wild members of the genus *Capra*) have both approximately 20 copies of type D-related endogenous retroviruses; the restriction profile of these elements is different between the two gene but it is similar among members of the same genus. This imply the most of the *enJSRVs* loci have been acquired after the divergence between sheep and goats that occurred 4 to 10 million years ago. From these data it is suggested that the *enJSRVs* are rather young from the evolutionary point of view and they can be considered as

“modern” endogenous retroviruses; the existence of the closely related exogenous JSRV and ENTV is indeed another clue that these elements are evolutionarily young.

While the methods and compositions described above are typical of those that can be used to carry out certain aspects of the invention, other procedures known to those skilled in the art can also be used.

In addition, numerous modifications and variations of the present invention are possible in light of the above teachings and, therefore, within the scope of the appended claims, the invention may be practiced otherwise than as particularly described. It is to be understood that, while the invention has been described with reference to the above detailed description, the foregoing description is intended to illustrate, but not to limit, the scope of the invention. Other aspects, advantages, and modifications of the invention are within the scope of the following claims. All publications, patent applications, patents, and other references mentioned herein are incorporated by reference in their entirety.

What is claimed is:

1. An isolated replication competent infectious Jaagsiekte sheep retrovirus (JSRV).

2. The isolated retrovirus of claim 1, wherein the retrovirus comprises:

a JSRV GAG protein;

a JSRV POL protein;

a JSRV ENV protein;

a JSRV genome comprising Long-Termal Repeat (LTR) sequences at the 5' and 3' end of the retroviral genome, wherein the LTR is active in pulmonary epithelial cells, a polynucleotide sequence encoding JSRV GAG protein, JSRV POL protein, and JSRV ENV protein; and

cis-acting nucleic acid sequences necessary for reverse transcription, packaging and integration in a target cell.

3. The isolated retrovirus of claim 1, having a genomic sequence as set forth in GenBank accession no. AF105220.

4. A recombinant replication competent Jaagsiekte sheep retrovirus (JSRV) comprising:

a JSRV GAG protein;

a JSRV POL protein;

a JSRV ENV protein;

a JSRV genome comprising Long-Termal Repeat (LTR) sequences at the 5' and 3' end of the retroviral genome, wherein the LTR is active in pulmonary epithelial cells, a heterologous nucleic acid sequence operably linked to a regulatory nucleic acid sequence; and

cis-acting nucleic acid sequences necessary for reverse transcription, packaging and integration in a target cell.

5. The retrovirus of claim 4, wherein the ENV protein further comprises a target-specific ligand sequence.

6. The retrovirus of claim 5, wherein the targeting specific ligand sequence is an antibody, receptor, or ligand.
7. The retrovirus of claim 5, wherein the target cell is a pulmonary cell.
8. The retrovirus of claim 5 wherein the target cell is a cell having a cell proliferative disorder.
9. The retrovirus of claim 8, wherein the cell proliferative disorder is selected from the group consisting of lung cancer, colon-rectum cancer, breast cancer, prostate cancer, urinary tract cancer, uterine cancer lymphoma, oral cancer, pancreatic cancer, leukemia, melanoma, stomach cancer and ovarian cancer.
10. The retrovirus of claim 5, wherein the heterologous polynucleotide sequence is a suicide gene.
11. The retrovirus of claim 10, wherein the suicide gene is a thymidine kinase.
12. The retrovirus of claim 5, wherein the heterologous sequence is a marker gene.
13. An isolated Jaagsiekte sheep retrovirus (JSRV) genome, comprising: a polynucleotide as set forth in GenBank accession no. AF105220.
14. The isolated JSRV of claim 13 contained in an expression vector.
15. The isolated JSRV of claim 14, wherein the vector is a plasmid.
16. The isolated JSRV of claim 14, wherein the vector contains a regulatory sequence in operable association with JSRV genomic sequence.
17. The isolated JSRV of claim 16, wherein the regulatory sequence is a CMV early promoter sequence.

18. An isolated polynucleotide comprising the nucleic acid sequence as set forth in GenBank accession number AF105220, sequences complementary thereto and variants and fragments thereof.
19. The isolated polynucleotide sequence of claim 18, wherein T can be U and sequences complementary thereto.
20. An expression vector having in operable association the polynucleotide of claim 18.
21. A host cell transformed with the expression vector of claim 20.
22. A method for producing an infectious Jaagsiekte sheep retrovirus (JSRV), comprising:
transfected a host cell with the vector of claim 20;
culturing the host cell under sufficient conditions and for sufficient time to allow expression of the plasmid to produce JSRV viral particles; and
obtaining the JSRV viral particles.
23. The method of claim 22, wherein the host cell is a pulmonary epithelial cell.
24. The method of claim 22, wherein the host cell is selected from the group consisting of a human 293T cell, a mtCCl-1 cell, and an MLE-15 cell.

25. A method of treating a subject having a cell proliferative disorder, comprising: contacting the subject with a retroviral vector, comprising, a JSRV GAG protein; a JSRV POL protein; a JSRV ENV protein; a JSRV genome comprising Long-Term Repeat (LTR) sequences at the 5' and 3' end of the retroviral genome, wherein the LTR is active in pulmonary epithelial cells, a heterologous nucleic acid sequence operably linked to a regulatory nucleic acid sequence; and cis-acting nucleic acid sequences necessary for reverse transcription, packaging and integration in a target cell.

26. The method of claim 25, wherein the subject is a mammal.

27. The method of claim 26, wherein the mammal is a human.

28. The method of claim 25, wherein the contacting is by *in vivo* administration of the retrovirus.

29. The method of claim 28, wherein the *in vivo* administration is by systemic, local, or topical administration.

30. The method of claim 25, wherein the contacting is by *ex vivo* administration of the retrovirus.

31. The method of claim 25, wherein the ENV protein further comprises a target-specific ligand sequence.

32. The method of claim 31, wherein the targeting specific ligand sequence is an antibody, receptor, or ligand.

33. The method of claim 25, wherein the target cell is a cell having a cell proliferative disorder.

34. The method of claim 33, wherein the cell proliferative disorder is selected from the group consisting of lung cancer, colon-rectum cancer, breast cancer, prostate cancer, urinary tract cancer, uterine cancer lymphoma, oral cancer, pancreatic cancer, leukemia, melanoma, stomach cancer and ovarian cancer.
35. The method of claim 25, wherein the heterologous polynucleotide sequence is a suicide gene.
36. The method of claim 25, wherein the suicide gene is a thymidine kinase.
37. A pharmaceutical composition useful for inducing an immune response to Jaagsiekte sheep retrovirus (JSRV) in an subject comprising an immunogenically effective amount of a JSRV or JSRV polypeptide in a pharmaceutically acceptable carrier.
38. The pharmaceutical composition of claim 37, wherein the JSRV is a non-infectious JSRV.
39. The pharmaceutical composition of claim 37, wherein the JSRV is a heat inactivated JSRV.
40. The pharmaceutical composition of claim 37, wherein the JSRV polypeptide is an env polypeptide.
41. The pharmaceutical composition of claim 37, wherein the pharmaceutically acceptable carrier contains an adjuvant.
42. A method of inducing an immune response to a JSRV or JSRV polypeptide in a subject, comprising immunizing the animal with the composition of claim 37.
43. An antibody which specifically binds to the replication competent infectious Jaagsiekte sheep retrovirus (JSRV) of claim 1.

44. The antibody of claim 43, wherein the antibody is a monoclonal antibody.
45. A method for inhibiting the binding of a JSRV to a cell comprising contacting the JSRV with an anti- JSRV-antibody.
46. The method of claim 45, wherein the anti-JSRV antibody binds to a JSRV envelop protein.
47. The method of claim 45, wherein the contacting is *in vivo*.
48. The method of claim 45, wherein the contacting is *in vitro*.
49. The method of claim 45, wherein the antibody is formulated in a pharmaceutically acceptable carrier.
50. A method for identifying a compound which binds to a Jaagsiekte sheep retrovirus (JSRV) comprising:
 - a) incubating components comprising the compound and the JSRV under conditions sufficient to allow the components to interact; and
 - b) measuring the binding or effect of binding of the compound to the JSRV.
51. The method of claim 50, wherein the compound is a peptide.
52. The method of claim 50, wherein the compound is a peptidomimetic.
53. The method of claim 50, wherein measuring the ability of the compound to bind to the JSRV is by detection of a infectivity of the JSRV.
54. A method for inhibiting the expression of Jaagsiekte sheep retrovirus (JSRV) in a cell comprising contacting the cell with an inhibiting effective amount of an antisense oligonucleotide that binds to a segment of an mRNA transcribed from the JSRV genome whereby the binding of the antisense to the mRNA segment inhibits JSRV gene expression.

55. A recombinant retroviral vector, comprising:

- a GAG protein;
- a POL protein;
- a ENV protein;
- a polynucleotide sequence comprising jaagsiekte sheep retrovirus Long-Termi
- Repeat (LTR) sequences at the 5' and 3' end of the polynucleotide sequence, wherein
- the LTR is active in pulmonary epithelial cells, a gag nucleic acid sequence, a pol
- nucleic acid sequence and an env nucleic acid sequence; and
- cis-acting nucleic acid sequences necessary for reverse transcription, packaging and
- integration in a target cell.

56. The retroviral vector of claim 55, further comprising a heterologous sequence.

57. The retroviral vector of claim 55, wherein the gag, pol and env sequence are letiviral gag pol and env sequences.

58. The retroviral vector of claim 55, wherein the ENV protein is a JSRV ENV protein.

59. A method of driving lung-specific expression of a heterologous polynucleotide sequence comprising contacting a lung cell with a vector comprising a jaagsiekte sheep retrovirus long terminal repeat sequence (LTR) operably linked to the heterologous polynucleotide sequence.

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
18 January 2001 (18.01.2001)

PCT

(10) International Publication Number
WO 01/04266 A1

(51) International Patent Classification⁷: C12N 1/12, 1/20

James, M. [GB/GB]; Pentlands Science Park, Penicuik,,
Midlothian EH26 0PZ (GB).

(21) International Application Number: PCT/US00/18856

(74) Agent: GRAY CARY WARE & FRIEDENRICH LLP;
Suite 1600, 4365 Executive Drive, San Diego, CA 92121-
2189 (US).

(22) International Filing Date: 8 July 2000 (08.07.2000)

(81) Designated States (national): AE, AG, AL, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE,
DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU,
ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS,
LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ,
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT,
TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(25) Filing Language: English

(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG,
CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

(26) Publication Language: English

Published:

— With international search report.

(30) Priority Data:

60/142,868 8 July 1999 (08.07.1999) US

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(63) Related by continuation (CON) or continuation-in-part
(CIP) to earlier application:

US 60/142,868 (CIP)
Filed on 8 July 1999 (08.07.1999)

(71) Applicant (for all designated States except US): THE
REGENTS OF THE UNIVERSTY OF CALIFORNIA
[US/US]; 22nd floor, 300 Lakeside Drive, Oakland, CA
94512-3550 (US).

(72) Inventors; and


(75) Inventors/Applicants (for US only): FAN, Hung, Y.
[US/US]; 1079 Van Dyke Drive, Laguna Beach, CA 92651
(US). PALMARINI, Massimo [IT/US]; Apartment A,
2012 Los Trancos Drive, Irvine, CA 92612 (US). SHARP,

WO 01/04266 A1

(54) Title: A LUNG CANCER ASSOCIATED RETROVIRUS, GENE DELIVERY VECTOR AND METHODS OF USE
THEREOF

(57) Abstract: A viral genomic sequence of Jaagsiekte sheep retrovirus (JSRV) is provided and characterized herein. Also provided are methods of using the JSRV in gene therapy and in the treatment and diagnosis of JSRV related disorders.

FIG. 1






FIG. 2




FIG. 3




FIG. 4

JSRV21	MGQTHSRQLFVHMLSVKLKHRGITVSKPKLINFLSFIGEEVCPWFPREGTVNLETWKKVGEQIRTHYTLHGPKEKVPVETLS	80
JSRV-SAH.....T.....	80
ENTV	80
enSF16	60
enS6A1W.....	80
VRI		
JSRV21	FWTLIROCLDFDNEDELKRLGNLLKQEQEDPLHTPDGSPSYDPPP----PPPPSLRM-KPSDNDDLLSSTDEAELDEEAAKYH	156
JSRV-SAV.....S.....	156
ENTVD..EN..A..H..HSSR.....	157
enSF16V..E.R.AV.EGVKSD..FSNLL.....	160
enS6A1C..V..V..E.R.AV.EGVKSD..FSNLLR.....	160
VR2		
JSRV21	QEDWGFLAQEKGALTSDKDELVECFKHLTIALQNAGISLP-HNNTPPSAPPFFPAYTPSVHAGLDPPPGFPPPSKHNSPLQ	235
JSRV-SAQ..SN.....T.....	236
ENTVK..AN.OK.....L..A..V.....PL..N.....	237
enSF16K..SN.AKS.....L..A..V.....P..EN.....	240
enS6A1V.....K..SN.AKS.....L..A..V.....P..EN.....	240
CA		
JSRV21	RALRQAQRLGEVVSDFSLAPPVFENNHQRYYESLPFKQLKELKIAQSQYGPTAPFTIAHIEHLGTQALPPNDWKQTARAC	315
JSRV-SAK.....S.....	316
ENTVK.....	317
enSF16K.....	320
enS6A1K.....F	320
HpaI		
JSRV21	LSGGDYLLWKSEFFEQQCARIADVNRQQGQTSYEHЛИGEГGPYQATDTQLNFLPGAYAQIshaарQAWKRLPSESTKTEDL	395
JSRV-SA	396
ENTV	397
enSF16H.....	400
enS6A1	400
CA		
JSRV21	SKVRQGPDEPYQDFVARLLDTICKIMSDEKAGHVLAKQLAFENANSACQAALRPYRKKGDLSDFIRICADIGPSYHQGIA	475
JSRV-SA	476
ENTV	477
enSF16	480
enS6A1Q.....A.....	480
CA		
JSRV21	MAAALQQGKSIKEVLFQQQARNKKGLQKSGNSGCFVCGQPGHRAAVCPQKQQGPVNTPNLCPRCKGKHARDCKSKTOVQ	555
JSRV-SAH..TS.....	556
ENTVR..R..S.....	557
enSF16L.....S.....	560
enS6A1S.....H.....	560
CA		
JSRV21	GNPLPPVSGNWRGQPLAPKQCYGATLQVPLQTSVEPQEAAROWTSVPPPIQY.	612
JSRV-SA	613
ENTVT.....T.....	614
enSF16G.....T...	617
enS6A1G.....T...	617

FIG.5

JSRV21	MPKRRAGFRKGWYARQRNSLTHOMQRTLSEPTSELPTQRQIEALMRYAWNEAHVQPPVTPTNILIMLLLLLQRVONGAA	87
JSRV-SAP.....	80
ENTVH.....Y.....N.T.NG.....V.....H.....A.IK.....I.....	80
enJSS6A1	87
enJSSF16HK.....	87
JSRV21	AAFWAYIPDPPMIO5LGWDRIVEPVYVNTSLLGGKSDIHISPOQANISFYGLTQYPMCFSYQSQHFCIQVSADISYP	167
JSRV-SA	160
ENTV	160
enJSS6A1K.T.....	167
enJSSF16K.T.....	167
JSRV21	RVTISGIDEKTGKKSYGNNSGPLDIPFCDKHLSIGIGIDTPWTLRARVASVYNINNANATFLWDWAPGGTPDFPEYRGQ	247
JSRV-SAT.....	240
ENTVR.R.T.....N.S.....I.....T.L.....	240
enJSS6A1R.RD.T.....PI.....T.L.....	247
enJSSF16R.RD.T.....I.....T.L.....	247
JSRV21	HPPIFSVNTAPIYQTELWKLLAAGHGNNSLYLQPNISGSKYGDVGVTFLYPRACVPYFFMLIQGHMETLISLNITHNC	327
JSRV-SAT.....	320
ENTVL.....F.....	320
enJSS6A1	327
enJSSF16L.....F.....	327
SU \longleftrightarrow TM		
JSRV21	SNCILTNCTRGVAKGEQVIIVKOPAFVMLPVEIAEWYDETALELLORINTALSRPKRGLSLIILGIVSLITLIATAVTA	407
JSRV-SA	400
ENTVT.E.....	400
enJSS6A1T.E.....	407
enJSSF16T.E.....	407
JSRV21	SV5LAQSIQAHTVDSLTSYNVTKVNGTQEDIDRKKIEDRLSALYDVRVLGEQVQOSINFRMKIQCHANYKWIICVTKPKYNT	487
JSRV-SA	C.....	480
ENTV	480
enJSS6A1S.....N.....	487
enJSSF16H.....	487
JSRV21	SDFPWDVKKHLQGINFTNLSLDLQLNNEILDENSPTATLNIAADTVDNFLQNLESNPESLHSILKTLIGVGILVFI	567
JSRV-SA	560
ENTVY.E.....V.....	560
enJSS6A1TV.....	RSI.AM.AVLTVV 567
enJSSF16V.....	OSI.AM.AVLTVV 567
VR3		
JSRV21	IVVILIFPCLVRGMVRDFLQMRVEMILHMKYRNMLQHQHILMELLKNGERGDAGD--D-P	622
JSRV-SA	AI..FV..V..L.....T.....R.....A....P.	616
ENTVLV....T..LIK..Q..I..LI.....Y..Y.K..DFV.KR.GSCG.QPAEG.	618
enJSS6A1	LII.CLA..I.SI.KE..H..LI.--K.....A....P	618
enJSSF16	LII.CLA..I.SI.KE..H..LI.--K.....R.....A....P	618

FIG.6




FIG. 7

PBS

JSRV21	TGGCGCCCAACGTGGGGCTCGAGCTCGACAGTTTCTTC-GCCACTACTCTCATTAATTGAAACAAGTGAGTATATGGAT	79
JSRV-SAC.....CT.....A.....	80
ENTVC.....C.....T.....T.....CA.....T.....A.....	73
enJSSF16C.....T.....AG.....	92
enJSS9A1A.....C.....AT.....C.....C.....T.....GC.....AG.....	89
enJSS6A1C.....C.....T.....AG.....	92
JSRV21	AAACGGGTGAATTAATTAAAGGAGGGTACTAAGGTATATAGTTGAGAGTATAAAAT	135
JSRV-SAAA....AGCC....A.....	136
ENTV	G....TAA....T....CA....A.....	129
enJSSF16C....AA....A....G.....	148
enJSS9A1T....AA....A....G.....	145
enJSS6A1C....AA....A....G.....	148

FIG.8




Fig 9




FIG. 10




Fig. 11

1/13




FIG. 1

2/13




FIG. 2a




FIG. 2b

3 / 13




FIG. 3a




FIG. 3b

4 / 13




FIG. 4

JSRV21	MGQTHSRQLFVHMLSVMLKHRGITVSKPKLINFLSFIGEVC	PWFPREGTVNLETWKVGEQIRTHYTLHGPEKVPVETLS	80
JSRV-SA	.. H T ..	80
ENTV	80
enSF16	80
enS6A1	..	W ..	80
VR1			
JSRV21	FWTLIRDCLD	FONDELKRLGNLLKQEEDPLHTPDSGPSYDPPP	156
JSRV-SA V ..	156
ENTV D .. EN .. A ..	157
enSF16 E .. R .. AV .. EGVKSD .. FSNLL ..	160
enS6A1 C .. V ..	160
VR2			
JSRV21	QEDWGFLAQEKGALTSKDELVECFKNLTIALQNAGISLP	-HNNTFPSAPPFPAYTPSVMAGLDPPPGFPSSKHMSPPLQ	235
JSRV-SA Q .. SN ..	236
ENTV K .. AN .. DK ..	237
enSF16 K .. SN .. AKS ..	240
enS6A1 V .. K .. SN .. AKS ..	240
CA			
JSRV21	RALRQAQRLGEVVSD	FSLAFPVFENNQRYYESLPPFKQKELKIAACSQYGYPTAPFTIAMENLGTQALPPNDWKQTARAC	315
JSRV-SA	K S ..	316
ENTV	K	317
enSF16	K	320
enS6A1	K F ..	320

FIG. 5-1

<i>HpaI</i>		395
JSRV21	LSGGDYLLWKSEFFEQQCARIADVNRRQQGIQTSYEMLIGEGPYQATDTQLNFLPGAYAQISNAARQAWKRLPSSSTKTEDL	395
JSRV-SA	396
ENTV	397
en5F16H.....	400
en56A1	400
CA		475
JSRV21	SKVRQGPDEPYQDFVARLDTIGKIMSDEKAGMVLAKQLA FENANSACQAAALRPYRKKGDLSSDFIRICADIGPSSYMQGIA	475
JSRV-SA	476
ENTV	477
en5F16	480
en56A1Q.....	480
CA		555
JSRV21	MAAALQGKSIKEVLFQQQARNNKKGLQKSGNSGCCFVCGQPGHRAAVCPQQGPVNTPNLCPRCKKGKHWARDCRSKTDVQ	555
JSRV-SA	556
ENTV	557
en5F16R.R.R.....	560
en56A1L.....	560
H		612
JSRV21	GNPPLPPVSGNWVRGQPLAPKQCYGATLQVPKEPLQTSVEPQEARDWTSVPPPIQY	612
JSRV-SA	613
ENTVT.....	614
en5F16	617
en56A1G.....	617

FIG. 5-2

10/030441

JSRV21	MPKRRAGERKGYARQRNSLTHQMQRMTLSEPTSELPTQRQIEALMRYAWNEAHVQPPVTPTNILIMLLLQRVQNGAA	87
JSRV-SAP.....
ENTVH.....Y.....N.T.NG.....V.....H.....A..IK.....I.....	80
enJS56A1I.....
enJS5F16HK.....	87
JSRV21	AAFWAYIPDPPMIQSLGWDREIVPVVYVNDTSLLGGKSDIHISPQQANISFYGLTTQYPMCFSYQSQHPHCIQVSAADISYP	167
JSRV-SA
ENTV
enJS56A1K.T.....	167
enJS5F16K.T.....	167
JSRV21	RVTISGIDEKTGKKSYGNGSGPLDIPFCDKHLSIGIGIDTPWTLCRARVASVYNINNANATFLWDWAPGGTPDFPEYRGQ	247
JSRV-SAT.....	240
ENTVR..R..T.....N...S.....I.....T.L.....	240
enJS56A1R..RD.T.....PI.....T.L.....	247
enJS5F16R..RD.T.....I.....T.L.....	247
JSRV21	HPPIFSVNTAPIYQTELWKLAAFGHGNNSLYLQPNISGSKYGDVGVTFLYPRACVPYPFMILIQGHMEITLSLNIYHLC	327
JSRV-SAT.....	320
ENTVL.....F.....	320
enJS56A1	327
enJS5F16L.....F.....	327

FIG. 6-1

SU → → TM

JSRV21	SNCILTNCIRGVAKGEQVIIIVKQPAFVMLPVEIAEAWYDETALELLQRINTALSRPKRGLSLIILGIVSLITLIATAVTA	407
JSRV-SA	400
ENTV	400
enJSS6A1	407
enJSS5F16	407

JSRV21	SVSLAQSIQAAHTVDSLSSYNVTKMGTDVDRSALYDVKIEDRISALYDVLGEQVQSVNFRMKIQCHANQKWCIVTKKPYNT	487
JSRV-SA	C.....	480
ENTV	480
enJSS6A1S.....N.....	487
enJSS5F16H.....	487

JSRV21	SDFPWDKVKKEHQGIWENTNLSLDLQLHNEILDIENSPKATLNIAADTVDNFLQNLFSNFPSSLWKTLLIGVILVFII	567
JSRV-SA	560
ENTV	...Y.....E.....V.....	560
enJSS6A1TV.....	567
enJSS5F16V.....	567

VR3

JSRV21	IVVILIFPCLVRGMVRDEFLKMRVEMLHKYRNMLQHQHLMELLKNKERGDAGD--D-P	622
JSRV-SA	AI...FV...V...L.....	616
ENTVLV...T..LIK...Q..I..LI.....	618
enJSS6A1	LII.CLA...I.SI.KE..H...-LI...-K.....	618
enJSS5F16	LII.CLA...I.SI.KE..H...-LI...-K.....R.....A.....	618

FIG. 6-2

10/030441

10/030441

9/13







FIG. 7


10/13

PBS	JSRV21	TGGGCCAACGTTGGGCTCGAGCTCGACAGTTCTTC-GCCACTACTCTCATTAACTGAAAGTGAATGGAT	79
JSRV-SA		C.....	CT.....
ENTV		C.....C.....T.....T.....T.....T.....	A.....CA.....T.....A.....
enJS5F16		C.....	AG.....
enJS59A1		A.....C---AT.....C.....C.....	AG.....AG.....AG.....
enJS56A1		C.....	AG.....
	<hr/>		
JSRV21	AAACGGGTGAATTAACTTAAAGGAGGTAGTAAAGGTATATAGTTGAGAGTAAAT	135	
JSRV-SAAA.....AGCC.....A.....	136	
ENTV	G.....TAA.....T.....CA.....A.....	129	
enJS5F16C.....AA.....A.....G.....	148	
enJS59A1T.....AA.....A.....G.....	145	
enJS56A1C.....AA.....A.....G.....	148	

FIG. 8

FIG. 9A**FIG. 9B****FIG. 9C**

12/13



13/13




FIG. 11

13 MAY 2002

UCI1150-1

DECLARATION FOR PATENT APPLICATION

As a below-named inventor, I hereby declare that:

My residence, post office address and citizenship is as stated below next to my name.

I believe that I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled **A LUNG CANCER ASSOCIATED RETROVIRUS, GENE DELIVERY VECTOR AND METHODS OF USE THEREOF**, the specification of which

_____ is attached hereto.

X was filed on January 7, 2002 (Attorney Docket No. UCI1150-1)

as U.S. Application Serial No. 10/030,441

and was amended on _____

if applicable (the "Application").

I hereby authorize and request insertion of the application serial number of the Application when officially known.

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

With respect to the Application, I hereby claim the benefit under 35 U.S.C. Section 119(e) of any United States provisional application(s) listed below:

60/142,868
(Application Serial No.)

July 8, 1999
(Filing Date)

Full name of third inventor: James M. Sharp

Inventor's signature: J M Sharp

Date: 22 JANUARY 2002

Residence: Pentlands Science Park, Penicuik, Midlothian EH26 0PZ

GBX

Citizenship: Great Britain

Post Office Address: Pentlands Science Park, Penicuik, Midlothian EH26 0PZ

GT0273199.1
100093-100420

PATENT
ATTORNEY DOCKET NO. UCI1150-1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Hung Y. Fan, et al. Art Unit:
Application No.: 10/030,441 Examiner
Intl. Filing Date: July 8, 2000
Title: A LUNG CANCER ASSOCIATED RETROVIRUS, GENE DELIVERY
VECTOR AND METHODS OF USE THEREOF

Commissioner for Patents
Washington, DC 20231

POWER OF ATTORNEY BY ASSIGNEE

As a below-named assignee of the above-identified application
("Application"):

I hereby appoint the following attorneys of the assignee to prosecute the
Application and to transact all business in the United States Patent and Trademark Office
connected therewith:

JAMES P. CLEARY	Reg. No. 45,843
CHARLES D. GAVRILOVICII, JR.	Reg. No. 41,031
LISA A. HAILE	Reg. No. 38,347
ERIC HOOVER	Reg. No. 37,355
RICHARD J. IMBRA	Reg. No. 37,643
JUNE M. LEARN	Reg. No. 31,238
ALAN LIMBACH	Reg. No. 39,749
GEORGE LIMBACH	Reg. No. 19,305
KARL LIMBACH	Reg. No. 18,689
TIMOTHY W. LOHSE	Reg. No. 35,255
TERRANCE A. MEADOR	Reg. No. 30,298
KELLY K. REYNOLDS	Reg. No. 51,154
GERALD SEKIMURA	Reg. No. 30,103
STEVEN R. SPRINKLE	Reg. No. 40,825
DAVID R. STEVENS	Reg. No. 38,626
MARK TAKAHASHI	Reg. No. 38,631
EMANUEL J. VACCHIANO	Reg. No. 43,964
EDWARD WELLER	Reg. No. 37,468
RONALD YIN	Reg. No. 27,607
BARRY N. YOUNG	Reg. No. 27,744

Gray Cary\GT\6286356.1
104695-160426

RECEIVED TIME MAY. 13. 9:58AM

PRINT TIME MAY. 13. 9:59AM

I hereby claim foreign priority benefits under Title 35, United States Code, § 119 of any foreign application(s) for patent or inventor's certificate or of any PCT international application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application for patent or inventor's certificate or any PCT international application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) of which priority is claimed:

COUNTRY	APPLICATION NO.	FILING DATE	PRIORITY CLAIMED
US	<u>PCT/US00/18856</u>	<u>July 8, 2000</u>	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of first inventor: Hung Y. Fan

Inventor's signature: Hung Y. Fan

Date: 1/15/02

Residence: 1079 Van Dyke Drive, Laguna Beach, California 92651 USA CA

Citizenship: USA

Post Office Address: 1079 Van Dyke Drive, Laguna Beach, California 92651 USA

Full name of second inventor: Massimo Palmarini

Inventor's signature: R. Pal

Date: 1/16/02

New: 1051 Joie Drive, Bogart, GA 30622

Residence: 2019 Los Trances Dr., Apt. A, Irvine, California 92612 USA

Citizenship: Italy

New: 1051 Joie Drive, Bogart, GA 30622 R. Pal 1/16/02
Post Office Address: 2019 Los Trances Dr., Apt. A, Irvine, California 92612 USA

I hereby claim foreign priority benefits under Title 35, United States Code, § 119 of any foreign application(s) for patent or inventor's certificate or of any PCT international application(s) designating at least one country other than the United States of America listed below and have also identified below any foreign application for patent or inventor's certificate or any PCT international application(s) designating at least one country other than the United States of America filed by me on the same subject matter having a filing date before that of the application(s) of which priority is claimed:

COUNTRY	APPLICATION NO.	FILING DATE	PRIORITY CLAIMED
US	<u>PCT/US00/18856</u>	<u>July 8, 2000</u>	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

Full name of first inventor: Hung Y. Fan

Inventor's signature: Hung Y. Fan

Date: 1/15/02

Residence: 1079 Van Dyke Drive, Laguna Beach, California 92651 USA *CA*

Citizenship: USA

Post Office Address: 1079 Van Dyke Drive, Laguna Beach, California 92651 USA

Full name of second inventor: Massimo Palmarini

Inventor's signature: _____

Date: _____

Residence: 2019 Los Trancos Dr., Apt. A, Irvine, California 92612 USA

Citizenship: Italy

Post Office Address: 2019 Los Trancos Dr., Apt. A, Irvine, California 92612 USA

In re Application of:
Application No.: 10/030,441
Intl.Filing Date: July 8, 2000
Page 2

PATENT
Attorney Docket No.: UCI1150-1

I hereby authorize and request insertion of the application number of the
Application when officially known.

Direct all telephone calls to:

LISA A. HAILE, PH.D.
Telephone: (858) 677-1456

Address all correspondence to:

LISA A. HAILE, PH.D.
GRAY CARY WARE & FREIDENRICH LLP
4365 Executive Drive, Suite 1100
San Diego, CA 92121

THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
a corporation of the state of California

By: Linda S. Stevenson

Name: Linda S. Stevenson

Title: Manager, Patent Prosecution

Date: 5/13/02

UC Case No. 2000-008-2
Gray Cary GT 6286356.1
104695-160426